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Abstract 
Nanodiamonds (NDs) are the most biocompatible member of the carbon nanofamily which are 
widely researched for diagnostic and therapeutic applications. Unlike other carbon nanomaterials, 
the surface of NDs is innately reactive, hence capable of conjugating various chemical moieties 
for targeted actions. This work focuses on utilizing the surface reactivity of NDs for gene 
therapeutics and addressing the challenges associated with its application in the biological 
environment. Pristine carboxylated NDs were functionalized with basic amino acids (lysine and 
lysyl-histidine) through covalent conjugation via a three carbon chain linker. Amino acid 
functionalized NDs were characterized by infrared spectroscopy, thermogravimetry and size and 
zeta potential measurements. Lysine conjugation was evident through a marked change in the 
zeta potential of ND dispersion from negative to a high positive value (-54.6 mV to +26.3 mV). 
The thermogram of lysine functionalized NDs (Lys-NDs) revealed a significant weight loss from 
150ᵒC to 700ᵒC confirming the functionalization through loss of amino acid conjugates from the 
surface and total loading was calculated as 1.97 mmols/g. Lys-NDs also showed optimum 
binding with pDNA and siRNA at weight ratios of 1:1 and 1:20 (pDNA/siRNA:ND), 
respectively. Functionalization of NDs with lysine contributed to limiting aggregation and 
enhancing the colloidal stability of ND dispersions in biological milieu. The aqueous dispersion 
of lys-NDs showed minimum sedimentation and remained stable over a period of 25 days. 
Average sizes under 100 nm and zeta potentials higher than +20 mV indicate a preservation of 
the cationic surface throughout the testing period. Moreover, size distributions and zeta potentials 
changed significantly upon incubation of lys-NDs with blood serum suggesting an interaction 
with biomolecules, mainly proteins and a possible formation of a protein corona.  
Cellular internalization of bare lys-NDs and their diamoplexes (i.e. complexes of NDs with 
nucleic acids) was assessed through scanning transmission X-ray microscopy and flow 
cytometry. Functional efficiency of lysine NDs was determined by flow cytometry monitoring 
the GFP knockdown through anti-GFP siRNA delivery. Results reveal a promising GFP 
knockdown of ~17% upon treating the cells with NDs/siRNA diamoplexes at a ratio of 20:1. 
Subsequent analyses regarding the effect of NDs to prevent cellular proliferation and to cause 
cellular apoptosis confirmed that they are innately biocompatible at a wide range of 
concentrations. Unlike lysine NDs, lysyl-histidine functionalization was limited and the surface 
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loading of this conjugate on NDs was very low. Therefore, they were unable to bind pDNA and 
siRNA even at high weight ratios and hence demand design modifications.  
Overall this work demonstrates a novel approach of functionalizing NDs with basic amino acids 
capable of enhancing colloidal stability and delivering of therapeutic genes into mammalian cells. 
It represents an important step in the development of safe and efficient gene therapy for inherited 
and acquired diseases. 
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Introduction 
Targeted medicine is a novel therapeutic concept which has dramatically shifted the treatment 
approaches for many life threatening and chronic human pathologies. It aims at delivering the 
therapeutic agent directly to the site of action to ensure maximum efficacy and minimum toxicity. 
A wide array of research is undertaken using this approach for the treatment of various cancers 
1,
 
2
 and devastating infections. 
3,
 
4
 Two major approaches for targeted medicine include the delivery 
of biotechnological drugs like genetic materials and antibodies or conventional drug molecules to 
a specific area in the body. The mechanism of action and toxicity profile of drugs change 
significantly upon targeted delivery, as it offers the advantage of limited dosing and reduced drug 
related adverse reactions.  
Genetic modifications using deoxyribonucleic acid (DNA), small interfering ribonucleic acid 
(siRNA) and antibody mediated approaches in particular hold a significant importance in clinical 
science. It mainly emerged through the research advancements regarding human genomics and 
molecular medicine. Comprehensively, gene therapy is an approach to target the disease at its 
most basic molecular level by relying on the cellular transfer of therapeutic genes in the diseased 
individual. In comparison to conventional pharmacological therapies which target mainly the 
disease management, gene therapy has a potential to offer a complete one-time cure of the 
molecular aberration related to the disease. 
5
 
Both of the above mentioned therapies offer advantages but require competitive delivery vehicles 
which can effectively bind, protect, carry and deliver the drug or the gene to its site of action. In 
particular, the gene delivery vectors should be capable of protecting the genetic material from 
serum nucleases during circulation 
6
 and lyzosomal degradation upon cellular entry. Viral vectors 
such as adenoviruses and retroviruses perform this function well 
7
 but with complications, mainly 
the immunogenic toxicity. 
8
 This has encouraged the need of developing non-viral alternatives 
which could provide the same benefit with limited toxicity. Although non-viral vectors have 
lower transfection efficiency in comparison to viruses, their relative safety and easy scale-up 
procedures are the major advantages that have driven the development of several types of 
nanoparticles (NPs). Continued optimization is underway for many of these NPs to maximize 
their transfection efficiencies.   
2 
 
Carbon nano family holds a significant standing both as drug delivery and non-viral gene 
delivery vectors. 
9,
 
10
 Among them diamond NPs; also called nanodiamonds (NDs) are the most 
biocompatible member of the carbon nanofamily that are widely researched for diagnostic and 
therapeutic applications. Unlike other carbon nanomaterials, the surface of NDs is innately 
reactive and contains diverse combinations of functional groups. Homogenizing these surface 
functionalities allows the conjugation of various chemical moieties to target specific actions. To 
date, NDs are conjugated to a range of inorganic and organic, natural or synthetic functional 
groups both through physical adsorption and chemical immobilization. 
11, 12, 13, 14, 15 
Due to this 
surface reactivity it provides a favourable system to induce a positively charged surface to 
electrostatically bind and deliver the therapeutic genes in mammalian cells. 
In light of the above mentioned knowledge, the aim of my research was to develop a competitive 
ND based gene carrier through surface functionalizations. To achieve this purpose I covalently 
functionalized the NDs with basic amino acids (AAs) to induce a cationic surface. This thesis 
provides a brief comparison between various carbon nanomaterials as delivery vehicles in 
therapeutics, detailed insight regarding the biomedical applications of NDs and novel analyses 
regarding synthesis, physicochemical characterization and cellular interactions of AA 
functionalized NDs. 
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1 Introduction to Carbon Nanomaterials as Nano-Delivery Devices 
1.1 Introduction 
Carbon nanomaterials have gained significant attention in biomedicine due to their enhanced 
stability and surface properties. This family basically include diamond, nanotubes and fullerenes 
which derive from several types of primary prototype nanostructures. They are classified based 
on the hybridization of carbon atoms and their characteristic sizes. 
16
 Figure 1.1 classify the 
important carbon nanoforms and also illustrate their inter-relationships. These materials allow 
variety of covalent and non-covalent surface functionalizations, and hence can be tailored to 
specific applications. This chapter will provide a comparison between widely researched carbon 
nanomaterials in terms of structure, surface properties and biological interactions. It will also 
elucidate a brief description regarding delivery applications of these nanomaterials in 
therapeutics.  
 
 
Figure 1.1 Classification of carbon nanostructures. Reprinted with permission from 
16
 
Copyright © 2002 Taylor & Francis (The mark ‘spn ‘indicates intermediate carbon forms 
with a non-integer degree of carbon bond hybridization) 
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1.2 Structure and properties of important carbon nanomaterials: fullerenes, 
carbon nanotubes and nanodiamonds 
The structure of all important carbon nanomaterials including fullerenes, carbon nanotubes 
(CNTs) and nanodiamonds (NDs) consists of carbon atoms arranged in different configurations 
(Figure 1.2) A CNT is a tube-like sp
2
 hybridized nano-structure having a hollow core (Figure 
1.2A). The number of layers defines whether it is a single walled (SWCNTs) or multi walled 
(MWCNTs) structure (Figure 1.2A). 
17
 These tubes typically range from sub-nanometers to about 
100 nm in size depending upon the number of rings in the structure. The neighbouring tube walls 
have weak Van der Waals forces, which tend to cause aggregation upon dispersion in the 
medium. 
17
 CNTs have an unreactive surface 
18
 and require chemical modifications to induce 
functionalizations. Pre-oxidation of the surfaces produce carboxylic and hydroxyl groups which 
can then be used for covalent coupling of different functional molecules. Although covalent 
modifications are possible on CNTs, this mode disturbs the structural homogeneity of the tubes 
and reduces their mechanical stability. 
19
 Therefore, physical adsorption of desired functionalities 
still remains the major mode of CNT functionalization. Other important carbon nanomaterials 
which are considered primitive species for most of the modern forms of carbon based NPs are 
fullerenes. The most common form of fullerene is the C60 molecule (Figure 1.2C) which has 60 
carbon atoms arranged as 12 pentagonal and 20 hexagonal conformations. Having a closed-cage 
morphology, they are considered the most symmetrical structures in the carbon nanofamily. 
20
 
Like CNTs, the carbon atoms in fullerene molecules are also sp
2
 hybridized. The overall 
reactivity of the surface is very high due to the electron deficient alkene structure which tends to 
react readily with electron rich molecules. Unlike other carbon nanomaterials, they can be 
solubilized in organic solvents like benzene, toluene and chloroform. 
20
 
       
A B 
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Figure 1.2 Structures of carbon nanomaterials: Nanotubes (A), nanodiamonds (B) and 
fullerene (C). (A) Shows the molecular structure of single walled and multiwalled carbon 
nanotubes. Reprinted with permission from 
21
 Copyright © 2010 Elsevier Ltd. (B) shows 
schematic representations of un-relaxed (initial) structures cleaved from a diamond lattice, 
showing examples of the (a) octahedral, (b) truncated octahedral, (c) cuboctahedral, and (d) 
cuboid shapes. Reprinted with permission from 
22
 Copyright © 2007, Royal Society of 
Chemistry (C) shows C60 and C70 fullerene structures along with common covalent 
modifications of C60 molecule (C60 -pyridine and C60 (OH)24). Reprinted with permission 
from 
23
 Copyright © 2015 Elsevier B.V. 
In contrast to above mentioned carbon nanomaterials, NDs possess sp
3
 hybridized diamond core 
surrounded by a graphitic shell having sp
2
 hybridized carbon atoms. The sp
3
 hybridization of the 
core provides ultrastability to their structure. Diamond nanocrystals can exist in multiple shapes 
and configurations, which arise due to different arrangements of the facets in the structure. Figure 
1.2 B shows few most basic configurations of lattice arrangements in NDs: (a) octahedral (b) 
truncated octahedral (c) cuboctahedral (d) cuboid shapes. 
22
 Innately, these structures also possess 
large number of functional groups which are covalently bonded to the ND particle. 
24, 25
  Unlike 
other carbon nanomaterials the surface is already reactive and do not require any induction of 
functional groups to conjugate other chemical species. Functionalization of NDs only demands 
homogenization of these reactive groups to confer predictable loading of functionally active 
molecules. Another interesting structural feature that makes NDs superior to other carbon 
nanomaterials is the presence of colored centres which are point defects in their structure 
C 
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commonly known as nitrogen vacancies (N-V)
0
 and (N-V)
- 
. 
26
 They absorb light at wavelengths 
of visible, infrared or ultraviolet spectral region, 
26
 and emit bright fluorescence at 550-800 nm. 
27
 
Fluorescent nitrogen vacancies in ND core are formed during synthesis and can be further 
enhanced later, which opens numerous arenas of theranostic applications. Table 1.1 provides a 
comparison of structural features and surface characteristics of different carbon nanomaterials.  
Table 1.1 Comparison of structural features and surface characteristics of different carbon 
nanomaterials 
Carbon 
nanomaterial 
Structure Surface Properties 
Fullerenes It is a combination of several 
pentagonal and hexagonal 
rings of carbon atoms forming 
a closed cage structure. 
20
 
Surface is highly reactive due 
to the electron deficient 
structure. 
20
 
It tends to react readily with 
electron rich molecules. 
20
 
Carbon 
nanotubes 
(multi-walled 
and single-
walled) 
SWCTs are circular hollow 
sheets of graphenes having 
planer-hexagonal arrangement 
of carbon atoms distributed in 
a honeycomb like lattice, 
while MWCTs are 
combination of several 
concentric SWCTs with 
different diameters. 
28
 
Seamless arrangement of 
hexagonal rings without any 
dangling bonds renders the 
surface to be unreactive 
innately. 
18
 
Pre-oxidation is required by 
various techniques to induce 
functional groups referred as 
reactive opening in the 
structure. 
18
 
Nanodiamonds It contains sp
3
 hybridized 
diamond core surrounded by a 
graphitic shell having sp
2
 
hybridized carbon atoms. 
24
 
Surface contains large number 
of functional groups which are 
covalently bonded to the ND 
particle. 
NDs only demands 
homogenization of these 
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reactive groups on the surface 
before functionalization.  
 
1.3 Carbon nanomaterials as drug delivery devices 
Carbon nanomaterials can be widely functionalized on the surface to function as delivery devices 
in therapeutics. CNTs are the most widely researched member of the carbon nanofamily for these 
applications; however NDs have also recently gained much attention in this area of therapeutic 
research. NDs offer many advantages over other carbon nanomaterials, which include innately 
reactive surface, ultrastable diamond core and presence of coloured centres in the diamond core. 
These characteristics also aid in their application in theranostics through multiple covalent and 
non-covalent functionalizations. Chapter 2 provides an elaborative discussion regarding the 
properties and applications of NDs in diagnosis and therapeutics. This section mainly focuses on 
providing a comparative summary regarding the application of different carbon nanomaterials for 
drug delivery.   
CNTs are functionalized on the external walls to impart favourable aqueous solubility 
29,
 
30
 and 
binding to therapeutic molecules. 
9
 Biological molecules can be attached to CNTs either by 
wrapping around the surface through functional groups or can be loaded inside the hollow core. 
31
 
Attachment of the functionalities along the surface is widely accepted and can be done through 
non covalent hydrophobic or Vander Waals interactions or through covalent binding of 
biocompatible groups on the surface. Non covalent interactions preserve the aromatic structure of 
the tubes but are not suitable for targeted delivery applications due to low stability in the 
biological media. 
32
  
CNTs have applications mainly in cancer therapeutics. Covalent conjugation of drugs on the 
surface is more preferred due to longer stability profile in the complex biological environment. 
An example of such an application is the delivery of anticancer drugs like paclitaxel. When CNTs 
were employed as a delivery vehicle for paclitaxel, a common plant alkaloid used for cancer 
treatment, it was attached covalently to the surface through a double functionalization approach. 
33
 In this approach the surface of CNTs was non-covalently functionalized with amine containing 
8 
 
polymers and paclitaxel was modified into carboxy-paclitaxel. Functionalization was achieved by 
secondary covalent interaction through amide bonds between the polymer amines on CNT 
surface and carboxyl groups attached to paclitaxel. 
33
 This approach to deliver paclitaxel reduced 
the required dose to achieve tumor suppression due to around 10 fold higher tumour uptake of the 
drug. On the other hand, successful paclitaxel delivery into the tumour and subsequent tumour 
suppression is also achieved through NDs. 
34
 However unlike CNTs; conjugation of the drug on 
NDs did not require any secondary functionalization and was done through direct covalent 
bonding on reoxidized NDs having carboxylate functional groups on the surface. 
34
  
Therapeutic molecules have also been attached to carbon nanomaterials by non-covalent 
hydrophobic or electrostatic adsorption. SWCNTs have been attached to doxorubicin through pi-
pi bonding and hydrophobic interactions between the aromatic rings of doxorubicin and external 
carbon walls of SWCNTs. 
35
 Another approach to increase surface loading of non-covalently 
bound anticancer drugs on CNTs involves primary functionalization of the external walls with 
surfactants followed by secondary complexation of the desired drug through surface bound 
surfactants. In this approach polyethylene glycol (PEG) with selective terminal functionalities is 
used to facilitate electrostatic interactions. 
32
 Like CNTs, NDs also allow non-covalent loading of 
drugs onto its surface. 
36
 All of the studies concluded that carbon carriers facilitated higher uptake 
of anticancer drug in the cells and reduced cancer cell proliferation.  
Although both CNTs and NDs have equal standing as vehicles in drug delivery research, physical 
adsorption of drugs on ND surface can be more convenient and straight forward. 
36
 Moreover, 
there are certain advantages presented by each member of the carbon nanofamily: 
 NDs have an advantage over CNTs: Complexation and release of the drug from ND surface 
is pH sensitive, with highest complexation observed at basic pH. 
36,
 
37,
 
38
 This is due to the 
presence of ionisable groups (e.g. −COOH, −CONH, −OH, −NH2, −SH) on the surface, due 
to which NDs possess a combinational pKa. Changes in pH with respect to pKa can cause 
variations in the electrostatic charge states of the surface functional groups which in turn 
facilitate interactions with drug molecules. 
38
 When the pH turns acidic, the conjugated drug 
becomes protonated and thus release from ND surface. 
36
 This phenomenon is promising to 
confine the release of anticancer drugs at the acidic tumour site and also facilitate their uptake 
by cancerous cells which have a lower pH (5.8) than normal cells (pH 7.00-8.06). 
39
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 CNTs have an advantage over NDs: Unlike NDs which allow drug loading only on the 
surface, CNTs can facilitate drug wrapping around the surface and drug filling in the hollow 
core (Figure 1.3). 
31,
 
40
   This type of loading can allow gradual and sustained drug release and 
also protects the therapeutic molecules from biological environment.  
 
                             
Figure 1.3 Loading of drugs and other active molecules on the surface (A) and in the hollow 
cavity (B) of single walled carbon nanotube. (A) Shows possible arrangements of the 
polymer wrapping around the nanotubes. Top image corresponds to a double helix, the 
middle scheme is a triple helix, whereas the bottom arrangement shows switch backs, which 
allow multiple parallel wrapping strands to come from the same polymer chain owing to the 
backbone bond rotations. Reprinted with permission from 
41
 Copyright © 2001 Elsevier 
Science B.V. (B) shows the structure of the single-walled carbon nanotube (SWCNT) 
complexed with the gemcitabine drug. Reprinted with permission from 
31
 Copyright © 2010 
Elsevier Inc. 
In addition to CNTs and NDs, fullerenes another member of the carbon nano-group also have 
interesting applications in drug delivery. Recently, amphiphilic fullerenes were designed to aid in 
the delivery of hydrophobic drugs like paclitaxel. 
42
 Amphiphilic fullerenes are functionalized in 
way that facilitates self-assembling like lipids into either a hydrophilic vesicle with an empty 
cage or a solid nanostructure with a hydrophobic interior. 
42,
 
43
 Water insoluble drugs like 
paclitaxel can be packed inside the hydrophobic pockets and the hydrophilic surface can facilitate 
optimum delivery without the use of irritating non-aqueous solvents. Fullerene-mediated 
anticancer drug delivery is also shown to deliver comparable amounts of drug (paclitaxel) at 
A B 
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tumour site compared to the commercially available nanoparticle albumin-bound form of 
paclitaxel (Abraxane). 
42
 Another common fullerene type is the metallofullerenes which 
encapsulate metallic ions inside the hollow cage, mostly researched for bioimaging (Figure 
1.4A). A classic example of its utilization is the development of gadolinium-encapsulated 
metallofulerene as contrast agents to enhance MRI quality. Fullerene caging protects the 
gadolinium against degradation allowing longer residence times. 
44,
 
45,
 
46
 Recently, a novel 
technique called ‘molecular surgery’ was introduced to encapsulate drugs and metals in the 
fullerene cage. 
47, 48
 In this approach, a hole is introduced in the sphere through chemical 
reactions like radical-oxidation and cycloadditions and the desired chemical is inserted in the 
cavity. Followed by encapsulation, high temperatures are used to reseal the orifice (Figure 1.4B). 
48 
 
 
 
Figure 1.4 (A) Encapsulation of gadolinium molecules in C92 fullerene cage and (B) The 
molecular surgery” approach for encapsulating chemical moieties in fullerene caging. (A) is 
reprinted with permission from 
49
 Copyright © 2008, American Chemical Society (B) shows 
hole generation by provoking σ and π bond scission, insertion of the guest molecule, and 
reconstruction of the fullerene structure. Reprinted from 
48
  Copyright © 2011, Royal 
Society of Chemistry.  
A 
B 
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1.4 Carbon nanomaterials as gene delivery devices 
Unlike small molecules, biomolecules like proteins and genetic materials cannot internalize the 
cells due to their anionic nature. In order for a nucleic acid to reach the target cells with full 
functional capacity and successfully transfect the host cell population, it requires to overcome 
five major barriers 
50, 51,
 
51,
 
52
 (Figure 1.5): 
 Extracellular degradation by exonucleases during circulation. 51 It makes the delivery of naked 
nucleic acids through blood circulation almost impractical. Moreover, cationic carrier systems 
rapidly interact with serum proteins resulting in recognition and elimination by reticulocyte 
endothelial system (RES). 
51
 
 Entry into the cells through anionic cell membrane. 52 Cationic carriers wrap the nucleic acids to 
bypass the cell membrane, however the positivity of the surface required to facilitate this 
phenomenon may also cause cellular damage. 
53
  
 Endosomal entrapment and subsequent lysosomal degradation is the third and most critical 
barrier for nucleic acid delivery.  Highly acidic nature of late endosomes (pH ~4) triggers their 
fusion with lysosomes that subsequently cause enzymatic degradation of therapeutic genes. 
54,
 
55
 
A wide array of mechanisms is studied to target the release of nucleic acid-carrier complexes 
from the lysosomes: 
1. Destabilization of the membrane through ion pairing between cationic carrier lipids and 
anionic lipids of endosomes 
56
  
2. Proton sponge effects through molecules with low pKa (like polyethylenimene or 
histidine) causing endosomal swelling and lysis 
57
  
3. Membrane destabilizing proteins that convert to hydrophobic membrane-active forms in 
acidic medium 
58,
 
59
 to cause endosomal lysis 
4. Hydrophobic modifications of cationic polymeric vectors to cause endosomal lysis 60  
5. pH sensitive degradable vector that consume hydrogen and  degrades in endosome. The 
hydrogen consumption ultimately increases the osmotic pressure and lyse the endosomal 
membrane. 
61
  
 Inability of the vector to release the nucleic acid due to excessive strength of binding. 62, 63 It is 
encountered as a hurdle after escape of the gene-carrier complexes from lysosomes. It is shown to 
be another rate limiting step for gene transfection.  
12 
 
 The final barrier for gene transfection is their delivery across nuclear membrane. 64, 65 In ideal 
cases, the gene at this stage is free from the carrier and fully functional. Nuclear delivery can 
occur either via nuclear membrane breakdown or through nuclear pore complexes, both of which 
pose different challenges to bypass the therapeutic genes. 
65
 However, this challenge is only 
associated for the transfection of pDNA which require nuclear entry and integration in human 
genome to produce effects. Conversely, RNA interference machinery is present in the cytoplasm 
and therefore nuclear delivery of siRNA is not required and the above phenomenon does not pose 
any challenges for its therapeutic action.  
 
Figure 1.5 Barriers to successful in vivo delivery of nucleic acids using non-viral vectors: 
(A) Degradation during circulation; (B) Cellular entry through anionic cell membrane; (C) 
Endosomal entrapment and subsequent lysosomal degradation; (D) Inability of the vector 
to release the nucleic acid due to excessive strength of binding; (E) DNA delivery across 
A 
B
  
 
C  
D
  
E  
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nuclear membrane. Reprinted with permission from 
66
 Copyright © 2014, Rights Managed 
by Nature Publishing Group.  
Carbon nanomaterials have shown tremendous progress to overcome these barriers and serve as 
delivery vehicles for biomolecules. Several types of surface functionalizations on carbon NPs 
creates a possibility to bind and deliver therapeutic genes in the cells. The common approach 
towards utilizing them as gene carriers is the creation of a cationic surface that can 
electrostatically bind the nucleic acids. It can be obtained through various covalent and non-
covalent functionalizations on the surface of carbon nanoparticles. Among some widely 
researched cationic molecules used for such functionalizations include peptides like poly-L-
lysine, 
67
 synthetic ammonium derivatives 
68
 and polymers. 
69
  
Although the cationic surface of functionalized carbon nanomaterials facilitate binding and 
intracellular delivery of genes, this interaction is required to be optimally controlled. As 
mentioned earlier, strong interactions between the carrier and the nucleic acid may hinder the 
release of the gene in the cytoplasm, thereby reducing the transfection efficiency of the system. A 
modern approach to counter the excessive strength of binding is the incorporation of reducible 
disulfide bonds on the surface of the carrier. 
50
 Disulfide linkages are stable in the extracellular 
environment, but protonates in the reductive intracellular glutathione rich environment. The 
cytoplasm of the cells contain 1000 fold higher concentration of glutathione, which favours the 
cleavage of disulfide bonds causing selective gene release from reducible carriers. Disulfide 
modifications in the carrier-gene complexes are done through cationic lipids, peptides like poly-
L-Lysine, polymers like polyethylenimine, thiol reactive polymers and disulfide modified genetic 
materials. 
50
 Recently, this strategy was applied on CNTs to optimally control their electrostatic 
interactions with nucleic acids. SWCNTs were decorated by a linker (Sulfosuccinimidyl 6-(3'-[2-
pyridyldithio]-propionamido) hexanoate) which conjugated thiolated siRNA through disulphide 
linkage. 
70
 Successful silencing of CXCR4 mRNA was obtained which is promising to knock 
down the principle receptor CXCR4 responsible for HIV viral entry in human T cells. 
70
 Amine 
functionalized SWCNTs were also decorated with disulphide bonds which interact with thiol 
derivatives of biomolecules. This functionlization has been successful in transporting, releasing 
and expressing DNA oligonucleotides better than the conventional transfecting agent 
14 
 
lipofectamine. 
10
 Detailed review of various functionalizations on ND surface for gene delivery is 
discussed in chapter 2.  
1.5 Comparative biocompatibility profiles of carbon nanomaterials 
Due to numerous biological applications of carbon nanomaterials, it is important to understand 
the biocompatibility of these systems at cellular, organ and organism levels. Toxicity of carbon 
based NPs is dependent upon mass, purity, surface functional groups, overall surface charge and 
particle size. 
71
  
To date, NDs are considered the most biocompatible member of the carbon nanofamily. When 
the toxicity of ND was compared with other members of the carbon nanofamily, i.e., carbon 
black, multi-walled carbon nanotubes and single walled carbon nanotubes, in neuroblastoma cells 
and macrophages, it was revealed that the degree of cytotoxicity occurs in following order: 
single-walled nanotube> multi-walled nanotube> carbon black>ND. 
71
 In another study, NDs 
were found to be more inert towards cellular proliferation as compared to CNTs which reduced 
the cell viability significantly up to 60% at similar concentrations and under same experimental 
conditions. 
72
  
The principal reason toward unpredictable and rudimentary understanding of the biological 
effects of CNTs is that they exist in different morphologies. By functionalization, these 
nanomaterials could be rendered as safe and effective as delivery vehicles. 
73,
 
74,
 
75
 However, 
details regarding effects of these functionalizations are beyond the scope of this chapter. 
Comparative biocompatibility of NDs and factors affecting their biological interaction are further 
discussed in chapter 2.  
1.6 Conclusion 
Carbon nanomaterials have enormous potentials as delivery vectors in nanomedicine; since they 
can be tailored according to the application through surface modifications. The comparative 
analysis provided above also builds an understanding that NDs being the novel members of 
carbon nano family has a potential to provide promising avenues for safer gene therapy by 
combining two key parameters: acceptable delivery efficiency and optimum biocompatibility.  
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2.2 Abstract 
Nanodiamonds (NDs) being the most biocompatible member of the carbon nanofamily is widely 
researched for diagnostic and therapeutic applications. Unlike other carbon nanomaterials, the 
surface of NDs is innately reactive and contains diverse combinations of functional groups. 
Homogenizing the surface through oxidation or reduction allows conjugation of various chemical 
moieties to target specific actions. To date NDs are bonded to a range of inorganic and organic, 
natural or synthetic functional groups both through physical adsorption and chemical 
immobilization. Functionalization of NDs also provides a chemical means to counter NDs 
aggregation, which is considered as a major challenge toward its biomedical applications. 
Physical approaches are also broadly studied to produce well-dispersed stable ND dispersions. 
NDs are also investigated extensively for its interaction with biological system at cellular and 
organism levels. They are distributed in the body but are trafficked significantly through various 
protective mechanisms similar to other nanoparticles. However, significant biocompatibility and 
affinity for diverse range of biomolecules and therapeutic agents still make them attractive for 
nanomedicine especially as biomarkers and delivery vehicles. This chapter provides a detailed 
outlook regarding the structure, composition and properties of NDs. Challenges associated with 
its utilization and recent approaches to counter them are also elaborated.  Diverse array of 
diagnostic and therapeutic applications of ND based systems are presented.  
2.3 Introduction 
Carbon is the one of the most abundant element in earth’s crust which is known to exist in all life 
forms. Diamond is considered the hardest allotrope of carbon possessing a tightly packed 
interpenetrating cubic lattice structure. Extremely high bond energy between two carbon atoms 
(83kcal/mol) and the directionality of tetrahedral bonds 
76
 account for the ultra-stable nature of 
the diamond core. 
Diamond nanoparticles, also called nanodiamonds (NDs) are carbon nanomaterials which exhibit 
unique biological, thermal, mechanical and optoelectronic properties. They possess high surface 
areas and tunable surface structures. Due to their inherent properties, NDs are widely utilized in 
electronics 
77
, medicine 
78
 and advanced research technologies. 
79,
 
80,
 
81
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2.4 Production of NDs 
This portion of the chapter is presented in Appendix 10.1. 
2.5 Core structure, surface chemistry and chemical composition of NDs 
A single detonation ND is composed of a 4-5 nm diamond particle having sp
3
 hybridized carbons 
atoms surrounded by an amorphous and graphitic sp
2
 hybridized carbon layer bearing large 
number functional groups on the surface, 
24
 as represented in Figure 2.2. 
 
Figure 2.1 Structure of a single ND particle exhibiting a layered morphology 
Chemical composition of NDs is well elucidated. They consist of carbon to an extent of 80-88%, 
and this carbon predominantly forms diamond phase. Along with carbon, NDs also contain 
oxygen (10% or more), hydrogen (0.5-1.5%), nitrogen (2-3%), and an incombustible residue 
(0.5-8.0%) by weight. 
77
 Recent elemental analysis reports 90% of carbon, 3% of oxygen and 
0.8% of hydrogen contents in ND. 
82
 The difference in oxygen and hydrogen contents can be 
attributed to water; since absolute removal of sorbed water is not possible. 
82,
 
83
 A single particle 
consist of a crystalline diamond core, surrounded by an amorphous shell (coat) comprised of 
functional groups. These groups are covalently bonded to ND particle and determine the 
chemical state of its surface. 
25
 The diamond core consists of sp
3 
hybridized carbons where all 
four carbons are bonded via sigma bonds with other carbon atoms and forms a tetrahedral 
symmetry. 
84
 ND shell consists of sp
2
 hybridized carbons in which central carbon is attached to 
18 
 
three more adjacent carbons via sigma bonds and has a cloud of delocalized pi-electrons. This sp
2
 
hybridized carbons arrange in two dimensional planar hexagonal graphite layers 
84
 and contain 
functional groups. These functional groups may include hydroxyl, carbonyl, ether or anhydride. 
Nitrogen containing groups like amine, amide, cyano or nitro groups might also appear, however 
evidence suggests that most of the nitrogen is accumulated in the core. 
85
 Minute quantities of 
sulfone, methyl or methylene groups may also be present on the ND surface. 
24
 Apart from 
functional groups, sorbed water may also be present in the pores between NDs resulting from 
aggregation. 
24
 The absence of free electrons in the structure accounts for its inert nature. 
84
 
Spectroscopic and scattering analysis of detonation NDs reveal a core size distribution that peaks 
at 5 nm. 
86,
 
87
 However clear signals of diamond core are not clearly detectable even after vibrant 
cleaning, due to extensive layering of non-diamond amorphous carbon appearing as various 
functional moieties like C–C, C=C, C–H, C–O and C=O. 87 High temperature high pressure 
synthesis of NDs greatly reduces this graphite contamination and the diamond peaks in 
spectroscopic analysis are more discernable. 
87,
 
88
 
2.5.1 Defects in ND structure 
Detonation NDs are considered to have a faulty and a defective structure. Experimental analysis 
using high resolution transmission electron microscopy reveals that the core of ND particle 
consists of regularly arranged carbon atoms, but may possess few structural aberrations. 
89
 A 
common structural defect in natural and synthetic ND is multiple twinning in which two 
individual crystals share same crystal lattice symmetry. 
90,
 
87
 Twins once formed; act as 
preferential sites for impurities and defects. 
91
 This process may also increase fragility of NDs. 
87
 
Nitrogen impurity is the most common point defect that may exist in the diamond structure as a 
result of detonation (Figure 2.2). It consists of a nearest-neighbor pair of nitrogen atom, which 
substitutes for carbon atom and forms a vacancy in the diamond lattice. 
91
 The nitrogen vacancy 
(N-V) centres are responsible for photoluminescence properties of NDs and exploited for medical 
imaging purposes.  
Conclusively, NDs appear to have spherical morphology having a well-defined diamond cage in 
the core. The structure of the surface varies with synthetic and post synthetic conditions. 
90
 This 
unique structure of ND provides many advantages over other carbon nanomaterials which usually 
feature a chemically inert bare graphitic surface like in the case of graphenes or carbon nanotubes 
19 
 
or structure-less mixture of different forms of carbon (amorphous or disordered carbon) with less 
controllable and less accessible external surface. 
92
  
2.6 Properties of NDs crucial for biomedical applications 
NDs have attracted significant attention in numerous applications due to their innate physical and 
chemical properties. In particular, detonation NDs have the propensity to form a porous cluster 
structure in solution, therefore many molecules can be adsorbed on its surface. This phenomenon 
is exploited for developing novel technologies in nanomedicine like a smart drug complex 
providing attractive features such as sustained release and targeting. Moreover, they also allow 
chemical modification of the surface which opens avenues for designing smart hi-tech tools.  
The following are some key properties of NDs making them attractive for electronic, mechanical 
and medicinal research.  
2.6.1 Toughness 
NDs possess many properties of bulk diamond, among which is the extra ordinary hardness and 
rigidity, 
93
 suggesting that NDs are highly resistant to deformation under corrosive environments. 
This property attracts extensive interest in utilizing NDs for designing biological implants. 
94
  
Implantable delivery systems require optimum hardness characteristics to ensure tunable release 
rates of the incorporated therapeutic molecule. 
95
 NDs due to their rigid structure introduce these 
properties and can develop biocompatible and mechanically durable implants for localized 
delivery.  
NDs are also investigated for engineering nanocomposites for bone tissue engineering. 
96
 
Substitution of the composite with NDs resulted in an increase in Young’s modulus (200%) and 
overall hardness (800%) of the system. It was also shown to have least negative impact on 
oestoblastic proliferation even at high concentrations of 100 µg/mL in vitro. Additionally, the 
proliferation of osteoblasts was also maintained upon direct interaction with the scaffolds 
containing up to 10% of ND complexes. Oestoblastic activity is critical component of a healthy 
bone mineralization and to reduce bone resorption. 
97,
 
98
 This opened new avenues to utilize NDs 
for making up bone scaffolds. 
96
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2.6.2 Inertness 
This property is particularly useful for biomedicinal application of NDs, where the particle must 
have intrinsic ability to protect its integrity in case of any impact from the surrounding 
environment. ND shows this chemical inertness to a large extent and is capable to maintain its 
inherent structure and properties in the presence of corrosive biological environment containing 
acids, bases, enzymes and many other chemicals. A study conducted by Yuan et al revealed that 
the diameter of NDs remained unchanged even after residing for several days in various organs, 
highlighting their resistance towards biotransformation and degradation following digestion. 
99
 
2.6.3 Large surface area and high adsorption potential 
Another important feature that makes NDs an interesting tool for biomedicine and engineering is 
the high surface area to volume ratio that allows a large amount of active moieties to be loaded 
onto its surface. For therapeutic applications, NDs can be functionalized with various chemical 
groups to allow adsorption and delivery of therapeutic small molecules and biomolecules. Using 
this property as a tool, many concepts have been generated to utilize NDs as delivery agents for 
nanomedicine. 
100,
 
101,
 
102
 The large surface area of NDs also facilitates their utilization in 
specialized areas such as an intestinal adsorbent for removing toxic metabolites of protein and 
non-protein origin like drugs, xenobiotics, radionuclides, metals and exotoxins out of the body. 
103,
 
104
 
NDs retain the functional properties of the adsorbed materials and hence can also be used as 
analytical tools for extraction and purification of proteins from natural origin and recombinant 
technologies. 
104
 
2.6.4 Photoluminescence of NDs 
NDs are optically transparent and are capable of producing luminescence from coloured centres. 
These colored centres are point defects in their structure commonly known as nitrogen vacancies 
(N-V)
0
 and (N-V)
- 
(Figure 2.2). They absorb light at wavelengths of visible, infrared or 
ultraviolet spectral region, 
26
 and emit bright fluorescence at 550-800 nm. 
27
 Fluorescent nitrogen 
vacancies in ND core are formed during synthesis, and can be further enhanced by altering the 
diamond properties through high energy ion beam irradiations and subsequent thermal annealing. 
105
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In relationship to NDs, fluorescence is often used interchangeably with photoluminescence to 
define spectroscopic properties of NDs. Photoluminescence is a broader term encompassing both 
fluorescence and phosphorescence properties of spectroscopically active molecules.
106
 
Photoluminescence of NDs is dependent on the particle size and excitation laser intensity. 
107
 For 
smaller particles (5-50 nm) the spectra show structure-less bands in an emission range of 550-700 
nm and for larger particles (100- 500 nm) structured emission bands in 580-720 nm range are 
observed. 
107
 Changes in the spectral patterns of NDs with particle size are correlated with the 
differences in structure and features contributing towards photoluminescence. For smaller 
particles, the surface is well-defined and hence the natural defects created on the surface are the 
major contributor towards photoluinescence. Additionally, surface carbons in three-fold 
coordinated state (i.e. sp
2
 hybridization) and the dangling bonds created with surface carbons of 
adjacent NDs in the cluster also contribute towards emission. The intrinsic diamond core defects 
are postulated to contribute for structure-less region in the spectra. 
107
 Unlike small NDs, larger 
diamond particles do not have a well-defined surface due to aggregation; hence the vacancy 
centres in the diamond core and the heterogeneity in the diamond phase resulting during 
synthesis or post synthetic treatment are competing origins of photoluminescence. 
107
 
Stable photoluminescence, lack of photobleaching and numerous opportunities of 
functionalization render the NDs an attractive probe for bioimaging. However, some limitations, 
such as low intensity of fluorescence, remain 
108
 requiring further optimization before its 
commercial use in diagnosis.   
2.6.5 Aggregation 
Small sized (5 to 10 nm) NDs possess a tendency to form aggregates of tens to hundreds of 
nanometers to minimize their surface free energy. 
109
 Multiple NDs can adhere together forming 
stable core aggregates. Adhesion between two detonation NDs can be strong enough to hold a 
large cluster of NDs, as depicted in Figure 2.3. Continuous application of mechanical or 
vibrational energy through methods such as heating or milling can overcome these adhesive 
forces leading to disaggregation of ND particles. 
87
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Figure 2.2 (A) Bright-field STEM picture of a DND cluster held in contact by adhesion of a 
single ND grain. (B) When the contact area was irradiated by a 100 times brighter 
stationary electron beam, creating heat energy, the cluster was cut off within a minute. 
(scale bar 10 nm) Reprinted with permission from 
30
 “Copyright (2008) IOP Publishing” 
Aggregation could be an advantageous property to a certain extent as the size of the aggregate 
majorly controls their cellular uptake in biological system. There is always an optimum particle 
size which facilitates controlled cellular uptake through a phenomenon called wrapping effect, a 
process by which the cell membrane encloses the NP for internalization. Very small particle size 
(5-10nm) results in minimal receptor-ligand interaction which is insufficient to stimulate the cell 
membrane to wrap around the particle. 
110
 Aggregation of primary NDs sized 2 to 8 nm to 20-30 
nm particle size range is favourable for cellular uptake. It could lead to enhanced interactions 
with receptors on the cell surface 
111
, undergoing receptor mediated endocytosis. Aggregation up 
to a certain degree will result in low surface energy, contributing to the increased stability of the 
system. 
However, there is a narrow range where aggregation results in favourable responses. Large 
aggregates of 100-200 nm might result in formulation challenges and biological incompatibilities. 
112
  These issues are discussed in the next chapter. 
A B 
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2.7 Dispersion stability of NDs - a challenge for biomedical application 
Formation and maintenance of well-dispersed NP formulation in biologically relevant media is a 
critical parameter for controlled therapeutic response. Propensity of NDs to aggregate in tight 
structures of 100 to 200 nm 
85
 is a major formulation challenge associated with their biological 
application, such as incompatibilities. Therefore, this issue is of great interest to researchers 
utilizing addressed NDs as imaging and therapeutic tools.  
2.7.1 Theories related to ND aggregation 
Several theories have been formulated to explain ND aggregation. These theories summarize the 
mechanisms promoting aggregation and the factors affecting these mechanisms.  
2.7.1.1 Aggregation mediated through surface functional groups 
Unlike other carbon nanomaterials, NDs possess a functionalized surface as a result of the 
detonation process. The functional groups present on detonation NDs facilitate aggregation 
through van der Waals interactions or hydrogen bonding between adjacent ND crystals. 
16,
 
113,
 
114
 
The Vander Waals forces are inversely proportional to the particle size of NDs. The typical 
proportionality of attractive forces to ND size is found to be 1/r
6, where ‘r’ represents the radius 
of particle. For NDs having size less than 10 nm, surface groups may react together forming 
covalent bonds (Figure 2.4) and yields aggregated crystal- like ordered structures. 
115,
 
116
 
 
 
 
 
Figure 2.3 Example of reactions for inter-particle covalent bonding in nanodiamond 
agglomerates. Reprinted with permission from 
116
  “Copyright (2006) Royal Society of 
Chemistry” 
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2.7.1.2 Aggregation mediated through ND facets 
This theory suggests self-assembly through electrostatic interactions between different facets of 
NDs. 
117
 
118
 
119
 Individual ND particles exhibit anisotropic facet variations i.e. it consists of two 
distinct facets. These include facets with a net positive charge and facets with either neutral or net 
negative charge depending upon the degree of graphitization. 
22
 This polyhedral and multi-polar 
structure of NDs can possibly attract each other and form aggregates. The type of interaction 
involving neutral facets as primary participants in aggregation of NDs is characterized as 
‘coherent interfacial Coulombic interactions’, while all other alternating configurations resulting 
from random interactions are termed as ‘incoherent interfacial Coulombic interactions’. 118 A 
variety of different one or two dimensional self-assembled networks and supra-structures are 
possible through these interactions as depicted in Figure 2.5. 
 
Figure 2.4 Schematic illustration of possible networks of NDs. (a) one-dimensional 
orientation (b) & (c) two-dimensional orientation based on (111)–(111) and (100)–(111) 
interaction configurations. (100) represents facets with a net positive charge and (111) 
represents facets with either neutral or net negative charge. Reprinted with permission 
from 
117
 “Copyright (2008) Royal Society of Chemistry” 
2.7.1.3 Aggregation mediated through graphitic soot 
This is the most widely addressed theory of ND aggregation. It suggests that the major cause of 
aggregation is the graphitic soot formed as a result of the detonation process around the NDs. 
There are three sets of major events that occur during the deposition of carbon atoms from the 
detonation mixture, which explains the mechanisms and the factors affecting the formation of 
core aggregates 
85
: 
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a. Excess carbon resulting from detonation is subjected to high temperature and high pressure 
conditions inside the chamber leading to their arrangement as a diamond lattice. This process is 
very fast leading to the growth of several diamond nuclei with uniform morphology. 
b. Alteration in the temperature and pressure conditions stops further growth of ND crystals. At this 
point the remaining carbons arrange themselves as a stable graphite layer over diamond crystals. 
Studies report two types of graphite arrangements including ribbon structures 
120
 and spherical 
graphitic shells 
121
 Graphitic ribbons are formed due to the carbon redistribution process which 
arrange carbons in haphazard and crumpled fashion (turbostratic structure). 
120
 On the other hand, 
spherical shells result from diamond-to-graphite phase transition. 
121
 Apart from carbon 
rearrangement as graphitic layers, this stage of synthesis also creates soot embryos which are 
spiral sub-NPs composed of several hundred sp
2
 carbon atoms. 
122
 
c. The final event that results in formation of a core aggregate involves coagulation of the soot 
embryos. These embryos continue to generate sphere-shaped but faulty NPs. When they reach an 
optimum diameter of 10 to 20 nm they begin to coagulate themselves into aggregate structures. 
These aggregate structures are commonly called soot areas. They may contain soot embryos 
along with graphitic shells or graphitic ribbon like structures. The aggregation of an irregular 
graphitic shell around the particle forms a core aggregate of NDs (Figure 2.6). 
85
 
 
 
Figure 2.5 A simplified model of core aggregate sowing NDs and graphitic soot. Reprinted 
with permission from 
85
 “Copyright (2005) Elsevier 
2.7.2 Methods to mitigate aggregation and produce stable ND dispersion 
There are varieties of methods targeting disintegration of the NDs from their core aggregate 
structures. They are either physical or chemical or a combination methods, selected based on the 
future applications of the NDs. Physical approaches tend to counter ND aggregation mediated 
Cubic 
diamond 
crystal 
Aggregate 
structure of 
soot 
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through graphitic layering, while chemical methods target the surface through various 
functionalizations to reduce electrostatic attraction and hydrogen bonding between individual 
particles.   
2.7.2.1 Physical methods: stirred media milling and dry-media assisted attrition milling 
Physical methods to deaggregate ND colloidal dispersions are widely employed during 
biomedicinal researches due to the ease of procedure. Stirred media milling, also called wet 
grinding is a traditional method to disintegrate NDs. It involves preparing of ND slurries and 
adding suitable grinding media 
123
. Conventionally, yttrium stabilized zirconia (YTZ) beads, 
which are available in variable sizes ranging from micrometres to millimetres are used as the 
grinding media. 
123
 When the ND dispersion containing zirconia beads is subjected to a degree of 
ultrasonication, the beads hits the graphitic soot and on the diamond core. These collisions induce 
high energy impact and sheer forces 
124
, ultimately causing the aggregation to break. In this 
process bath sonication additionally creates shock waves 
124
 adding to the effect of zirconia beads 
to produce high intensity impact (Figure 2.7). 
 
Figure 2.6 Bead assisted deaggregation of NDs under bath sonication 
The zirconia beads are softer than the ND core; therefore the impact with the diamond core leads 
to their erosion during milling. 
82,
 
125
 These eroded zirconia particles are difficult to remove and 
yield a measurable quantity (0.2%) of contamination in the dispersion. 
82
 Certain comprehensive 
modifications (Figure 2.8) in the parameters of this technique are found effective in reducing this 
27 
 
contamination.  Osawa et al. elucidated that the milling conditions should adjusted to mild levels, 
so that the bead only hits the susceptible deformed areas of the core aggregates, that is the 
graphitic soot, and not with the diamond particles. Reducing the milling agitation, milling 
duration and particle size of the beads to ~30 µm can reduce the susceptibility of bead 
destruction. Additionally, the broken beads can be removed by centrifugation, adsorption onto 
activated charcoal, or diffusion through an osmotic membrane 
125
. Modification of the dispersion 
media is also recommended to control contamination. Solvents such as ethanol are preferred over 
water to avoid re-aggregation at the end of the milling process. 
125
 The aqueous medium shows 
better grinding properties and produces finer ND particles as compared to organic medium 
however, it is shown to induce re-aggregation unlike the organic dispersion medium. 
126
 
Moreover, water is a biocompatible solvent for medical applications. These strategies are 
summarized in Figure 2.8. 
 
Figure 2.7 Parameters that could improve stirred media milling 
Dry-media assisted attrition milling is also a noteworthy approach to formulate stable ND 
dispersion. In this process, water soluble nontoxic and non-contaminating crystalline materials 
like sodium chloride or sucrose are used. These crystals can be later removed by rinsing the NDs 
28 
 
with water, hence reduces the susceptibility of contamination unlike ceramic beads. The process 
is capable to produce NDs of <10 nm, that is close to the primary particle size. 
127
 
2.7.2.2 Chemical methods: surface functionalization of NDs 
Unlike other carbon nanomaterials, the surface of NDs is not inert, therefore opens several 
avenues for functional group modification and conjugation. Conjugation of various organic or 
inorganic molecules on the surface of NDs can control aggregation and simultaneously impart 
specific properties for biological applications.  
Surface functionalization to control ND aggregation involves induction of surface homogeneity 
by modifying variety of functional group (hydroxyl, carbonyl, ether or anhydride) already present 
on the surface of detonation NDs to facilitate electrostatic repulsion by inducing uniform 
distribution of similar functional groups.  NDs are also functionalized to confer chemical affinity 
to therapeutic molecules. For example several approaches are kept forward to synthesize a 
cationic surface for biomolecular conjugation. 
128,
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 Recently, ND functionalization is also 
focused to target the therapeutic system for enhanced site specific activity 
129
, reduced toxicity 
and limited wastage through processes like opsonisation. 
130
 Functionalization of NDs with 
various chemical moieties to confer specified biomedical application will be discussed later. 
The chemical functionalization is a multistep process. First, the surface of the NDs needs to be 
prepared, and then the actual conjugation of the functional moieties takes place. 
2.7.2.2.1 Pre-treatment of NDs before functionalization 
All types of ND functionalization begin with pre-treatment to homogenize the surface 
functionalities. This step is aimed at converting a heterogeneous surface to contain, as much as 
possible, a single type of functionality. It ensures a similar conjugation behavior of the entire ND 
surface during functionalization (Figure 2.9). The pre-treatment process can control aggregation 
mainly by facilitating electrostatic repulsion between similar functional groups on the surface. 
131
 
132
 
133
  
Most often, the pre-treatment step involves oxidation (Figure 2.9a). This step removes all 
impurities like carbon soot and metal ions from the ND surface. Among some complex functional 
groups involved in oxidation include chromenes (C9H8O), pyrones (C5H4O2), phenols and 
epoxides that are mainly at the edges of graphite surfaces. 
82
 Difference in the oxidative agents 
29 
 
may result in variable functional group distribution on the surface after oxidation. For example 
combination of nitric acid and sulphuric acid may result in carboxylate (COO
-
) rich surface 
134,
 
135
, while the combination of potassium permanganate and sulphuric acid mainly result in SO3
- 
or 
O
-
 derivatives of phenol. 
82
 Oxidation with strong mineral acids causes conversion of many 
chemical species into carboxylic functional groups which imparts hydrophilicity to NDs. 
136
 
Oxidation of NDs can also be done by various other methods which include oxidation in air or 
utilizing other oxidizing agents. 
137
  
Air oxidation is a much simple and inexpensive approach for disaggregation of NDs. 
131
 
138
 It 
utilizes either non processed air 
138
 or air with enriched oxygen or ozone, 
131
 and does not require 
any toxic substances or specific catalyst. It is particularly important to produce NDs with 
enhanced nitrogen vacancies for biological imaging. It involves a subsequent oxidation step in a 
tube furnace at controlled temperature of 600 ᵒC for specific time of 30 minutes using air as the 
medium.  Depending on the temperature of air oxidation, different materials are removed from 
the diamond surface. NDs of 8 nm with stable optical characteristics can be obtained by this 
technique. 
138
 Air oxidation also allows to selectively remove sp
2
-bonded carbon from ND 
providing control over sp
2
/sp
3
 carbon ratio on the surface. 
139
 
Multi-step oxidation including combinations of more than one technique is also considered 
effective to counter aggregation. 
133
 One of such techniques includes graphitization – oxidation 
method. 
140
 It begins with conventional treatment of graphitic soot with strong mineral acids and 
also involves a subsequent step of re-graphitization in which NDs are heat treated in nitrogen at 
1000 ᵒC for an hour resulting in complete blackness of ND particulates. Graphitization is then 
followed by re-oxidation in which the sample is treated in air at 450 ᵒC for several hours. The 
black colour of the product starts to fade and eventually disappears indicating that the thin 
graphite layer has been completely removed, yielding purified NDs. The NDs are then dispersed 
in water by ultrasonics. This process produces particles of less than 50 nm in size which indicates 
disaggregation of the NDs core aggregates. 
140
 However, in most cases oxidized ND presents an 
overall negative surface charge. 
Another mode of pre-treating ND surface is reduction (Figure 2.9b), which is aimed at converting 
most of the functionalities into hydrogen or hydroxyl groups. Therefore, reduction of NDs can 
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create either positive surface through hydrogenation or negative surface through hydroxylation of 
ND surfaces. 
137
  
Choice of the pre-treatment method is very crucial to control the overall functionalization 
process. Oxidation or reduction of NDs is selected based on the terminal functional groups 
required on the surface. For example, carboxylate functionality serves as a typical ligand for 
covalent conjugation of amine containing chemicals like amino acids (AAs) or proteins. 
134,
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This conjugation is mediated through the formation of an amide bond (R-CO-NH-R). Therefore, 
in order to functionalize NDs with biomolecules, oxidation is the best suited approach for pre-
treating the surface. On the contrary, certain molecules require hydroxylated surface for 
conjugation. A typical example is the biotinylation of NDs, before which the surface is reduced 
through borane forming hydroxyl groups. The hydroxylated surface is then covalently conjugated 
to biotin through silane linker (3-aminopropyl trimethoxysilane). 
142
 
 
Figure 2.8 Modes for pre-treatment of ND surface. Reprinted with permission from 
137
 
“Copyright (2008) Royal Society of Chemistry” 
2.7.2.2.2 Functionalization chemistry 
Surface functionalization occurs after the pre-treatment step ensures homogeneity of the ND 
surface. It utilizes three different types of surface chemistries: wet chemistry, gas phase methods 
or atmospheric plasma treatments (Figure 2.10, blue shaded) Different approaches to 
31 
 
functionalize NDs may result in variations in the binding energies and electrostatic features of the 
surface. 
143
 Due to high surface to volume ratio of detonation NDs, extensive functional group 
conjugation is possible.  
 
Figure 2.9 Wet chemistry and gas phase treatments for ND functionalization. Reprinted 
with permission from 
93
 “Copyright (2011) Nature Publishing Group” 
Wet chemistry treatment makes use of suitable solvent systems to introduce functional groups of 
interest. Depending upon the nature of functional groups to be attached on the surface oxidized 
carboxylated NDs or reduced hydroxylated NDs can be used. 
136
 For example, carboxylate 
functionalized NDs can be reacted with thionyl chloride to form highly reactive acyl chloride 
functionalities which can be further attached to amine containing chemical moieties. 
93
 The NDs 
treated by this pathway can be used to conjugate AAs or proteins on their surface. 
93
 Wet 
chemistry treatments maintain the crystal characteristics of diamond core even at the size of 5 
nm. 
136
 
Use of novel concepts has significantly advanced wet chemistry approaches of ND 
functionalization. A relatively new approach for modifying the surface utilizes a process called 
atom transfers radical polymerization. 
128,
 
144
 This process utilizes compounds called radical 
initiators (benzoyl peroxides, hydroxyethyl-2-bromoisobutyrate or 2, 2, 2-trichloroethanol) which 
32 
 
are attached covalently to oxidized NDs through esterification. Chemical groups are then 
introduced in the system which polymerize and arrange as brush arrays on the surface. This 
process can create hydrophilic or hydrophobic surface depending upon the nature of the polymer 
and hence provide better control over surface reactivity. 
144
 The radical polymerization 
phenomenon is also employed to develop a simple approach for introducing polar and non-polar 
functionalities on graphitized ND surface. 
11
 It begins with surface graphitization and then 
introduction of these graphitized NDs in a mixture containing monomers of hydrophilic 
compounds in aqueous medium and hydrophobic compounds in organic medium. Exposing the 
reactive NDs to polar and non-polar groups at the same time resulted in a combined 
hydrophilic/hydrophobic surface without undergoing multi-step complex procedures. 
11
 
Another approach for surface functionalization involves the treatment of NDs in gas or a vapour 
reactive medium (Figure 2.10, pink shaded side). 
145
 This approach is efficient to purify a very 
low dimensional fraction of the powder having narrow particle size distribution. It facilitate 
greater penetration into the inter particle spaces than strong acid or salts in liquid phase. 
145
 The 
gas phases used can include hydrogen, ammonia, carbon tetrachloride or argon. NDs treated with 
ammonia  yield carbonyl, amine or cyano groups on the ND surface, while treatment with 
chlorine  results in the formation of chloro-NDs or acyl-chloride functionalized NDs. Acyl 
chloride, in particular, is extremely reactive, since chlorine is readily replaced by the upcoming 
functional group like alcohol, phenols or amines. 
146
 Therefore, this mode is particularly 
important for biomolecular conjugation, where acyl-chloride is reacted with amine containing 
moieties to facilitate amide bond formation similar to the natural peptides. High temperature gas 
treatments with hydrogen produces alcohol functionalized NDs or hydrogenated NDs. A 
complete removal of all functional groups on ND surface might result from thermal treatments of 
NDs in argon, nitrogen or vacuum medium, which gives rise to graphitic carbon nano onions. 
Both, hydrogenated NDs and carbon nano onions are inert and hydrophobic in nature. 
93
 
Gas phase treatments are conducted in quartz reactors, in which NDs are treated with flowing gas 
or vapours at high temperatures ranging from 400 ᵒC to 1100 ᵒC and atmospheric pressures for 
durations ranging from 30 minutes to 5 hours. 
145
 Gaseous functionalization can result in 
hydrophilic or hydrophobic and acidic or basic ND terminations. 
145
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All these functionalization methods lead to the improvement of the dispersibility of the NDs. In 
addition, the homogeneous surface can serve as a template for binding molecules acting as a 
carrier, discussed in Chapter 5. 
2.7.2.3 Grafting biomolecules on NDs 
Introducing protonable biomolecules, including AAs, peptides and proteins on ND surface is a 
novel approach for functionalization. This is mainly targeted for controlled release of small drug 
molecules and targeted delivery of biomolecules such as peptides, proteins, RNA and DNA. 
Functionalization of NDs with biologically active molecules is achieved through non-covalent 
adsorption or covalent immobilization at the surface. Classic example of non-covalent 
biomolecular functionalization is presented by decorating the surface with poly-L-lysine, a 
polypeptide that can bind and isolate DNA oligonucleotides during mass spectrometric analysis. 
147
 Poly-L-lysine functionalized NDs are also employed to synthesize fluorescent NDs for 
possible application in human stem cell research. 
148
 Recently, a more complex system consisting 
of polyols like glycerol and polypeptides chained with basic AAs (glycine, arginine, lysine and 
histidine) are also used to functionalize NDs for gene delivery. 
149
 Similarly, NDs are also 
adsorbed with specific enzymes like lysozyme for antibacterial activities. 
150
 These systems are 
extensively characterized over time for stability, biological interactions and efficacy. 
151
 
152
  
Another approach for grafting biomolecules on the surface involves covalent conjugation that 
permanently immobilizes the molecules of interest on the surface and creates a controlled and 
relatively stable functionalized system. 
14
 Lysozyme, an antibacterial enzyme was covalently 
attached to the pre-treated carboxylated ND surface. 
150
 Covalent conjugation did not 
compromise the antibacterial activity of the lysozyme. The fully functional capacity of the system 
was ensured up to 10 hours at room temperature and up to weeks if stored at 5 ᵒC following 
covalent conjugation of the enzyme. 
150
 NDs modified through biotinylation are also shown to 
covalently bind coenzymes (vitamins) like biotin. 
14
 
A relatively new concept highlights the use of simpler biomolecules like AAs through covalent 
immobilization. 
134
 This approach creates a primary amine rich ND surface, which facilitate 
electrostatic interaction with genetic materials (DNA or RNA) to utilize NDs as gene delivery 
vectors. The concept of grafting AAs on the NP surface arises from the process of natural DNA 
wrapping in eukaryotic cells. The nuclei of all eukaryotic cells consist of histone proteins which 
34 
 
are alkaline in nature. 
153,
 
154
 These histone proteins are rich in lysine and arginine AAs. 
155
  The 
DNA wraps around histone proteins which condense and package the DNA to form nucleosomes. 
155
 There are many types of interactions between histone proteins and DNA during nucleosome 
formation. 
156
 Among these interactions one of the major interactions is the formation of salt 
bridges between side chains of basic AAs (especially lysine and arginine) of histone proteins and 
phosphate oxygen of DNA. The salt bridges are the combination of electrostatic interactions and 
hydrogen bonding between the positively charged amines and the negatively charged phosphate 
oxygen (Figure 2.11). This natural process is replicated artificially by functionalizing NDs with 
basic AAs covalently 
134
 or non-covalently 
157
 to induce similar interactions with anionic nucleic 
acids forming diamoplex (complex of diamond NP with DNA or RNA). Moreover, basic AAs 
also impart water solubility to the complex for stability in hydrophilic environment of the cell. 
156
 
 
Figure 2.10 Electrostatic interaction and hydrogen bonding (salt bridges) between primary 
amine of lysine residue and phosphate oxygen of DNA 
2.8 Biomedical applications of NDs 
2.8.1 Biodistribution and cellular uptake of NDs –mechanisms, challenges and controlling 
factors  
The route of administration into the body is one of the factors that influence the design decisions 
regarding biomedical devices and delivery systems. The functionalization of the NDs is also 
governed by the route of administration. After systemic administration, NDs like all other NPs 
are distributed in the body through blood circulation. The particle size and the shape, surface 
functionalities and the overall charge in dispersing medium play a critical role in defining their 
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distribution in the body. 
158
 NPs less than 5 nm are rapidly cleared, mainly through renal 
mechanisms and also through extravasations, which promote the discharge of fluids into 
extravascular spaces and subsequent removal of materials through lymphatics. 
159
 
160
 
161
 On the 
other hand, as the particle size increases from nanometers to micrometers, new challenges appear 
which mainly include NP accumulation in the metabolic organs like liver, spleen and bone 
marrow. 
162
 The metabolism of NDs can be stimulated through a process called opsonisation that 
is associated with non-specific protein adsorption on the surface. 
76,
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164
 It causes 
recognition and uptake of NDs by circulating macrophages followed by degradation and 
excretion, a process called mononuclear phagocytosis (Figure 2.12a). The risk of elimination of 
the NDs through this process is reduced by functionalizing the surface with polyethylene glycol 
(PEG). Pegylated NDs reduce opsonisation and phagocytosis, thus increase the chance for tissue 
accumulation. 
130
 
165
 Another removal pathway which presents a major challenge for ND survival 
in the body is associated with mechanical filtration through sinusoids in the spleen and Kuppfer 
cells in the liver. These systems are powerful machinery that removes the NDs through 
reticulocyte-endothelial system. 
166
 This process is also stimulated by nonspecific protein 
adsorption on ND surface.  
In addition to general biodistribution, mechanisms and factors involved in cellular uptake is also 
an extensively studied area to evaluate biological interactions of NDs. Properties mainly the 
particle size, shape and surface characteristics influence the cellular uptake processes. 
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Difference in the particle size defines the mechanism involved in its internalization and in turn 
the microenvironment experienced by them intracellularly. Most NPs are internalized in the cells 
through endocytosis mainly pinocytosis, a process to internalize fluids and molecules within 
small vesicles formed by the cell membrane folding (Figure 2.12b to e). 
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 Pinocytosis of 
NPs can occur through different mechanisms mainly dictated through their particle size. 
However, not all cell types are equipped with the necessary machinery to allow the entire 
spectrum of endocytotic processes. 
170
  The major pathway associated with carbon NPs is 
clathrin-mediated endocytosis. 
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173
 It is a form of receptor mediated endocytosis, which 
naturally functions for cellular uptake of proteins such as lipoprotein and transferrin. 
169
 
174
 
175
 It 
is also involved in cell and serum homeostasis by regulating membrane electrolytic pumps, for 
example voltage gated calcium cannels. 
175
 This endocytotic process forms coated pits having 
transmembranous and cytosolic proteins mainly clathrin (Figure 2.12d). They detach from the 
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membrane and form a vesicle in the cytoplasm of the cell. The assembly of these vesicles is 
controlled by another set of proteins called assembly proteins. 
175
 Another mechanism elucidated 
for ND uptake is macropinoccytosis, 
176,
 
177
 which is responsible to internalize larger particles of 
1µm. 
158
 It involves actin-driven membrane protrusion to enclose NDs in aggregated forms 
(Figure 2.12b).  Macropinocytosis seems similar to phagocytosis, however rather than zippering 
around the engulfed particle in latter it causes the protrusions to collapse and fuse again to the 
plasma membrane  
Investigations regarding ND uptake provide evidence for both macropinocytosis (Figure 2.12b) 
and clathrin-mediated endocytosis (Figure 2.12d), however latter is more commonly observed. 
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178
 Clathrin-mediated endocytosis is mediated through intact microfilament architecture as 
observed for poly-L-lysine coated NDs. 
148
 The same mechanism was observed in both healthy 
and cancerous cells, which indicates that the uptake process is not cell-type specific. However, 
recent investigation suggests that the uptake is approximately 30% higher in cancerous cells 
compared to healthy cells at the longest time interval (480 seconds) 
178
, presumably due to 
structural, genetic and phenotypic alterations. A study also reveals that slightly larger particles, of 
100 nm follow a combination of both mechanisms for cellular uptake. 
176
 This is due aggregation 
of NDs resulting in non-uniform particle size distribution that may stimulate a combination of 
pathways, each specific for a particle size range.  NDs ranging from 46-150 nm are found to be 
internalized via clathrin mediated endocytosis; however aggregated NDs of 1 µm in size can be 
internalized via macropinocytosis. 
177
  
The kinetics and extent of ND cellular uptake like all other NPs can be controlled by two 
parameters: thermodynamic driving force for membrane wrapping (determined by particle size) 
and diffusion kinetics of the receptors responsible for NP interaction. 
179
 Thermodynamic driving 
force for wrapping creates the required free energy for NP internalization while the diffusion 
kinetics of receptors corresponds to the availability of receptors to initiate receptor mediated 
endocytosis. 
179
 Research indicates that the optimal particle size for wrapping and receptor 
interaction is 55 nm. 
180
 Smaller NPs do not have enough energy for membrane wrapping and 
therefore cannot undergo endocytosis. For bigger NPs (>50 nm) more time will be consumed for 
membrane wrapping and hence will have reduced cellular uptake. 
180
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NDs conjugated to more sophisticated targeting moieties adopt a different pathway for cellular 
uptake as compared to the NDs without these molecules. 
129
 They follow caveolin-dependent 
endocytosis, which result in the formation of flask-shaped invaginations of the plasma membrane 
(Figure 2.12c). 
175
 Endothelial cells that lack the machinery for caveolin-mediated endocytosis 
are unable to bind and uptake serum proteins, 
181
 and therefore this pathway can facilitate uptake 
of protein coated NPs. 
182
 Unlike other receptor mediated endocytotic pathways, caveolin pits can 
also encapsulate larger amounts and sizes of NPs. A single caveolin mediated membrane 
invagination was found to accommodate three 20 nm and two 40 nm and one 100 nm polymeric 
NPs. 
182
 This highlights that ND aggregates may be internalized in the cells through this mode as 
well. However limited studies are available to date to support this mechanism for cellular uptake 
of NDs. 
 
 
Figure 2.11 Uptake of micro and nanoparticles. Internalization of large particles is 
facilitated by phagocytosis (a). Nonspecific internalization of smaller particles (>1 μm) can 
occur through macropinocytosis (b). Smaller nanoparticles can be internalized through 
several pathways, including caveolar-mediated endocytosis (c), clathrin-mediated 
endocytosis (d) and clathrin-independent and caveolin-independent endocytosis (e). 
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Nanoparticles are represented by blue circles (> 1 μm), blue stars (about 120 nm), red stars 
(about 90 nm) and yellow rods (about 60 nm). Reprinted with permission from 
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“Copyright (2010) Nature Publishing Group” 
Another interesting phenomenon that affects cellular uptake kinetics is the interaction of NDs 
with serum proteins. It is extensively researched to learn about the in vivo utilization of ND 
complexes. NDs have a reactive surface and hence are capable of adsorbing proteins forming a 
layer called protein corona. 
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 Several studies indicate that adsorbed proteins down 
regulate the cellular uptake of NPs and also lead to aggregation. 
148,
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184,
 
185
 Serum proteins can 
adsorb rapidly on NP surface leading to an increase in the overall particle size 
186
 as well as flip 
the surface charge into high negative values inherent to the protein itself. 
186
 This process can 
compromise the electrostatic interactions of cationic NPs with cell membrane and hence affects 
cellular uptake and toxicity profiles.  Protein coronas are formed on all NPs irrespective of their 
surface charges; 
187
 however the composition of the layer might vary with positivity or negativity 
of the surface. In general, adsorption of proteins on NP surface is a dynamic process, such that 
the identities of adsorbed proteins may change over time but the total amount remains roughly 
constant. 
188
 There are certain conflicting evidences that suggest that serum proteins mainly 
albumin enhance cellular uptake of carbon nanomaterials. 
189
 Therefore, understanding the 
behaviour of NDs in native biological environment is a prerequisite for their therapeutic 
evaluation. 
After cellular internalization ND based delivery systems face many challenges intracellularly. 
One of such challenges is the entrapment of NDs in endosomes following internalization. 
190
 The 
endosome is an acidic organelle due to the presence of digestive enzymes, and therefore 
endosomal entrapment especially affects gene transfection and delivery of acid-labile small 
molecules. 
191
 
192
 Disruption of the endosomal membrane through proton sponge effect is one 
way to protect NDs from endosomal degradation. 
193
 It is mediated by chemical groups with high 
buffering capacity and propensity to swell upon protonation. Protonation causes influx of H
+
 ions 
causing membrane to rupture. 
194
 These groups may include pH sensitive molecules like histidine 
which can be covalently attached to ND surface 
195
 to reduce endosomal trapping.  Another study 
also suggests that diverting the uptake process in favour of macropinocytosis also increase the 
potential of gene (siRNA) transfection. 
177
 This diversion is observed to depend on size and well 
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as the shape of NDs. In aggregated NDs weak electrostatic interactions may change the spherical 
shape of the particle. This may result in variations in the surface area acquired during membrane 
adhesion, which may ultimately change the mechanism of uptake. 
177
 Overall, size, surface 
properties, interactions with biomolecules, serum proteins, cell membranes and cellular 
organelles are all factors that contribute to the biological effect and toxicity of the NDs. 
2.8.2 Biocompatibility and biological affinity 
Biocompatible nature is a major pre-requisite for all therapeutic and diagnostic aids used in 
biomedicine. NDs certainly provide well-established evidence of limited toxicity at cellular and 
organ levels, demonstrating the highest biocompatibility among the members of the nanocarbon 
family.  
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When the toxicity of ND was compared with other carbon nanomaterials including carbon black, 
multi-walled carbon nanotubes and single walled carbon nanotubes, the degree of cytotoxicity 
occurred in following order: single-walled nanotube>multi-walled nanotube>carbon black>ND. 
71
 NDs do not induce any mitochondrial membrane damage and preserving high cell viability. 
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Unlike other carbon nanomaterials, they do not fragment DNA 
37
 or alter gene and protein 
expression profiles of living cells at a wide range of concentrations and particle sizes. 
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Regardless of the terminal functional moieties, NDs show no over expression of genes like 
interleukin-6, tumor necrosis factor alpha, and inducible nitric oxide synthase, hence are expected 
to show absence of inflammatory responses upon administration. 
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These properties are particularly advantageous to develop ND based delivery vectors. Serum 
proteins are also shown to play a significant role in influencing the biocompatibility of NDs. 
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In vitro studies reveal that the cell culture medium containing serum proteins enhance the 
biocompatibility of oxidized carboxylated NDs even at high doses. This builds an evidence for 
ND safety in protein rich biological system. The adsorbed serum proteins are not only protective 
but are also shown to increase hydrophilicity and stability of ND dispersion. 
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In vivo biocompatibility of NDs is also addressed. The most important organ system considered 
for its effects is the respiratory system, since powdered detonation NDs may cause environmental 
pollution. 
197
 NDs are considered non-toxic to the respiratory system as did not show any 
oxidative damage to lung tissues upon long term residence. 
197
 They are shown to be excreted out 
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of the body mainly through lymphatic tissue or directly through cough. 
197
 NDs also maintain 
their biocompatibility after prolonged exposures through oral 
198
 or subcutaneous 
104
 routes.   
2.8.3 Application of NDs in bioimaging and research technologies 
Artificial induction and enhancement of fluorescing centres have gained much attention over 
years to utilize NDs as biological probes. 
199,
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2.8.3.1 Fluorescence imaging 
This portion of the text is presented in Appendix 10.1 
2.8.3.2 Combined fluorescence and magnetic imaging 
This portion of the text is presented in Appendix 10.1 
2.8.3.3 Scattering imaging 
This portion of the text is presented in Appendix 10.1 
2.8.4 Applications of NDs in therapeutics 
Due to continuous advancements in the knowledge of disease conditions at molecular levels, 
many traditional therapies are now under constant optimizations to treat these diseases at their 
most basic levels. These novel approaches include targeted and controlled drug delivery, gene 
therapy and personalized medicine. Targeted drug and gene therapy appears to be the most 
widely researched approaches especially for various chronic illnesses like cancers. They require 
efficient and biocompatible carriers. NDs due to their innate biocompatibility and extensive 
functionalization opportunities can be utilized to protect and deliver new or conventional 
therapeutic moieties to specific targets in the physiological system (Figure 2.14), rendering ND 
technologies highly desirable for biomolecular and drug delivery applications. 
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Figure 2.12 A schematic diagram representing the binding of detonation nanodiamonds 
with (A) small molecules (B) proteins (C) plasmid DNA and (D) siRNA. Reprinted with 
permission 
84
 from “Copyright (2013) Dove Medical Press” 
2.8.4.1 NDs for small molecule delivery 
This portion of the text is presented in Appendix 10.1 
2.8.4.2 NDs for protein delivery 
This portion of the text is presented in Appendix 10.1 
2.8.4.3 NDs for the delivery of genetic materials 
NDs have attracted great attention as non-viral vectors for gene therapy. For this application NDs 
must possess a cationic surface to bind and carry genetic materials which are anionic in nature.
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Cationic NDs are synthesized through a variety of methods ranging from non-covalent 
functionalization with polymers like polyethyleneimine (PEI) to covalent conjugation of derived 
organic moieties like triethylammonium groups. 
68 
NDs adsorbed with LMW PEIs produce 
higher transfection efficiency and reduced toxicity in comparison to polymer used alone. 
69
 ND-
PEI complex showed a protein expression at four order of magnitude higher compared to naked 
DNA. Cell viability was sufficiently maintained up to 80% after administration of ND-PEI 
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complexes at a concentration of 90 µg/mL, thus reduced the innate cytotoxicity of cationic 
polymers.  
Hydroxylated NDs functionalized inorganic molecules like triethylammonium groups also bind 
and deliver plasmid DNA in the nucleus of cancerous cells, as evidenced qualitatively by the 
induction of fluorescence. The cells treated with free plasmid DNA did not show any 
fluorescence, while the cells treated with the plasmids bound to these functionalized NDs showed 
optimum fluorescence as well as protein expression. 
68
 
Carboxylated NDs, functionalized covalently with 2-bromoisobutyric acid to 
128
 polymerize 
methacrylates on the surface to function as gene delivery vectors and as biolabels to track 
intracellular processes. 
128
 These functional groups gather on the surface to form a cationic brush 
like borders which condense DNA into stable NPs. 
Cationic brushed NDs efficiently transfect the plasmid DNA and produce a gene expression of 
106 -106 RLU/mg of proteins. Different types of methacrylate borders were coated on NDs, all of 
them producing several folds higher transfection efficiency as compared to naked DNA and DNA 
complexed to polyethyleneimine. 
Functionalizing NDs with protonable biomolecules like AAs 
134
 is also a potential approach for 
gene delivery. Covalent immobilization of basic AAs directly on the oxidized ND surface can 
form stable diamoplexes with DNA and RNA, 
134
 and thus are promising as vectors for gene 
therapy. Peptides like poly-L-lysine can also be coated on NDs to create a positively charged 
surface.  
147,
 
148
 Such funtionalization can also facilitate electrostatic binding with genetic 
materials, however limited investigations are done to utilize peptide modified NDs for gene 
delivery.   
2.9 Conclusion 
Innate biocompatibility at micro and macro levels with biological systems, new methods to 
overcome aggregation challenges and novel approaches for specific surface funcionalization have 
greatly introduced NDs as encouraging platform for numerous biomedicinal applications. 
Continual evaluations are still required to understand the surface changes occurring under various 
biological conditions with special focus on newly derived synthetic approaches. Also, more 
research is needed to further elaborate on the cellular interaction of NDs, localization in sub-
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organelle levels, biodistribution after in vivo delivery and consequences of long term residence in 
biological system. This information will encourage development of more sophisticated nano-
delivery systems with better control and accurate predictions that will improve modern medicine. 
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3 Hypothesis and Research Objectives 
 
From the previous chapters it is evident that NDs are an emerging class of nanomaterials for 
biological applications. It provides numerous advantages as delivery vectors; but with a major 
challenge of achieving stable dosing dispersion due to aggregation. With an aim to overcome this 
barrier and to further enhance the ND based gene delivery approach, I put forward the hypotheses 
and research objectives of my study. 
3.1 Hypotheses 
 Detonation NDs functionalized with lysine, histidine alone or in combination will facilitate in 
limiting aggregation leading to the formation of a stable colloidal dispersion. 
 The amino acid functionalized NDs will form diamoplexes capable of delivering therapeutic 
genes safely into mammalian cells. Additionally, lysyl-histidine functionalized NDs will present 
a gene delivery vehicle capable of escaping endosomal degradation to increase the transfection 
efficiency of the system. 
3.2 Research Objectives 
I. To functionalize NDs with amino acid (AA) conjugates. 
 To optimize the covalent attachment process for lysine functionalized NDs. 
 To introduce histidine as a pH sensitive molecule covalently linked with lysine AAs on ND 
surface to facilitate endosomal escape of the diamoplexes. 
 To characterize & evaluate degree of functionalization for lys-NDs & lysyl-histidine-NDs. 
II. To evaluate the physicochemical properties of functionalized NDs (fNDs). 
 To determine the changes in the size and the surface characteristics of NDs after functionalization 
 To analyse the stability of fNDs in various biologically relevant media as a function of time. 
 To select the most suitable medium for the design of fNDs formulations capable of maintaining 
dispersion stability for in vitro experiments.  
III. To evaluate the functional efficiency of AA-fNDs as novel gene delivery vector. 
 To complex fNDs with nucleic acids and to evaluate their binding efficacies with genetic 
materials  
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 To perform physical characterization of the resulting diamoplex. 
 To monitor the internalization of bare fNDs and diamoplexes in HeLa cells (cervical cancer 
cells). 
 To evaluate the efficiency of the diamoplex to transfect functionally active siRNA within 
GFP/HeLa cells for expression. 
 To evaluate in vitro toxicity of fNDs as gene delivery vector within HeLa cells. 
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4 Lysine and Lysyl-Histidine Functionalized Nanodiamonds: 
Synthesis and Physicochemical Characterizations 
Saniya Alwani, Jackson M Chitanda, Ferenc Borondics, Ildiko Badea 
4.1 Author’s Contributions 
Saniya Alwani 
 Conducted the synthesis of lysine NDs in its entirety under the guidance of Dr. Jackson M 
Chitanda and using the protocol published in: 
“Kaur R, Chitanda JM, Michel D, Maley J, Borondics F, Yang P, Verrall RE, Badea 
l, Lysine functionalized nano diamonds: synthesis, physiochemical characterization 
and nucleic acid binding studies. Int J Nanomed 2012, 7, 3851–3866” 
 Developed the method and conducted synthesis of lysyl-histidine NDs in its entirety 
under the guidance of Dr. Jackson M. Chitanda. 
 Performed all physicochemical characterizations reported in the text except 
thermogravimetry and Infrared spectroscopy. 
Dr. Jackson M Chitanda 
 Provided guidance and supervision for the synthesis of functionalized NDs. 
 Assisted in the interpretation of 1HNMR results. 
 Performed thermogravimetric analysis of functionalized NDs. 
Dr. Ferenc Borondics 
 Performed infrared spectroscopic analysis of lysine and lysyl-histidine NDs and amino 
acid conjugates. 
Dr. Ildiko Badea 
 Supervised the entire work. 
 Assisted in the revision and editing of the text in the chapter. 
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4.2 Abstract 
Nanodiamonds present an innately reactive surface with different functional groups to facilitate 
chemical modification suited for therapeutic application. In this chapter, covalent conjugation of 
lysine and lysyl-histidine with NDs is presented. It is important to homogenize the functional 
groups on the surface to confer predictable conjugation of chemical moieties during 
functionalization. Homogenization of the surface is achieved by pre-treating the NDs either 
through oxidation or reduction. Suitable synthetic chemical reaction is designed according to the 
functional groups on the conjugate to achieve functionalization. Since carboxylic acid groups 
were required on the surface to facilitate amide bond formation with three carbon chain linker (1, 
3 diaminopropane), oxidation with strong mineral acids was performed to homogenize the 
surface during pre-treatment.  Lysine and lysyl-histidine amino acid (AA) conjugates with 1, 3 
diaminopropane were synthesized separately using peptide chemistry. 
1
HNMR and mass 
spectrometry was used at all steps of the conjugate synthesis to confirm the presence of the 
desired compound and identify the product impurities. These AA conjugates were then covalently 
attached to NDs after converting the surface carboxylic acids into acyl chloride groups to 
increase reactivity. Functionalization of lysine on the surface of NDs was evident through 
infrared spectroscopy, thermogravimetry, size and zeta potential measurements. However, lysyl-
histidine functionalization was limited and the surface loading of this conjugate on NDs was very 
low. Lys-NDs also showed optimum binding with pDNA and siRNA at minimum ratios of 1:1 
and 1:20 (pDNA/siRNA:ND) respectively. Due to the lack of positive surface charges lysyl-
histidne NDs were not able to bind pDNA and siRNA even at high weight ratios.   
4.3 Introduction 
Lysine functionalization of NDs was performed with two aims: 1) to confer surface homogeneity 
that can minimize aggregation by allowing repulsive forces to dominate in the colloidal 
dispersion and 2) to induce a primary amine (NH3
+
) onto the surface of ND to electrostatically 
bind genetic materials for cellular delivery. Histidine was introduced in the system as a pH-
sensitive AA to allow endosomal destabilization and the release the gene in the cytosol, avoiding 
lysosomal degradation. However, optimum surface loading of lysyl-histidine on NDs was not 
achieved which demand further optimization of synthetic approach used for functionalization. 
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4.4 Materials and methods 
4.4.1 Materials 
Dry dimethylformamide (DMF), 4 M hydrochloric acid (HCl) (in dioxane) and ethidium bromide 
solution (∼1% in water) were obtained from Sigma-Aldrich (Oakville, ON, Canada). Boc-
lysine(boc)-OH, fmoc-NH(CH2)3NH2⋅HCl, Nα-fmoc-Nε-boc-L-lysine, Z-1, 3-
diaminopropane·HCl, Nα,Nim-bis-boc-L-histidine-N-hydroxysuccimideester, 
diisopropylethylamine (DIPEA), piperidine, and HATU [N,N,N′,N′-tetramethyl-O-(7-
azabenzotriazol-1-yl)uroniumhexafluorophosphate] were obtained from Chem-Impex 
International, Inc (Wood Dale, IL). Dichloromethane (DCM) (high-performance liquid 
chromatography grade) was purchased from Thermo Fisher Scientific (Waltham, MA) and was 
dried using a solvent purification system (MBraun Incorporated, Stratham, NH). Thionyl chloride 
was acquired from Alfa Aesar (Ward Hill, MA). Molecular porous cellulose membrane (MWCO: 
6000-8000) was obtained from Spectra/Por®. 
4.4.2 Functionalization of NDs 
Standard Schlenk technique was used to maintain all the reaction steps under inert nitrogen 
environment. Ultrasonication was applied in certain steps using a bath sonicator to maintain 
dispersion and improve the reaction possibilities on the surface of individual nanosized particles. 
Scheme 1 and 2 describes the schematic illustration for synthesis of lysine and lysyl-histidine 
NDs 
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Scheme 1 Preparation of lysine-NDs in the presence of diaminopropane as a three carbon 
chain linker: (A) Synthesis of N’- (Nα,Nε-bis-boc-lysyl)-N”-fmoc-diaminopropane; (B) Fmoc 
deprotection from N’ (Nα,Nε-bis-boc-lysyl)-N”-fmoc-diaminopropane; (C) Reoxidation of 
pNDs (D) Acid chlorination of rNDs (E) Attaching fmoc deprotected N’(Nα,Nε-bis-boc-
lysyl)-N’’-diaminopropane to acyl chloride fNDs (F) Boc deprotection from lysine-NDs 
 
50 
 
 
 
Scheme 2 Preparation of lysyl-histidine-NDs in the presence of diaminopropane as three 
carbon chain linker: 
(A) Synthesis of N’-(Nα-fmoc- Nɛ- boc-lysyl)-N’’-cbz-diaminopropane; (B) Fmoc 
deprotection from N’-(Nα-fmoc- Nɛ- boc-lysyl)-N’’-cbz-diaminopropane; (C) Attachment of 
Nα-Nim-bis-boc histidine to fmoc deprotected N’-(Nα- Nɛ- boc-lysyl)-N’’-cbz-
diaminopropane; (D) Cbz deprotection from N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-
lysyl)-N’’-cbz-diaminopropane; (E) Attaching Cbz deprotected N’-(Nα-(Nα-Nim-bis-boc 
histidine) Nɛ- boc-lysyl)-N’’-diaminopropane to acyl chloride fNDs; (F) Boc deprotection 
from lysyl-histidine-NDs 
4.4.2.1 Reoxidation of NDs 
Pristine NDs (pNDs) (150 mg) were added in a dry Schlenk flask with YTZ grinding media (200 
mg). A mixture of concentrated H2SO4 and HNO3 (3:1 v/v) was added in the reaction flask in a 
volume sufficient to cover the pNDs. The reaction mixture was ultrasonicated at 25 kHz (without 
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heating) for 12 hours followed by overnight reflux under inert nitrogen environment using oil 
bath. To ensure the completion of the reaction, the mixture was again ultrasonicated for one hour 
and was finally refluxed for two hours. 
In order to remove the unreacted acid content from the reoxidized NDs (rNDs), dialysis was 
performed using cellulose membrane (cut off MWCO: 6-8,000), deionized Millipore water (pH 
~7) as external bath and diluting the reaction mixture up to 5% with deionized water. The dialysis 
was continued until the pH of the reaction mixture and the external bath was no more acidic and 
came close to the pH of deionized water. The process of dialysis was terminated upon obtaining 
an equilibrium between internal and external dialysis environments. 
4.4.2.2 Acid chlorination of rNDs 
Reoxidized NDs (rNDs) (150 mg) were added in a dry Schlenk flask maintained under nitrogen 
atmosphere along with YTZ grinding media (200 mg). Thionyl chloride (10 mL) was added in 
the reaction flask. Thionyl chloride itself acted as a solvent. The reaction mixture was 
ultrasonicated at 25 kHz without heating for 4 hours. Ultrasonication was followed by refluxing 
of the reaction mixture for 18 hours using an oil bath. During reflux the temperature of the oil 
bath was maintained at 100 ᵒC. To ensure the completion of the reaction, the mixture was 
resonicated for 2 hours and refluxed for 3 hours.  
An excess of thionyl chloride was pumped off using high vacuum pump/ Schlenk line technique. 
Exposure to moisture or air was avoided at all times during and after the reaction to maintain the 
stability of acyl chloride functional groups.  
4.4.2.3 Preparation of functional moieties: Lysine 
4.4.2.3.1 Step 1: Synthesis of N’- (Nα, Nε-Bis-Boc-Lysyl)-N”-fmoc-diaminopropane 
(conjugation of lysine with the linker) 
Nα, Nε-bis-boc-lysine-OH (8.661 mmoles) was dissolved in dry DMF (10 mL) in Schlenk flask 
maintained under nitrogen atmosphere. This dissolution was followed by addition of HATU and 
DIPEA. HATU was added at a mole ratio of 1:1.25 (lysine: HATU) while DIPEA was added in 
mole ratio of 1:1.7 (HATU: DIPEA). The mixture was stirred for 15 minutes, after which fmoc-1, 
3-diaminopropane hydrochloride was added in the reaction mixture in mole ratio of 1:1.15 
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(Lysine: linker). Dry DMF (15 mL) was added to ensure complete dissolution of all the starting 
materials. The reaction was kept under constant stirring for 20 hours after which DMF was 
removed under high vacuum from the reaction mixture by rota vapour. The solid was then 
dissolved in DCM (100 mL) and extracted using saturated aqueous solution of sodium 
bicarbonate (3x 100 mL). The purified organic phase obtained as a result of extraction was dried 
by the addition of sodium sulphate, followed by vacuum filtration to remove the hydrated sodium 
sulphate from the organic phase. DCM was removed under high vacuum and the obtained solid 
was washed with excess ether. The precipitates obtained as a result of ether washing were filtered 
under vacuum and subjected to solvent evaporation under vacuum to produce the desired 
compound which appeared as light yellow powder.  
The percentage yield of N’- (Nα, Nε-bis-boc-lysyl)-N”-fmoc-diaminopropane was 79 %.  
4.4.2.3.2 Step 2: Fmoc deprotection from N’ (Nα, Nε-bis-boc-lysyl)-N”-fmoc-
diaminopropane 
The removal of fmoc protecting group of N’ (Nα,Nε-bis-boc-lysyl)-N”-fmoc-diaminopropane 
(5.773  mmoles) was done by dissolving it in 50% dry DCM/piperidine (v/v, 12 mL) mixture 
under nitrogen atmosphere in the Schlenk flask. The reaction was kept overnight. The precipitates 
observed in the reaction mixture at the end of the reaction were filtered and dried DCM was 
removed under high vacuum. Excess quantity of hexanes was added to the dry compound and 
allowed to stand for 15 minutes. The hexane-soluble portion was decanted to separate hexane-
insoluble precipitates of the desired compound. The precipitates were washed with fresh portion 
of hexane (3x100 mL) and filtered to obtain purified desired compound. The clean precipitate 
was subjected to solvent evaporation to obtain dry compound.  
The percentage yield of fmoc deprotected N’ (Nα, Nε-bis-boc-lysyl)-N’’-diaminopropane was 
48.1%. 
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4.4.2.4 Preparation of functional moieties: Lysyl-histidine 
4.4.2.4.1 Step 1: Synthesis of N’-(Nα-fmoc- Nɛ- boc-lysyl)-N’’-cbz-diaminopropane 
(conjugation of lysine with the linker) 
Nα-fmoc- Nɛ- boc-lysyl (8.661 mmoles) was dissolved in 15 mL of dry DMF, followed by the 
addition of HATU (10.82 mmoles) and DIPEA (17.97 mmoles) maintained under nitrogen 
atmosphere in the Schlenk flask. The reaction mixture was stirred for 15 minutes.  
Cbz-diaminopropane (9.925 mmoles) was dissolved in 10 mL of dry DMF and DIPEA (10.92 
mmoles) was added into it. The solution of cbz-diaminopropane was added to the reaction 
mixture. The reaction was kept under constant stirring overnight. After completion of the 
reaction, DMF was removed under vacuum and a solid white compound was dissolved in 100 mL 
of DCM. Vortexing was done to ensure complete dissolution. The compound was extracted using 
a saturated solution of sodium bicarbonate (3x 100 mL), dried with sodium sulphate and filtered 
under vacuum. The obtained purified organic phase was subjected to solvent evaporation under 
vacuum. The solid compound was redissolved in a minimum amount of DCM and washed with 
excess ether. The precipitates obtained as a result of ether washing were filtered and dried under 
vacuum to produce desired compound which appeared as white powder. 
The percentage yield of N’-(Nα-fmoc- Nɛ- boc-lysyl)-N’’-cbz-diaminopropane was 71 % 
4.4.2.4.2 Step 2: Fmoc deprotection of N’-(Nα-fmoc- Nɛ- boc-lysyl)-N’’-cbz-
diaminopropane: 
N’-(Nα-fmoc- Nɛ- boc-lysyl)-N’’-cbz-diaminopropane (6.1173 mmoles) was dissolved in 50% 
dry DCM (10 mL) and 50% piperidine (10 mL) under nitrogen atmosphere in the Schlenk flask. 
The reaction was monitored for completion by TLC. The reaction was completed in two hours. 
After completion, excess acetone was added to the reaction mixture. Upon standing, white 
crystalline precipitate of piperidine by-product was formed in the mixture which was filtered 
under vacuum. Solvent evaporation was performed to obtain dry compound. The compound was 
redissolved in minimum amount of DCM and washed with excess hexane. The hexane insoluble 
portion was separated and subjected to solvent evaporation producing yellowish oil as the desired 
compound.  
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The percentage yield of fmoc deprotected N’-(Nα-Nɛ-boc-lysyl)-N’’-cbz-diaminopropane was 
77.7% 
4.4.2.4.3 Step 3: Attachment of Nα-Nim-bis-boc histidine to fmoc deprotected N’-(Nα- Nɛ- 
boc-lysyl)-N’’-cbz-diaminopropane 
Nα-Nim-bis-boc histidine (2.35 mmoles) was dissolved in 15 mL of dry DMF, followed by 
addition of DIPEA (4.86 mmoles) under the nitrogen atmosphere maintained in the Schelnk 
flask. HATU was not added since histidine was already in the form of an activated ester. Fmoc 
deprotected N’-(Nα- Nɛ- boc-lysyl)-N’’-cbz-diaminopropane (2.35 mmoles) was dissolved in 10 
mL of dry DMF and the solution was added to the reaction mixture. The reaction was kept under 
constant stirring overnight. After completion, DMF was removed under vacuum and the 
compound was dissolved in 100 mL of DCM followed by extraction using saturated sodium 
bicarbonate (3x100 mL) and 10% sodium chloride (1x100 mL). The organic phase was dried 
using sodium sulphate and filtered under vacuum. Purified organic phase was subjected to 
solvent evaporation to obtain dark yellow oil as the desired compound. 
The percentage yield of N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ-boc-lysyl)-N’’-cbz-
diaminopropane was 73.9% 
4.4.2.4.4 Step 4: Cbz deprotection from N’-(Nα-(Nα-Nim-bis-boc-histidine) Nɛ-boc-lysyl)-
N’’-cbz-diaminopropane 
A catalytic amount of palladium on carbon (Pd/C) approx. 50% was suspended in 10 mL of 
methanol under nitrogen environment in the Schlenk flask. N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- 
boc-lysyl)-N’’-cbz-diaminopropane (1.7443 mmoles) was dissolved in 10 mL of methanol and 
the solution was added in the reaction mixture. A hydrogen filled balloon was attached to the 
reaction flask using a syringe connection. Nitrogen supply was stopped to allow hydrogen to flow 
through the reaction mixture. The reaction was kept under constant stirring overnight. After 
completion, filtration was performed to remove palladium. Minute quantities of palladium left in 
the filtrate were removed by refiltration using celite. The clean filtrate was then subjected to 
solvent evaporation to remove methanol under vacuum and white crystalline powder of the 
desired compound was obtained.  
55 
 
The percentage yield of Cbz deprotected N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ-boc-lysyl)-N’’-
diaminopropane was 99% 
4.4.2.5 Conjugation of AA functional moieties with NDs 
Acid chloride NDs (150 mg) were suspended in dry DMF (10 mL) under nitrogen atmosphere 
maintained in the Schlenk flask.  
Fmoc deprotected N’ (Nα,Nε-bis-boc-lysyl)-N’’-diaminopropane (0.772 mmoles) was dissolved 
in dry DMF (5 mL) and air was purged from the solution by bubbling nitrogen through it. The 
solution was added to the reaction mixture under nitrogen. The reaction mixture was sonicated at 
25 kHz for 4 hours and refluxed using oil bath for 20 hours. The temperature was maintained at 
100 ᵒC. After completion, the mixture was again sonicated under same conditions for 2 hours 
followed by reflux for 3 hours. DMF was removed under vacuum and the lys-NDs were 
suspended in methanol for dialysis to remove unattached starting material and by-product 
impurities using cellulose membrane and 90% ethanol as the bath. The ethanol bath was changed 
at regular intervals until all the starting material and by-product impurities were eliminated. 
Cbz deprotected N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-lysyl)-N’’-diaminopropane (0.468 
mmoles) was attached to another set of acyl chloride fNDs (150 mg) by the same procedure to 
prepare lysyl-histidine-NDs.  
4.4.2.6 Boc Deprotection from N’ (Nα, Nε-bis-boc-lysyl)-N’’-diaminopropane fNDs and N’-(Nα-
(Nα-Nim-bis-boc histidine) Nɛ- boc-lysyl)-N’’-diaminopropane fNDs: 
N’ (Nα,Nε-bis-boc-lysyl)-N’’-diaminopropane fNDs and  N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- 
boc-lysyl)-N’’-diaminopropane fNDs were subjected to solvent evaporation to remove methanol. 
The dry fNDs were suspended in 10 mL of DCM in the separate Schlenk flasks maintained under 
nitrogen environment and 10 eq. 4 M HCl (in dioxane) was added into each. The reaction 
mixtures were stirred for 90 minutes and the solvent was pumped off after completion. They were 
then subjected to freeze drying for 3 days to obtain boc deprotected lys-NDs and lysyl-histidine-
NDs. 
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4.4.3 Physicochemical Characterization of fNDs 
4.4.3.1 Nuclear Magnetic Resonance and Mass spectrometric characterization 
Proton Nuclear Magnetic Resonance (1HNMR) spectra were recorded for fmoc deprotected 
N’(Nα,Nε-bis-boc-lysyl)-N’’-diaminopropane and cbz deprotected N’-(Nα-(Nα-Nim-bis-boc 
histidine) Nɛ- boc-lysyl)-N’’-diaminopropane before attaching these AA residues to acyl NDs. 
Chemical shifts for 
1
HNMR are reported in ppm in reference to the residual 
1
H resonances of 
deuterated chloroform (CDCl3) (δ 7.26) which was used as the solvent.  
A mass spectrum was obtained for Cbz deprotected N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-
lysyl)-N’’ diaminopropane to confirm the HNMR result using the QSTAR ® XL MS/MS system 
with electrospray ionization source. 
1
HNMR was also done after all subsequent steps of the synthesis to confirm the formation and 
purity of the resulting compounds.  
4.4.3.2 Infrared Spectroscopy 
Infrared spectra were recorded at Canadian Light Source  (CLS) for pNDs, rNDs, lys-NDs, lysyl-
histidine-NDs and cbz deprotected N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-lysyl)-N’’-
diaminopropane using Bruker IFS 66v/S Fourier transform spectrometer in the mid-IR region 
having a mercury cadmium telluride detector. However, infrared spectra of fmoc deprotected N’ 
(Nα, Nε-bis-boc-lysyl)-N’’-diaminopropane from the previous batch was used for comparison. 
134
 
All samples were measured in solid state as homogenous powder dispersions in potassium 
bromide (KBr) pellets. Absorbance spectra were calculated based on the average of individual 
interferograms for both the background and the sample measurements. Data analysis was 
performed with a Bruker OPUS software package (v6.5, Bruker Optics). 
4.4.3.3 Thermogravimetric Analysis 
Thermogravimetric analysis (TGA) was carried out using TGA Q500 V20.13TGA (TA 
instruments, DE, USA). Samples (ca. 5-10 mg) were heated in a nitrogen atmosphere from 25
o
C 
to 700
o
C at a heating rate of 10
o
C/min, and the % weight loss was obtained as a function of the 
temperature. It was assumed that pNDs primarily have carboxylic acid functional groups on the 
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surface and upon reoxidation most of the remaining functionalities on the surface of pNDs were 
also changed to carboxylic acid functional groups. Based on this assumption, surface loading 
pNDs, rNDs, lys-NDs and lysyl-histidine-NDs were calculated using the following relationship: 
                
                                           
                                                      
 …………………… (Eq 4.1) 
4.4.3.4 Size and Zeta Potential Measurements 
2 mg/mL dispersion of pNDs, rNDs, lys-NDs and lysyl-histidine-NDs were prepared in purified 
water (Millipore, Milford, MA). YTZ grinding media was added to all the ND dispersions. The 
ND dispersions were then subjected to ultrasonication for 4 hours at a frequency of 25 kHz 
without heating. The ultrasonicated dispersions were then centrifuged at 5200 g for 5 minute to 
sediment the YTZ grinding media and the aggregated ND particulates. Particle size distributions 
of aqueous ND dispersions were obtained using Malvern zetasizer Nano ZS instrument (Malvern 
Instruments Ltd, Malvern, Worcestershire, UK). Solvent properties were as follows: refractive 
index = 1.330, dielectric constant = 78.5 and viscosity at 25ᵒC = 0.8872 cP. Using CONTIN 
algorithm, the decay rates as a function of the translational diffusion coefficients of the particles 
‘D’ were analysed. The hydrodynamic radius RH of the particles was then calculated using the 
Stokes-Einstein equation (RH= kT/6πηD), where k = Boltzman constant, T is the temperature (25 
ᵒC), and η = viscosity of water at 25 ᵒC. The calculated particle size is an estimate based on the 
hydrodynamic radius of spherical particles having the translational diffusion coefficient equal to 
the particles in the dispersion. All the size distribution readings were derived from six 
measurements.  Each measurement had a minimum of ten individual runs. The resulting data was 
reported as volume distribution. The size distribution was plotted as a graph to compare the 
polydispersity and the average particle size of four ND dispersions. 
Zeta potential measurements were performed for pNDs, rNDs, lys-NDs and lysyl-histidine-NDs. 
These measurements were based on Doppler electrophoresis and phase analysis. All the reported 
zeta potentials are the average of three measurements. Each measurement had hundred individual 
runs.  
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4.4.4 Binding of fNDs to nucleic acids 
4.4.4.1 Agarose gel electrophoresis 
1% agarose gel was prepared in purified water to determine successful binding of lys-NDs and 
lysyl- histidine-NDs with pDNA. Complexes of lys-NDs and lysyl-histidine-NDs with pDNA 
were prepared by dispersing pDNA and NDs in different weight ratios (NDs: pDNA ranging 
from 1:1 to 1:30) and incubating the dispersions for 30 minutes at room temperature. pDNA 
without fND dispersion was used as the control. The amount of pDNA in each sample was 500 
ng. The samples were loaded in the gel and were subjected to electrophoresis at 100 V for one 
hour using Bio-Rad PowerPac HC electrophoresis apparatus (Bio-Rad Laboratories, Tnc. 
Mississauga, ON, Canada). The gel was then imaged using AlphaImager imaging system (Alpha 
Innotech Corporation, San Leandro, CA) to detect fluorescence.  
Binding of lys-NDs and lysyl-histidine NDs to siRNA was also analysed using 2% agarose gel in 
the same way. 50 µM negative control siRNA (Ambion Inc.) was used as the stock solution of 
siRNA and 2 mg/mL stock solutions of lys-NDs and lysyl-histidine-NDs were used. The amount 
of siRNA in each sample was 500 ng. Complexes of lys-NDs and lysyl-histidine NDs with 
siRNA were prepared by dispersing SiRNA and NDs in different weight ratios (NDs: siRNA 
ranging from 1: 10 to 1: 50) and incubating the dispersions for 30 minutes at room temperature. 
siRNA without fND dispersion was used as the control. Electrophoresis was run for 30 minutes at 
50 V and the samples were analysed similar to the pDNA complexes.  
4.5 Result and discussion 
4.5.1 Synthesis of fNDs 
Lysine and lysyl-histidine conjugates with diaminopropane spacerwere synthesized and were 
covalently bonded to NDs. The NDs were pre-functionalized with acyl chloride groups to 
enhance amide bond formation between the carbonyl group on ND surface and free amine group 
of diaminopropane acting as a linker.  
Completion of reaction of the lysine linked to diaminopropane was evident from the 
1
H NMR 
Spectrum (Figure 4.1). The 
1HNMR spectrum of N’- (Nα,Nε-bis-boc-lysyl)-N”-fmoc-
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diaminopropane was used to confirm the structure: 
1
H NMR (500 MHz, deuterated chloroform 
CDCl3) δ  7.75 (d, 2H, fluorenyl of fmoc protecting group), 7.60 (d, 2H, fluorenyl of fmoc 
protecting group), 7.39 (t, 2H, fluorenyl of fmoc protecting group), 7.30 (t, 2H, fluorenyl of fmoc 
protecting group), 7.26 (s, solvent chloroform), 6.72(s, 1H, NH of amide), 5.47 (s, 1H, NH of 
amide), 5.23 (s,1H, NH of amide), 4.67 (s, 1H, NH of amide), 4.38 (d, 2H CH2 of fluorenyl), 4.20 
(t,1H, CH of the central ring of fluorenyl in fmoc protecting group), 4.03 (s,1H, fluorenyl ring of 
fmoc protecting group), 3.47(q, 1H, CH group of lysine bonded to amide linkage between lysine 
and linker), 3.29 (m, 2H), 3.20 (m, 2H), 3.09 (m, 2H) 1.64-1.9 (m, 4H) and 1.43 ( s,18H boc 
protecting group). However in the 
1
H NMR spectra the peaks in the range of 1.39 to 1.49 
integrates for 24H which may be the combination of a singlet peak of tertiary butyl groups (CH3)6 
of boc and CH2 groups of lysine. The methylene groups of lysine may be at 1.37 integrating for 
2H and at 1.46-1.49 integrating for 2H for the remaining CH2 group. The 
1
H NMR spectra for 
N’- (Nα, Nε-bis-boc-lysyl)-N”-fmoc-diaminopropane integrates for 49H, which is relevantly 
consistent with the compound structure having 48H. Therefore it is evident that the compound is 
intact. The four NH peaks appearing within the range of 4 to 7 indicates four different amide 
linkages, that are two amide linkages on lysine with boc protecting groups, one amide linkage 
between lysine and the linker and one amide linkage between the linker and fmoc protecting 
group. Before attaching the AA conjugate to acyl chloride functionalized NDs, the fmoc 
protecting group attached to the linker (1, 3- diaminopropane) was removed. The 
1
H NMR of N’ 
(Nα,Nε-bis-boc-lysyl)-N’’-diaminopropane (Figure 4.2) shows absence of peaks in aromatic 
region, indicating removal of fmoc from the linker.  
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Figure 4.1 1H NMR spectra for N’- (Nα, Nε-bis-boc-lysyl)-N”-fmoc-diaminopropane at 500 
mHz 
 
Figure 4.2 1H NMR spectra of N’ (Nα,Nε-Bis-Boc-Lysyl)-N’’-Diaminopropane at 500 mHz 
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Synthesis of lysyl-histidine linked to diaminopropane was also analysed by using 
1
H NMR 
(Figure 4.3). The spectrum showed the presence of the compound; however it integrated for more 
protons than expected in the aliphatic region as well as the aromatic region, suggesting an 
impurity of the starting material. Therefore to confirm the presence of compound mass 
spectrometry analysis was performed. Lysyl-histidine linked with diaminopropane was identified 
through the mass spectrum (Figure 4.4) and MS/MS spectrum (Figure 4.5) of N’-(Nα-(Nα-Nim-
bis-boc histidine) Nɛ- boc-lysyl)-N’’-cbz-diaminopropane (C38H59N7O10). Electrospray ionization 
mass spectrometry mass-to-charge ratio calculated for C38H59N7O10: 773.43 [M] and 774.43 
[M+H]
+
, found 774.57 [M+H]
+
. The compound was also confirmed by its distinct fragmentation 
pattern obtained in the MS/MS spectra. The fragmentation spectrum indicates subsequent loss of 
boc protecting groups as indicated in Scheme 3. C33H52N7O8: 674.40 [M+H]
+
 indicates loss of 
boc from imidazole ring of histidine AA, C28H44N7O6: 574.32 [M+H]
+
 indicates subsequent loss 
of boc from terminal amine of lysine AA and C23H36N7O4: 474.24 [M+H]
+
 indicates subsequent 
loss of boc from histidine AA (Figure 4.5).  
 
Figure 4.3 1H NMR of N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-lysyl)-N’’-cbz-
diaminopropane at 500 mHz 
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Figure 4.4 MS spectra of N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-lysyl)-N’’-cbz-
diaminopropane 
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Scheme 3 Probable fragmentation pattern of N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-
lysyl)-N’’-cbz-diaminopropane (C38H59N7O10) 
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Figure 4.5 MS/MS spectra for fragmentation of N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-
lysyl)-N’’-cbz-diaminopropane (C38H59N7O10) 
Before attachment of the AA conjugate to acyl chloride functionalized NDs the carboxybenzyl 
(Cbz) protecting group attached to the linker (1, 3-diaminopropane) was removed. The 
1
H NMR 
spectrum of N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-lysyl)-N’’-diaminopropane (Figure 4.6) 
shows absence of cbz peaks in the aromatic region indicating deprotection. N’- (Nα, Nε-bis-boc-
lysyl)-N”-fmoc-diaminopropane 1HNMR (500 MHz, deuterated chloroform CDCl3) δ 7.26 (s, 
solvent chloroform), 8.01 (d, 1H, imidazole ring of histidine), 7.20 (d, 1H, imidazole ring of 
histidine). The aliphatic region consist of three boc peaks at around 1.59, 1.42 and 1.41 indicating 
the presence of intact compound. However, the aliphatic region of the spectrum shows excess 
number of proton depicting the presence of a possible impurity. Therefore to confirm presence of 
the compound mass spectrometric analysis was performed. The mass spectrum of N’-(Nα-(Nα-
Nim-bis-boc histidine) Nɛ- boc-lysyl)-N’’-diaminopropane (C30H54N7O8) (Figure 4.7) and MS/MS 
spectrum (Figure 4.8) showing particular fragmentation of the compound is an indication of 
deprotection. Electrospray ionization mass spectrometry mass-to-charge ratio calculated for 
C30H54N7O8: 639.395 [M] and 640.395 [M+H]
+
, found 640.41 [M+H]
+
. The compound was also 
confirmed by its distinct fragmentation pattern obtained in the MS/MS spectra. The 
fragmentation spectrum indicates subsequent loss of boc protecting groups as indicated in 
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Scheme 4. C25H46N7O6: 540.40 [M+H]
+
 indicates loss of boc from imidazole ring of histidine 
AA, C20H38N7O4: 440.48 [M+H]
+
 indicates subsequent loss of boc from terminal amine of lysine 
AA and C15H30N7O2: 340.72 [M+H]
+
indicates subsequent loss of boc from histidine AA (Figure 
4.8).  
 
Figure 4.6 1HNMR spectra of N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-lysyl)-N’’-
diaminopropane at 500 mHz 
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Figure 4.7 MS spectra of N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-lysyl)-N’’-
diaminopropane 
 
 
Scheme 4 Probable fragmentation pattern of N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-
lysyl)-N’’-diaminopropane (C30H54N7O8) 
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Figure 4.8 MS/MS spectra of N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-lysyl)-N’’-
diaminopropane (C30H54N7O8) 
4.5.2 Infrared Spectroscopy (IR) 
Lysine and lysyl-histidine functionalization of NDs was confirmed by performing IR of pNDs, 
rNDs, lys-NDs, lysyl-histidine-NDs and N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ-boc-lysyl)-N’’-
diaminopropane (Figure 4.9). NDs possess a fingerprint region in the range of 1000 cm
-1
 to 1500 
cm
-1
 where they show a combination of many overlapping peaks. 
93
 The FTIR spectra of all the 
NDs showed distinct peaks at ~ 1130 cm
-1
 and ~ 1260 cm
-1
 which are the characteristic peaks of 
diamond. 
201
 These peaks represent C-O (stretch) due to vibrations of ether like groups. 
134
 This 
ether like linkages might arise due to inter-particle interaction between carboxylic acids or 
hydroxyl groups on the surface of NDs. 
134
 The peak at ~1650 cm
-1
 which is consistent in the IR 
spectra of all NDs and the AA conjugate corresponds to C=O (stretch) of amide bond and 
carboxylate in fNDs and non-functionalized pNDs and rNDs respectively.  Carboxylate 
functionality is expected to be compromised after functionalization due to the formation of an 
amide linkage between the carbonyl on NDs and amines on the linker.  Unlike rNDs, fNDs do 
not show the broad peak at ~3400 cm
-1 
corresponding to O-H (stretch) of carboxylate 
functionality further confirming the functionalization. The absence of a sharp O-H (stretch) peak 
in pNDs indicates the completion of reoxidation process where most of the functionalities are 
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converted to carboxylic acid. The presence of peaks for N-H (stretch) at ~ 3000 cm
-1
 and N-H 
(bend) at ~1490 cm
-1
 in the spectra of AA conjugate, lysine NDs and lysyl-histidine NDs 
indicates the presence of amide linkages. These peaks are absent for pNDs and rNDs, thereby 
suggesting successful functionalization.  
Primary amines are identified by two N-H (stretch) bands in the region of ~3000 to 3500 cm
-1
: 
one due to symmetric stretching, the other due to asymmetric stretching. Presence of another 
pronounced peak of N-H (stretch) at ~3090 cm
-1
 in lys-NDs IR spectra indicates the presence of 
more primary amines as compared to lysyl-histidine-NDs in which one primary amine is lost due 
to histidine attachment. Therefore, the IR spectrum for lysyl-histidine NDs shows a very weak 
signal for another N-H (stretch) in this region.  The presence of a peak for C-N (stretch) at ~1080 
cm
-1
 in the spectra for lys-NDs and lysyl-histidine-NDs further confirms the presence of amines 
on their surface. These peaks are absent in pNDs and rNDs, therefore they indicate successful 
functionalization. Peaks for H-C-H (stretch) at ~2900 cm
-1
 and H-C-H (bend) at  ~1400 cm
-1
 in 
the spectra of AA conjugates, lys-NDs and lysyl-histidine-ND indicates the presence of aliphatic 
CH2 groups of AA on the ND surface. 
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Figure 4.9 Infra-red spectra of pNDs, rNDs, lysine-NDs, lysyl-histidine-NDs and AA 
conjugate (N’-(Nα-(Nα-Nim-bis-boc histidine) Nɛ- boc-lysyl)-N’’-diaminopropane) Infrared 
spectra for N’ (Nα,Nε-bis-boc-lysyl)-N’’-diaminopropane was referenced from 
134
 and hence not 
shown above. 
4.5.3 Thermogravimetric Analysis (TGA) 
Surface functionalization of NDs is also shown by TGA (Figure 4.10). The thermograms of 
pNDs and rNDs did not show considerable weight loss in the range of 100-500ᵒC depicting lack 
of functional groups which may be labile in the specific temperature range.  It is reported that 
CO2 yielding complexes like carboxylic acids, anhydrides and lactones start to decompose at 500 
K (227 ᵒC) with maximum desorption occurring at 600 K (327 ᵒC) and 900 K (627 ᵒC). 202,203 The 
thermogram of rNDs shows an increased weight loss in this range as compared to pNDs which 
illustrates more abundance of COOH groups on ND surface as a result of reoxidation. 
Thermograms of lys-NDs and lysyl-histidine-NDs show a sharp weight loss from 150 ᵒC to 700 
ᵒC illustrating the loss of AA functional groups which is an evidence of surface functionalization. 
It should be noted that weight loss for fNDs is reported at high temperatures (200 ᵒC to 700 ᵒC) 
which indicates covalent nature of surface functionalization. 
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Surface loading of functional groups onto the NDs was calculated from the respective 
thermograms (Table 4.1). The surface loading of carboxylic acid (COOH) groups  on pNDs and 
rNDs was estimated to be 1.0 and 1.74 mmoles/g respectively, while the surface loading of lysine 
AA conjugated with 1, 3-diaminopropane on lys-NDs was higher being 1.97 mmoles/g. However 
surface loading of lysine and histidine AA conjugated with 1, 3-diaminopropane on lysyl-
histidine-NDs was estimated to be only 0.55 mmols/g. The surface loading for rNDs is 
significantly higher as compared to pNDs, which indicates that reoxidation step was successful in 
increasing the number of COOH groups onto the NDs surface. Moreover, the surface loading of 
COOH groups on rNDs is very close to the surface loading of lysine conjugate functionalities on 
lys-NDs, which indicates that the process of functionalization was capable of converting most of 
the COOH groups on the rND surface. The low surface loading for lysyl-histidine-NDs may be 
explained by the large surface area covered by this AA conjugate that may create stearic 
hindrance for adjacent COOH groups to be functionalized. Alteration in the spacer length or the 
design sequence for attaching histidine moiety can possibly counter the stearic hindrance 
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allowing complete surface functionalization. This design modification is further discussed later in 
the thesis.   
 
Figure 4.10 Thermograms of pNDs, rNDs, lys-NDs and lysyl-histidine NDs 
Thermogram of lysine NDs shows the highest % weight loss followed by lysyl-histidine NDs, 
rNDs and pNDs 
Type of NDs Surface Loading (mmols/g)  
   
pNDs 1.0  
   
rNDs 1.74  
   
lys-NDs 1.97  
   
lysyl-his NDs 0.55  
Table 4.1 Surface Loading of NDs as calculated from respective thermograms 
Weight loss below 115 ᵒC is excluded considering it due to water loss from the samples 
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4.5.4 Particle size distribution of NDs 
Size of the NP system is an important characteristic in gene delivery as the kinetics of cellular 
uptake and saturation concentration varies with NP size. 
204
 NP size is also crucial to enhance 
therapeutic effects and to control toxicity. 
205
 Moreover, polydispersity of NP system affects their 
behaviour inside the cell and therefore has to be critically controlled. NP gene delivery systems 
should have uniform sized particle dispersion in order to obtain a predictable response. 
204
 NPs 
within 2-100 nm size range can alter signaling processes essential for basic cell function. 
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Therefore, particle size and polydispersity were measured for all functionalized NDs. The 
pristine NDs (pNDs) exhibit wide size distribution, with two major peaks obtained at 68.55 
(30%) and 15 nm (14%) (Figure 4.11). The polydispersity index is high (0.244) (Table 4.2). This 
may be explained due to non-uniformity of functional groups present on the surface of pNDS. 
Reoxidized NDs (rNDs) show considerable reduction in size variability. The process of re-
oxidation creates uniform sized NDs majority centered around 79 nm (Figure 4.11); due to the 
conversion of majority of functionalities on NDs surface to COOH. However, the rNDs system 
also contains aggregated NDs in 106-190nm size range (Table 4.2). Lys-NDs show a sharp peak 
at 50.8 nm (Figure 4.11), depicting that lysine functionalization was able to create highly 
uniform ND dispersions having most of the particles possessing a desirable size of approximately 
50 nm. 
179
 Lys-NDs system show minimum amount of aggregated particles in 106-190 nm size 
range (Table 4.2). On the contrary, lysyl-histidine-NDs were found to form a polydispersed 
system (0.419) (Table 4.2) with wider particle size distribution centered in the range of 615-955 
nm (Figure 4.11). This may be a result of uneven functionalization. 
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Figure 4.11 Size distribution curves for pNDs (blue), rNDs (red), lysine NDs (green) and 
lysyl histidine NDs (purple) 
Each size distribution curve is measured by dynamic light scattering and is derived from three 
measurements with 10 individual runs 
Type of 
NDs 
Particle Size 
range (nm) 
Mean volume 
% 
Polydispersity 
Index (PDI) 
pNDs 10-24 
38-91 
106-190 
28% 
54.5% 
15.5% 
 
0.244 
rNDs 44-51 
59-91 
106-190 
7 % 
50% 
35.5% 
0.145 
Lys-NDs 33-91 
106-190 
89 % 
10% 
0.142 
Lysyl-his 
NDs 
295-531 
615-955 
1106-1484 
32% 
47 % 
13% 
0.419 
Table 4.2 Particle size distribution and polydispesity of pNDs, rNDs, lysine NDs and lysyl-
histidine NDs 
Each size distribution data indicates mean of three measurements with 10 individual runs 
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4.5.5 Zeta potential of NDs 
Charges possessed by a particle also play a vital role in NP-cell interaction. 
204
 It has been 
reported that cationic particles can bind to negatively charged cell membrane, 
207
 and can easily 
translocate across the cell membrane. Moreover, cationic NPs are used as primary gene delivery 
systems, since they possess positive ionic groups to bind with the negatively charged genetic 
material. Therefore, zeta potentials were measured for all four types of NDs to obtain a 
comprehensive view of surface charges. pNDs and rNDs showed a highly negative zeta potential 
of -54.6 mV and -32.2 mV, respectively, while lysyl-NDs show a positive zeta potential of +26.3 
mV (Figure 4.12). The positive zeta potential of lys-NDs indicates the dominance of positively 
charged amine groups on the surface which in turn may lead to high binding capacity with 
genetic material and higher interaction with negatively charged cell membrane. Lysyl-histidine-
NDs also showed a positive zeta potential of +2.65 mV (Figure 4.12) indicating that fewer 
positively charged amine groups are present on the surface compared to lysyl-NDs. 
 
 
Figure 4.12 Comparison of zeta potentials of NDs before and after functionalization 
   Each value represents the mean ± standard deviation of three measurements with 100            
individual runs 
-60 
-50 
-40 
-30 
-20 
-10 
0 
10 
20 
30 
40 
Ze
ta
 p
o
te
n
ti
al
 (
m
V
) 
Type of NDs 
Pristine NDs 
Reoxidized NDs 
Lysine NDs 
Lysine Histidine 
NDs 
74 
 
4.5.6 Binding of fNDs with pDNA and siRNA 
In order to act as an efficient nucleic acid delivery vehicle, lys-NDs and lysyl-histidine-NDs 
should be capable of binding the genetic material to a degree that enables the transfer of nucleic 
acid inside the cell and release them near the cell nucleus. 
208
 To analyse the nucleic acid binding 
capacity of fNDs, gel electrophoresis was performed for fNDs: pDNA complexes (Figure 4.13) 
and fNDs : siRNA (Figure 4.14) complexes. Results for fNDS: pDNA show a visible band for 
naked pDNA. Lys-NDs: pDNA complexes ranging from ratio 1:1 to 1:30 show no visible band 
for pDNA, which indicates that lys-NDs are capable of binding to pDNA and prevent migration, 
even at minimum ratio of 1:1. However, the lysyl-histidine-NDs: pDNA complexes ranging from 
1:1 to 1:30 show a visible band for pDNA, which indicate that lysyl-histidine-NDs are not 
capable to bind the pDNA even in high ratios. This can be explained due to low positive surface 
charge of lysyl-histidine NDs as explained earlier.  
 
Figure 4.13 Binding of lysine-NDs and lysyl-histidine NDs with pDNA 
Result of agarose gel electrophoresis for lysine NDs/lysyl histidine NDs-plasmid DNA with 
increasing weight ratios of fNDs to pDNA 
Results for fNDS: siRNA show a visible band for naked siRNA. Lys-NDs: siRNA complexes 
show a light band at 1:10 ratio, which indicates a weak binding of lys-NDs with SiRNA at this 
ratio. However, lys-NDs: siRNA complexes ranging from ratio 1:20 to 1:50 show no visible band 
for siRNA, which indicates that lys-NDs are capable of binding to siRNA completely at a weight 
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ratio of minimum 1:20. The lysyl-histidine-NDs: siRNA complexes ranging from 1:10 to 1:50 
behaved similarly to lysyl-histidine-NDs: DNA complexes, showing a visible band for siRNA, 
which indicate that lysyl-histidine-NDs are not capable to bind siRNA even in high ratios. This 
can be explained due to low positive surface charge of lysyl-histidine NDs as explained earlier. 
 
Figure 4.14 Binding of lysine-NDs and lysyl-histidine NDs with SiRNA 
Result of agarose gel electrophoresis for lysine NDs/lysyl histidine NDs-small interfering RNA 
with increasing weight ratios of fNDs to siRNA 
4.6 Conclusion 
NDs were successfully functionalized with lysine with a high surface loading capable of creating 
a cationic surface. Lysine functionalization was also able to limit aggregation and produced 
uniform sized ND particulates to generate stable dispersion in aqueous medium. However, lysyl-
histidine functionalization was limited and very low surface loading was obtained. An altered 
synthetic approach is designed to synthesize lysyl-histidine NDs with an aim to limit stearic 
hindrance and increase the surface loading of this AA conjugate. Details of this approach are 
summarized under the heading of conclusions and future directions.  
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5.2 Abstract 
Purpose: Nanodiamonds (NDs) are emerging as an attractive tool for gene therapeutics. To reach 
their full potential for biological application, NDs should maintain their colloidal stability in 
biological milieu. This study describes the behavior of lysine-functionalized ND (lys-ND) in 
different dispersion conditions with an aim to limit aggregation and improve the colloidal 
stability of ND-gene complexes called diamoplexes. Furthermore, cellular and macromolecular 
interactions of lys-NDs are also analysed in vitro to establish understanding of ND mediated gene 
transfer in cells.  
Methods: Lys-NDs were synthesized earlier through covalent conjugation of lysine AA to 
carboxylated NDs surface generated through re-oxidation in strong oxidizing acids. Here, 
dispersions of lys-NDs were prepared in various media and the degree of sedimentation was 
monitored for 72 hours. Particle size distributions and zeta potential measurements were 
performed for a period of 25 days to characterize the physicochemical stability of lys-NDs in the 
medium. The interaction profile of lys-NDs with fetal bovine serum (FBS) showed formation of a 
protein corona which was evaluated by size and charge distribution measurements. Uptake of lys-
NDs in cervical cancer cells was analyzed by scanning transmission X-ray microscopy, flow 
cytometry and confocal microscopy. Cellular uptake of diamoplexes (complex of lys-NDs with 
small interfering RNA) was also analyzed using flow cytometry.   
Results: Aqueous dispersion of lys-NDs showed minimum sedimentation and remained stable 
over a period of 25 days. Size distributions showed good stability, remaining under 100 nm 
throughout the testing period. A positive zeta potential of over +20 mV indicated a preservation 
of surface charges. Size distribution and zeta potential changed for lys-NDs after incubation with 
blood serum suggesting an interaction with biomolecules, mainly proteins and a possible 
formation of a protein corona.  Cellular internalization of lys-NDs was confirmed by various 
techniques such as confocal microscopy, soft x-ray spectroscopy and flow cytometry.   
Conclusion: This study establishes that dispersion of lys-NDs in aqueous medium maintains 
long-term stability, and also provides an understanding that lysine functionalization enables NDs 
to interact effectively with the biological system to be used for RNAi therapeutics.   
Keywords: colloidal stability, particle size, zeta potential, protein corona, diamoplex, 
microscopy, flow cytometry  
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5.3 Introduction 
Diamond nanoparticles, also called nanodiamonds (NDs) exhibit unique thermal, mechanical and 
optoelectronic properties. In recent years much attention has focused towards utilizing NDs for 
biomedical applications. The key feature that makes their utilization so attractive in therapeutics 
is their innate biocompatible nature at cellular 
71,72 
and organ levels. 
197
 NDs are the most 
biocompatible member of the carbon nano family 
71
 and show no structural damage, such as 
fragmentation of the genetic materials, 
37
 and thus can act as efficient gene carriers. Despite 
several favourable characteristics, the major challenge associated with utilizing NDs for 
biological applications is the high degree of aggregation, which leads to the formation of 
extremely tight structures of 100 to 200 nm in size. 
209 
Unlike other carbon nanomaterials, NDs 
possess a functionalized surface as a result of its synthesis method. The functional groups present 
on detonation NDs can facilitate aggregation through Van der Waals interactions or hydrogen 
bonding between adjacent ND crystals. 
210, 211, 16
 However, the major cause of aggregation is the 
graphitic soot formed around the NDs as a result of the detonation process which creates core 
aggregates. 
85
 These aggregates give rise to several complications in terms of formulation, 
colloidal stability and cellular uptake. Several physical methods, such as micro bead, sugar or salt 
assisted stirred media milling have employed to limit aggregation and to produce stable, well-
dispersed ND formulations. 
123, 127
  
To control aggregation and ensure long term stability of ND dispersions, chemical modification 
of the surface can be utilized. 
212, 140, 138
 Rational functionalization of ND surfaces with different 
moieties to serve multiple purposes is a relatively new approach. For example, functional groups 
can be grafted to simultaneously counter aggregation and facilitate binding with small chemical 
molecules or biomolecules with a purpose to serve as drug, protein and gene carriers. 
212,
 
134,
 
213  
Utilizing NDs and other carbon nanomaterials for gene delivery is of high interest nowadays due 
to the advantages of DNA or siRNA based therapeutics targeted towards malignant forms of 
cancer and viral infections like HIV. 
214, 215, 216 
In order to synthesize ND based gene carriers, the 
aim is to generate a cationic surface which can electrostatically interact with anionic genetic 
materials. 
128, 217
 Such examples are non-covalent functionalization with polymers like 
polyethyleneimine (PEI) 
69
 and covalent conjugation of derived organic moieties like 
triethylammonium groups. 
68
 Introducing protonable biomolecules, including amino acids (AAs), 
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peptides and proteins on the ND surface is a novel approach for functionalization. Its first 
application was centered on a physical adsorption, such as coating the ND surface with poly-L-
lysine, a polypeptide frequently used as carrier for genetic materials. 
147
 The coating occurs 
through non-covalent adsorption of chemicals on the nanoparticle surface through electrostatic 
interactions and van der Waals forces. It is easy to achieve but may lead to desorption and 
competitive displacement of active moieties in complex biological environment, thus 
compromising the long-term stability of the system. 
218
 To overcome this deficiency, covalent 
conjugation could permanently immobilize the molecules of interest on the surface and create a 
controlled and relatively stable functionalized system. 
142
 We demonstrated for the first time that 
covalent immobilization of basic AAs mainly lysine directly on the ND surface can form 
diamoplexes with DNA and siRNA and can be used for gene delivery purposes. 
134
 Lysine 
functionalization imparts a primary amine rich cationic surface that is capable of binding anionic 
genetic material and proteins. This concept is modeled on the natural DNA wrapping in the 
eukaryotic cells by histone proteins, rich in lysine and arginine AAs forming salt bridges. 
156
 
Positive charges on the surface can also aid in cellular uptake through electrostatic interaction 
with the acidic residues on the mammalian cell membrane.  Surface functionalization of NDs 
with lysine AA conjugates is evident through various complimentary techniques reported in our 
previous publication. 
134
 
Previously, we reported that lysine functionalization induced homogeneity of the surface limiting 
aggregation of NDs in aqueous environment for a short period of time. 
134 
Here, we expand the 
stability assessment of lysine-functionalized NDs (lys-NDs) in biologically relevant media to an 
extended time period of 25 days.
 
Moreover, the interaction of lys-NDs with serum proteins was 
also investigated.  
Interaction of (nanoparticles) NPs with physiological proteins is an extensive area of research, 
since their random adsorption on NP surfaces can alter formulation properties and carrier stability 
profiles. 
185, 219, 220
 A protein adsorption layer (protein corona) can rapidly evolve as a result of 
nanoparticle interacting with biological fluids and is a critical issue as it can affect the fate of 
NPs. 
221, 222, 183, 184
 Several studies have shown that formation of a protein corona hinders cellular 
uptake of the gene delivery NPs, leading to diminished biological activity. 
183, 223
 However, 
recently it has been observed that serum can serve as a dispersant for carbon nanomaterials, 
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without compromising the cellular uptake. 
224
 For example, serum albumin can facilitate cellular 
uptake of carbon nanotubes in white blood cells. 
189
 Therefore, understanding the effect of a 
protein corona on cellular uptake of lys-NDs is a prerequisite for their therapeutic evaluation. 
 
Lastly, cellular uptake of lys-NDs and the diamoplexes was also investigated in the study. NDs, 
like many other carbon nanomaterials, commonly follow an energy-dependent clathrin mediated 
endocytosis pathway for internalization in mammalian cells. 
148, 173
 However, the pathway and 
extent for ND uptake may vary depending on the particle size and surface coatings. 
177
 Cellular 
uptake of lys-NDs and the siRNA conjugated diamoplexes was assessed by a variety of 
techniques, including confocal microscopy, scanning transmission x-ray microscopy (STXM) 
and flow cytometry. 
5.4 Results and Discussion 
5.4.1 Dispersion stability of lysine NDs in formulations 
The choice of a dispersion medium is critical in attempting to define optimum physicochemical 
characteristics of and biological responses to the NPs. Therefore, a series of biologically relevant 
media were evaluated for preparing lys-NDs dispersions. The dispersions in phosphate buffer 
saline (PBS) showed extensive sedimentation within 3 days (Figure 5.1A). Lys-NDs in 0.5% 
methylcellulose gel aggregated slightly, observed by visual monitoring for 3 days (Figure 5.1B), 
whereas aqueous dispersion of lys-NDs showed minimum sedimentation over a period of 25 days 
(Figure 5.1C). PBS promotes ND aggregation due to its high ionic strength which disturbs the 
charge distribution on the ND surface. This ultimately causes destabilization which is mediated 
through random van der Waals interactions. 
225, 226 
Methylcellulose is an amphiphilic molecule 
which is commonly employed in stabilizing hydrophobic carbon nanomaterials, especially 
uncharged carbon nanotubes (CNTs). 
227
 However, in the case of cationic NPs it can reduce the 
positive charge density of the surface by masking the functional groups through adsorption. 
228
 
This phenomenon can ultimately lead to flocculation and reduce colloidal stability of the lys-
NDs. It could also hamper the binding efficacy with genetic materials and hinder the formation of 
diamoplexes.  
Lys-NDs remained well dispersed in water showing minimum sedimentation over 25 days, thus 
the stability of aqueous ND dispersion was further analysed using particle size distribution and 
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zeta potential measurements. The distributions remained relatively mono-modal (Figure 5.1D) 
throughout the period of analysis and hence average particle sizes were calculated. The average 
particle size of the fresh ND dispersion (day 1) was 51±16 nm (PDI: 0.142) (Figure 5.1D) with 
89% of the particles in the optimal size range of 33-91 nm (Supplementary Information: Table 
5S.1). Subsequently, the size increased slightly to 79±10 nm on day 3 to 91±13 and 91±12 nm by 
days 15 and 25, respectively. The zeta potential remained relatively stable being +26.3±0.3 mV 
on day 1, +21.2±0.4 mV on day 3, +31.3±0.6 mV on day 15 and +29.6±0.4 mV on day 25 (Table 
5.1). The stability is due to the fact that the aqueous medium does not compromise the positive 
charges on lys-NDs, thus electrostatic repulsion between homogenous adjacent surfaces is 
maintained and the formation of core aggregates is hindered. 
                                                     
 
 
 
 
Day 1 
(A) Lys-NDs in PBS (B) Lys-NDs in methylcellulose 
Day 3 Day 1 Day 3 
Day 1 Day 3 Day 15 Day 25 
(C) Lys-NDs in Water 
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Figure 5.1 Dispersion of lys-NDs in different media. Dispersions of (A) Lys-NDs in 
phosphate buffered saline (PBS) (B) Lys-NDs in methylcellulose gel and (C) Lys-NDs in 
aqueous medium at different time points showing maximum aggregation of ND particles in 
PBS upon 3 days of standing and minimum aggregation of ND particles in aqueous medium 
over 25 days; (D) Size distribution curves for lys-NDs in aqueous medium on day 1, day 3, 
day 15 and day 25. Each curve is derived from an average of 6 distributions with 10 
individual scans 
Aqueous dispersion of lys-NDs 
Time point Zeta Potential (mV) 
Day 1 +26.3 ± 0.3 
Day 3 +21.2 ± 0.4 
Day 15 +31.3 ± 0.6 
Day 25 +29.6 ± 0.4 
Table 5.1 Zeta potentials of lys-NDs in aqueous medium at different time points 
*Each zeta potential measurement indicates mean of six measurements with 100 individual 
runs. 
5.4.2 Interaction of lys-NDs with biological growth medium 
Additional to the inherent properties of NPs, physicochemical changes mediated through the 
biological growth medium can also modulate the transfection efficiency. 
229, 230 
Therefore, we 
investigated the behavior of NPs in biologically relevant media used for in vitro transfection 
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(mainly, cell culture medium and protein rich serum). Stability analysis of lys-NDs was 
performed in both serum free and supplemented DMEM to understand this behavior.  
Lys-NDs in serum free DMEM exhibited poor dispersibility and showed visible sedimentation 
within 24 hours after sonication (Figure 5.2A). Particle size distribution also revealed a high 
degree of aggregation with the majority of ND particles having a diameter of 500±10 nm (Figure 
5.2B) (Supplementary Information, Table 5S.2). A zeta potential of -2.2±2.6 mV (Table 5.2) 
indicated that the positively charged surface of lys-NDs was also compromised. Since the 
systems were highly aggregated within 24 hours, analyses at further time points were not 
performed. We postulate that lys-NDs become unstable in DMEM due to high ionic strength of 
the growth medium, which promotes the flocculation of the colloidal system. 
111, 231, 232
 
Macromolecules and electrolytes in growth media show random electrostatic interactions with the 
functional groups on the ND surface, thus concealing the positive charges of primary amines 
responsible for repulsion of individual particles, similar to the effect of PBS. Ultimately, inter-
particle interaction is enhanced resulting in increased level of aggregation and particle 
sedimentation, due to the screening effect of counter ions. 
231
  
Interaction of lys-NDs with serum proteins was also investigated in fetal bovine serum (FBS) to 
assess the formation of a protein adsorption layer on ND. The Lys-ND/protein interaction was 
analyzed by observing the change in particle size and zeta potential as a function of incubation 
time with FBS. Upon visual inspection, the lys-NDs showed no visible sedimentation up to 3 
days (Figure 5.2C) indicating good dispersibility. However, lys-NDs exhibited an approximately 
5 fold increase in diameter immediately after protein adsorption with size distributions ranging 
from 150 to 500 nm (Figure 5.2D) (Supplementary Table 5S.2) compared to lys-NDs in water 
(range of 33-91 nm) or the serum alone (range of 4-11 nm) (Figure 5.2D), which remained fairly 
constant for 3 days. The disappearance of the lys-ND and serum peaks indicates dynamic 
association of serum proteins with cationic ND surface. In nanoparticulate systems, an increase in 
diameter after protein adsorption can vary greatly depending upon the size of adsorbing proteins 
233, 234
 and the surface-to-volume ratio of the particles, 
235
 as observed for systems reported 
herein. Adsorption of the serum proteins was confirmed by the change in zeta potential of the ND 
system from +26.3 mV to -12.4 mV (Table 5.2) suggesting the formation of an anionic protein 
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corona. Due to positively charged surface of lys-NDs, there is an increased possibility for 
adsorption of proteins with low iso-electric points (<5.5) such as albumin. 
235 
Protein adsorption is a two edged process. It can change the biological identity of NPs affecting 
its cellular uptake and distribution, 
183
 but also can be beneficial for limiting nanoparticle 
mediated cellular toxicity and conferring target specificity. 
235
 In the present study, the ability of 
lys-NDs to adsorb proteins can be utilized in the future for improving the cellular uptake and 
targeting by allowing the formation of a selective protein corona, like  apolipoproteins, which 
have been employed to enhance cellular uptake of NPs. 
235, 236 
 
                                               
 
      
 
Figure 5.2 Interaction of lys-NDs with serum free DMEM and with FBS. Dispersions of (A) 
Lys-NDs in serum free DMEM showing sedimentation within 24 hours due to reduced 
dispersibility (B) Size distribution curve for lys-NDs in serum free DMEM compared to the 
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aqueous dispersion. (YTZ grinding media was added at 1:1 ratio in the DMEM dispersion) 
(C) Lys-NDs/FBS dispersion at different time points showing no sedimentation up to 3 days 
suggesting uniform dispersibility over time; (D) Size distribution curves for lys-NDs after 
serum incubation: FBS alone, lys-NDs alone, lys-ND/FBS on day 1 and lys-NDs/FBS on day 
2. Each curve is derived from an average of 6 distributions with 10 individual scans 
Time Point  
Zeta Potential (mV)* 
Lys-NDs in serum free DMEM 
Day 1 -2.2 ± 2.6 
Lys-NDs after incubation with FBS  
FBS alone (Day 1) -8.0 ± 0.8 
Lys-NDs alone (Day 1) +26.3 ± 0.3 
Lys-NDs/ FBS (Day 1) -12.4 ± 0.1 
Lys-NDs/ FBS (Day 3) 0.3 ± 2.1 
Table 5.2 Zeta potential of lys-NDs in serum free DMEM and after serum incubation 
*Each zeta potential measurement indicates mean of six measurements with 100 individual runs. 
To measure the extent of protein adsorption, the thickness of the protein adsorption layer (Tprotein) 
was calculated. This calculation was based on the assumption that formation of a protein corona 
around NDs resembles a classical ligand binding model, and thus follows the law of mass action. 
237 
Accordingly, the affinity of protein for NDs can be defined by the dissociation constant (KD), 
corresponding to the concentration at which half of the NDs are saturated with proteins at 
equilibrium. 
237 
Tprotein with FBS was 157 nm immediately after incubation of lys-NDs with 
serum, which correlates with multiple layers of proteins and other biomolecules on the ND 
surface. A negligible decrease in the thickness of the adsorption layer to 155 nm and significant 
increase in zeta potential towards positive value of 0.3 ± 2.1 mV (Table 5.2) in three days 
indicates the occurrence of a continuous adsorption and desorption of proteins (Vroman effect). 
188
 These results suggest that the identities of adsorbed proteins may change over time but the 
total amount remains roughly constant. Neutral zeta potential after 3 days can also be the result of 
electrostatic interactions between protein coated and bare lys-ND particles resulting in the 
formation of coagulated masses with reduced electrophoretic mobility. 
238
 While the particle size 
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increased significantly in the presence of serum, the lack of sedimentation in the 3 days of the 
testing period renders these dispersions pharmaceutically acceptable. 
5.4.3 Cellular Internalization of lys-NDs 
Cellular uptake of lys-NDs was studied by using three complimentary techniques providing a 
combination of spectroscopic, microscopic and light scattering principles. Soft X-rays offered 
microscopic imaging with detailed spectral sensitivity, by allowing microspectroscopy to record 
the cellular spectra from identified spots on the image. Further indication of ND internalization in 
the cells was obtained using flow cytometry which utilized light scattering patterns to 
differentiate the cells before and after ND uptake.  Finally, laser confocal scanning microscopy 
was used to confirm the presence of lys-NDs in the cells by utilizing their innate fluorescence 
property.  
5.4.3.1 Scanning Transmission X-ray Microscopy 
In order to identify NDs in a biological environment a unique spectrum, different from cellular 
macromolecules (mainly proteins and lipids) is sought. Soft X-ray spectroscopy of the cells 
incubated with lys-NDs was carried out by scanning transmission X-ray microscopy (STXM). 
This technique provides many advantages over conventional techniques used for characterizing 
NPs and investigating their cellular interaction. It allows high resolution imaging which enables 
evaluation of interactions on the level of individual particles. 
239, 240, 241 
Most importantly, it can 
be applied to fully hydrated biological materials, which allows functional analysis of molecular 
mechanisms in a living cell under native biological conditions. 
242
 Soft X-rays also provide 
spatial resolution of around 50 nm 
243
 and spectral resolution on the order of 100 MeV, 
244, 245
 that 
can differentiate between classes of biomolecules and can identify NPs as therapeutic carriers in 
cells and tissues. 
240 
 
The spectrum of lys-NDs (red) (Figure 5.3A) recorded as a reference, shows identifiable peaks at 
288.2 eV, 292.5 eV and 297.5 eV, indicated by arrows, which are absent in the spectrum of 
intracellular proteins (green) (Figure 5.3A) obtained from the untreated cells. For detailed 
evaluation, untreated cells and lys-ND treated cells were scanned separately through STXM at 
wide range of photon energies. Spectra from the identifiable regions in the cells were recorded 
(Figures 5.3B and E).  In untreated cells (Figure 5.3C), the green spectrum showed absorption at 
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peaks 285 and 287.5 eV and hence was assigned to proteins. 
245
 The red spectrum also indicated 
absorption peaks at the same x-ray energies but with relatively lower intensities, and therefore 
was assigned to proteins from the cellular growth media (DMEM) surrounding the cell. The blue 
spectrum can be assigned to nucleus-and near-nucleus-derived mixture of macromolecules.  
The lys-ND treated cells (Figure 5.3F), scanned at the same x-ray energy also indicate absorption 
spectra of non-protein macromolecules (blue), intracellular (green) and growth medium-derived 
proteins (red). However, the red spectrum exhibit weak features of absorption at 288.2, 292.5 and 
297.5 eV corresponding to the specific lys-ND signals as indicated by black arrows separately in 
Figure 5.3A. Clear lys-ND signals are masked and appeared weak due to the interference of the 
overlapped intracellular and growth medium derived proteins on lys-ND surface. Unlike for 
untreated cells (Figure 5.3D), color composite image of lys-ND treated cells indicate localization 
of NDs (red) overlapped with proteins mostly around cellular edges and cytoplasm, with some 
being in close proximity to the nucleus (Figure 5.3G), indicated by arrows. While these 2D 
images in STXM show the cellular uptake of lys-NDs, future work is planned to use the high 
resolution capability of STXM (30 nm) combined with 3D imaging for a more precise 
localization of the lys-ND particles within the cells. 
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  (B)                               (C)                  (D) 
     
 (E)                 (F)                                                           (G) 
Figure 5.3 SXTM images and spectra for lys-ND internalization. (A) Comparison of 
intracellular protein spectra of lys-ND treated cells (blue) and untreated cells (green) with the 
reference spectrum of lys-NDs (red). The arrows indicate the ND derived features in the treated 
cells in comparison with the reference lys-ND spectrum. STXM image of (B) untreated cells and 
(E) lys-ND treated cells taken as an average of stack images from 280-295 eV along with their 
absorption spectra (untreated cells (C) and lys-ND treated cells (F)). Images (D) and (G) 
indicate color composite maps of macromolecular and ND distribution in untreated and lys-ND 
treated cells respectively. 
5.4.3.2 Flow Cytometry 
Flow cytometry was used to assess the molecular and morphological changes in the cells when 
treated with lys-NDs. Changes in forward and side scattering patterns were recorded to encounter 
the internalization of lys-NDs in cells. Side scattering, i.e. the light scattering measured at 90° 
angle, increases with an increase in granularity and internal complexity of the cell, thus the 
uptake of NPs can be detected by monitoring this scattering intensity. 
246
 A dose dependent 
increase was observed in side scattering resulting after administration of lys-NDs to the cells 
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(Figure 5.4). The untreated cells exhibit the least side scattering (Figure 5.4A) and showed a 
tightly condensed population (Supplementary Figure 5S.7A). However, after treatment with lys-
ND, the cell populations became increasingly dispersed (Supplementary Figure 5S.7B to 5S.7D) 
and   exhibited an increase in side scattering with concentration ranging from 25 µg/mL to 250 
µg/mL (Figure 5.4A). This dose dependent increase in side scattering can be correlated with an 
increase in the internal complexity and light scattering moieties inside the cells. 
246
 NDs are 
efficient light scattering moieties, since they possess high refractive index (n= 2.42) owing to 
their diamond core. 
247, 248
 Due to the high refractive index, the elastically scattered light from a 
ND particle is estimated to be 300-fold brighter than a same sized cell organelle. 
248
 In addition to 
increased light scattering, there can be an increased activation of lysosomes for trapping the 
internalized ND particles, 
249
 which also contributes toward side scattering. 
250
  
While there is a change in the side scattering, the forward scattering (indicative of the size of the 
cell) remained unchanged before and after the treatment (Figure 5.4B), suggesting that the NDs 
are internalized into the cells and not adhered to the surface. Forward scattering of light based on 
refraction is directly proportional to the cell size and surface area, thus a larger surface area is 
associated with more forward scattering.
251
 We inferred that if NPs are adhered to the surface of 
the cell it would increase the overall surface area and can contribute towards the refraction of 
light. However, the cells treated with all concentrations of NDs show similar refraction patterns 
to the untreated cells (Figure 5.4B). There were no significant positive shifts in forward scattering 
which indicate absence of surface adhered ND particles. Although this finding cannot be 
attributed to an absolute absence of surface adhesion, it indicates that there is no significant 
surface localization of NDs. The combination of the above two parameters corresponds to a dose 
dependent cellular uptake of lys-NDs.  
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Figure 5.4 Flow cytometry histograms showing concentration dependent uptake of lys-NDs 
through forward and side scattering. Histograms indicating side scattering (A) of untreated 
cells (red) and lys-ND treated cells at concentrations of 25 µg/mL (blue), 100 µg/mL (green) 
and 250 µg/mL (pink) showed a significant dose dependent increase.  Histograms indicating 
forward scattering (B) of untreated cells (red) and lys-ND treated cells at concentrations of 
25 µg/mL (blue), 100 µg/mL (green) and 250 µg/mL (pink) shows no significant difference. 
The horizontal axis represents side scattering (A) and forward scattering (B) signal value in 
channel numbers and the vertical axis represents the number of events per channel. Events 
observed are lined into a channel of its corresponding signal value. Brighter the signals 
displayed in the channel, higher would be the rightward shift.  
5.4.3.3 Laser Confocal Scanning Microscopy 
To further confirm the cellular uptake of lys-NDs, laser scanning confocal microscopy was 
carried out. The fluorescence (Figure 5.5A), brightfield (Figure 5.5B) and overlay of brightfield 
and fluorescence (Figure 5.5C) images of the top, middle and bottom z-positions (corresponding 
to the 44th, 22nd and 1st section, respectively) of a lys-ND treated cell are shown. An overlay of 
brightfield and fluorescence images of the middle slice of lys-ND treated live cells revealed 
internalization of a few ND particles, as marked by the red circle (Figure 5.5C, middle). These 
particles appear to be localized near the nucleus of the cell. However the fluorescence of these 
particles in the middle z-section was not distinctly identified due to the interference originating 
from cellular auto-fluorescence. Upon longer exposure time, the auto-fluorescence of the cells 
was quenched and the fluorescence (Figure 5.6A) and brightfield images (Figure 5.6B) of four 
consecutive slices when overlaid revealed more distinct ND fluorescence emission (Figure 5.6C).  
Untreated cells 
25 µg/mL treated cells 
100 µg/mL treated cells 
250 µg/mL treated cells 
Untreated cells 
25 µg/mL treated cells 
100 µg/mL treated cells 
250 µg/mL treated cells 
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Figure 5.5 Laser scanning confocal microscopic images of the live cell treated with lys-NDs 
for 24 hours. From left to right- (A) fluorescence images, (B) bright field images and (C) 
overlay of fluorescence and bright field images. Excitation was performed using a 476 nm 
wavelength laser source and emission was collected from 492 to 677 nm wavelengths. A 
total of 44 slices were imaged with 0.38 μm intervals. 
Top 
Middle 
Bottom 
A B C B 
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Figure 5.6 Laser scanning confocal microscopic images of four consecutive sections from 
the middle towards the bottom of the cell treated with lys-NDs. From left to right; (A) 
fluorescence images, (B) bright field images and (C) overlay of fluorescence and bright field 
images. From top to bottom; sections 21, 20, 19 and 18 (intervals of 0.38 μm). Excitation 
was performed using 476 nm wavelength laser source and emission was collected from 492 
to 677 nm wavelengths. 
5.4.4 Cellular Internalization of lys-NDs as diamoplexes 
Previously, we reported that lys-NDs can bind to siRNA. 
134 
 This fact was implemented to 
enhance the investigation of lys-NDs suitability for gene delivery as described here. Although 
detonation NDs show a slight innate fluorescence as observed during the confocal microscopy, 
but this fluorescence is not sufficiently intense for detection during flow cytometry. Therefore, 
lys-NDs were complexed with FITC labelled siRNA to provide an intense fluorescence for 
probing these diamoplexes inside the cells.  After treating the cells with these diamoplexes, the 
presence of FITC fluorescence from siRNA was correlated with cellular association of lys-
NDs/siRNA diamoplexes.  
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Cells treated with diamoplexes prepared from lys-NDs dispersed in serum free DMEM showed 
no positive shift for FITC fluorescence (Supplementary Figure 5S.1), attributed to the poor 
binding of lys-NDs with siRNA secondary to their unstable charge distribution in DMEM. Cells 
treated with diamoplexes prepared from aqueous dispersion of lys- NDs showed a statistically 
significant positive shift in FITC fluorescence of 14±2.1% compared to the untreated cells 
(5±0.2%) (Figure 5.7) (Supplementary Figure 5S.2). The positive fluorescence shift indicates 
successful internalization of the labelled siRNA. Addition of serum to the formulation enhanced 
the FITC fluorescence shift to 20±2.3% (Figure 5.7) (Supplementary Figure 5S.3). This increase 
in fluorescence is an indicative that protein corona facilitates the cellular uptake of diamoplexes.   
In order to confirm that primary amine-rich cationic surfaces created through functionalization of 
NDs facilitates electrostatic binding with negatively charged siRNA; diamoplexes were also 
prepared with carboxylated red fluorescent nanodiamonds (COOH-FNDs). Here, the NDs used 
were additionally treated to induce brighter fluorescence capable of detection in flow cytometry. 
The cells treated with these diamoplexes showed no significant positive shift for FITC 
fluorescence (Figure 5.7) (Supplementary Figure 5S.4) revealing that the COOH-FNDs are 
unable to carry nucleic acids inside the cells due to the negative surface charge. However, 
interestingly they show cellular internalization independent of siRNA carriage, as observed 
through the positive shift obtained for the treated cells in the wavelength region exclusive to the 
fluorescence of NDs (550-800 nm). (Supplementary Figure 5S.5 and 5S.6).  
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Figure 5.7 Percent fluorescence shift in flow cytometry for cells treated with lys-
NDs/COOH-FNDs alone (blue) & diamoplexes of lys-ND or COOH-FNDs with FITC 
labelled siRNA (40:1) (red) compared to untreated cells (green) in the wavelength range of 
FITC (emission maximum 525 nm). The three treatment groups are: 1) lysine-ND in the 
presence of serum 2) lysine-ND in the absence of serum and 3) COOH-FNDs. Each group 
further comprise of treatments with ND alone, diamoplexes and their subsequent controls. 
Each bar represents mean ± S.D. of three measurements.*One way ANOVA; Tukeys post hoc for multiple 
comparison; p<0.05 & **Kruskal Wallis ANOVA; Mann Whitney U test for comparison; p<0.05 
The efficacy of each siRNA delivery method was quantitatively analyzed by comparing the 
fraction of fluorescence shift caused exclusively due to siRNA independent of the weak 
interference from ND fluorescence. The fraction of FITC fluorescence is considered directly 
proportional to the amount of labelled siRNA delivered to the cells. Only 0.15 fraction of siRNA 
fluorescence was observed when the cells were treated with 75 pmoles of naked siRNA. The 
fraction of siRNA fluorescence increased significantly, to 2.7 folds (0.4±0.01) (Figure 5.8) when 
the same amount of siRNA was delivered in conjugation with lys-NDs at a ratio of 40:1. This 
illustrates the ability of the lys-NDs to perform intracellular delivery of nucleic acids.  
Moreover, the fraction of siRNA fluorescence was 1.8 times (0.7±0.05) greater in the presence of 
serum (Figure 5.8) compared to the serum-free environment, which might indicate that proteins 
can protect the integrity of diamoplexes and facilitate their cellular uptake. 
Despite previous reports indicating an inhibitory effect of serum on cellular uptake of 
nanoparticle-gene complexes, 
252, 253
 we observed that serum proteins can cause increased cellular 
uptake of diamoplexes. Protein adsorption on NP surface can alter the particle size and the 
overall surface charge of the system. Therefore, the serum-induced increase in cellular uptake of 
diamoplexes can be attributed to multiple factors. Lys-NDs have a cationic surface due to the 
presence of primary amines, which may result in favourable interaction with the negatively 
charged albumin, the main component of the serum. This interaction could impede the 
electrostatic interaction between lys-NDs in the diamoplexes and the phospholipids of the cell 
membrane. Therefore, the change in surface charge does not explain the increase in cellular 
uptake.  
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It was also determined that the size of the diamoplexes increased significantly due to protein 
adsorption. The adsorbed proteins increased the hydrodynamic radius of the NPs. There are 
previous studies indicating that protein adsorption increases the overall cellular uptake of hard 
NPs like polysyterene. 
254
 It is speculated that the serum-induced increase in the particle size of 
diamoplexes can switch the most prominent clathrin mediated endocytosis of NDs to claveoli 
mediated endocytosis, 
255 
which is responsible for the uptake of complexes sized around 500 nm 
or above. 
256, 257
 Moreover albumin, the main component of FBS, can also facilitate cellular 
uptake of diamoplexes. 
258, 259
 Upon incorporation it can act as a ligand that binds to the albumin-
binding protein on the claveolar plasma membrane to induce more affinity for claveoli or lipid 
raft mediated endocytosis of diamoplexes. 
182, 260, 261
 Moreover, the bio-reactivity of the surface 
due to the adsorption of physiologically active proteins like albumin on the surface can also serve 
to facilitate specific receptor mediated endocytosis. Unfolding of the adsorbed proteins resulting 
in a specific conformation can induce differential binding to target receptors on the cell 
surface.
262, 263
 Although the optimum size for cellular uptake is defined to be 20-40 nm,
182
 the 
altered endocytic pathway might facilitate cellular association of larger sized protein-coated 
diamoplexes by altered pathways, thus increasing the intracellular amount of FITC labelled 
siRNA. Detailed mechanistic analysis will be conducted to understand this altered cellular uptake 
behavior of diamoplexes. 
 
Figure 5.8 Fraction of fluorescence shift from FITC labelled siRNA when administered 
directly or as diamoplexes with lys-NDs at a ratio of 40:1 (in presence and absence of serum 
proteins). Each bar (except naked SiRNA) represents mean ± S.D. of three measurements. 
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ANOVA (p-value ≤ 0.05), Tukey’s post hoc multiple comparisons (*p-value<0.001, **p-
value=0.007, ***p-value=0.002) 
5.5 Conclusion 
In this study, we demonstrated that aqueous dispersion of lys-NDs exhibit excellent dispersibility 
and preservation of their physicochemical properties for at least 25 days. Unlike in aqueous 
medium, the stability of lys-NDs is significantly compromised in physiological growth media, 
which in turn diminishes their siRNA binding capacity and cellular uptake. Lys-NDs interact 
with serum to form a protein shell around the core. This protein corona stabilizes ND/siRNA 
complexes and facilitates the process of cellular uptake. The increased cellular uptake in the 
presence of serum proteins is a promising finding, rendering the lys-ND diamoplexes amenable 
for parenteral administration for gene therapy. Successful cellular uptake of lys-NDs, alone, and 
as stable complexes with siRNA encourages further investigations to evaluate their transfection 
efficiency and biocompatibility as gene carriers for RNAi therapeutics.  
5.6 Methodology 
5.6.1 Materials 
Pharmaceutical-grade (ND98) carboxylic acid–functionalized NDs with an average particle size 
of 5 nm were purchased from Dynalene Inc. (Whitehall, PA). Lysine functionalized NDs (lys-
NDs) were synthesized in house following the procedure previously described. 
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Carboxylated 
fluorescent NDs (COOH-FNDs) were obtained from Adamas Nanotechnologies (Raleigh, NC). 
Tosoh Corporation (Grove City, OH) graciously provided YTZ® (Yttrium Stabilized Zirconia) 
grinding media (0.05 mm). Methylcellulose USP (4000 mPa.s) was obtained from Medisca 
(Richmond, BC). 0.5% Methylcellulose gel was prepared in deionized distilled water obtained 
from a Milli-Q Integral Water Purification System, EMD Millipore (Billerica, MA). HyClone® 
HyPure Molecular Biology Grade Water, HyClone™ 1x Phosphate Buffered Saline (1xPBS) and 
HyClone™ Dulbecco's Modified Eagle's medium (DMEM)/High; glucose with L-glutamine and 
sodium pyruvate was obtained from ThermoFisher Scientific (Waltham, MA). Fetal bovine 
serum (FBS) was acquired from Gibco (ON, Canada). HeLa cells (human cervical cancer cells) 
were obtained from American Type Culture Collection (VA, United States). Trypsin and 
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antibiotics were obtained from Sigma Aldrich (ON, Canada). Anti-GFP siRNA was purchased 
from Ambion (ON, Canada). Fluorescein isothiocyanate (FITC) conjugated control siRNA was 
purchased from Santa Cruz Biotechnology Inc (CA, United States). Cell culture flasks and plates, 
centrifuge tubes and cell strainer tubes were purchased from Falcon BD (ON, Canada).  
5.6.2 Preparation of primary ND dispersions 
Primary dispersions of lys-NDs were prepared in purified deionized water, PBS, 0.5% 
methylcellulose gel and serum free DMEM separately. Primary dispersion of COOH-FNDs was 
prepared in purified deionized water. All dispersions were prepared at a concentration of 2 
mg/mL. YTZ grinding media was added in all dispersions at a ratio of 1:1. All primary 
dispersions were subjected to ultrasonication for 4 hours at a frequency of 25 kHz without 
heating. The ultrasonicated dispersions were then centrifuged at 5200 g for 5 minute to sediment 
the YTZ grinding media and the aggregated ND particulates. The resulting dispersions were used 
in the subsequent experiments.  
5.6.3 Selection of the most compatible dispersion medium 
In order to select the best medium to disperse lys-NDs for subsequent physicochemical analysis 
and cellular experiments, primary dispersions of lys-NDs in purified deionized water, PBS and 
0.5% methylcellulose solution and serum free DMEM were allowed to stand for 72 hours at room 
temperature without any additional ultrasonication and centrifugation. Images were obtained at 
24 and 72 hours to compare the degree of sedimentation for lys-NDs in different media. 
5.6.4 Particle size and zeta potential measurements 
Particle size distribution and zeta potential measurements were performed over a period of 25 
days by using Malvern Zetasizer Nano ZS instrument (Malvern Instruments Ltd, Worcestershire, 
UK). Values for water properties used for measurement were as follows: refractive index = 
1.330, dielectric constant = 78.5 and viscosity at 25ᵒC = 0.8872 cP. Solvent properties were 
changed for DMEM as hydrodynamic viscosity η = 3 cP, refractive index = 1.345 264 and 
dielectric constant = 80. 
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Particle size was measured as a function of the light scattered by individual diamond particles at 
an angle of θ= 173ᵒ, which allowed the calculation of translational diffusion coefficients ‘D’ of 
particles by applying the CONTIN algorithm. The hydrodynamic radius RH of lys-NDs was then 
calculated using the Stokes-Einstein equation (RH= kT/6πηD), where k = Boltzman constant, T is 
the temperature (298K), and η is the viscosity of water at 25ᵒC. All size distributions were 
derived from 6 measurements with 10 individual scans. Particle size distributions for all time 
points were plotted as mean volume % to compare the degree of aggregation that occurred over 
the period of analysis. Polydispersity indices (PDI) were also calculated by cumulant fitting. Zeta 
potential measurements were based on Laser Doppler Electrophoresis and values reported are an 
average of 6 measurements with 100 individual scans. 
5.6.5 Interaction of lys-NDs with serum proteins 
Aqueous dispersion of lys-NDs at a concentration of 2 mg/ 500 µL concentration was prepared as 
mentioned above. After ultrasonication and centrifugation, 500 µL of FBS dispersion was added 
and allowed to stand at room temperature for 45 minutes to allow the formation of protein 
adsorption layer around the ND particles. The dispersion of lys-ND/FBS was then lyophilized for 
3 days to obtain complete desiccation. The powder obtained was then dispersed in purified water 
by gentle shaking at a final concentration of 2 mg/mL. Aggregation of the dispersion was 
monitored visually at 24 and 72 hours. Changes in particle size and electrokinetic charge 
distribution resulting from interaction of lys-NDs with FBS were analysed similarly as above 
over a period of 3 days. Zeta potentials were recorded as a function of time to monitor the 
formation and stipulate the stability of the protein corona. The average particle diameter obtained 
from volume weighted size distributions was used to calculate the approximate thickness of the 
protein adsorption layer (Tprotein) by equation 1: 
          
                                                                                    
 
 …. (Eq 5.1) 
Since the lys-ND/FBS system shows polymodal distribution (PDI: 0.265), the Z-average 
calculated by the instrument’s cumulants technique might cause an overestimation of average 
particle diameter, even in the presence of minimum core aggregates. In order to minimize the 
erroneous estimation of Tprotein, average particle diameter was calculated before and after protein 
adsorption using the mean volume % obtained by size distribution data.  
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5.6.6 Cell Culture 
Frozen HeLa cells were grown in DMEM (containing L-glutamine and sodium pyruvate) 
supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic. The cells were incubated at 37 ᵒC and 
5% CO2 and allowed to grow up to 90% confluency. When the cells were confluent, they were 
sub passaged to allow the growth of healthy population. The sub-passaged cells were then seeded 
in well plates for subsequent cellular experiments. 
5.6.7 Scanning Transmission X-Ray Microscopy (STXM) 
Cell samples used to obtain STXM were prepared on silicon nitride windows. Optical images of 
the cells plated on membranes are shown in supplementary information Figure S5.8. HeLa cells 
were seeded and treated with lys-NDs at an amount equalizing 40:1 diamoplex ratio, i.e. 41.5 
µg/well. The treated cells were resuspensed in 2.5 mL of serum supplemented media and added 
to the silicon nitride windows in a 6 well plate. The cells were incubated for 24 hours at 37 ᵒC 
and 5% CO2 again to allow cellular attachment to the silicon nitride (Si3Ni4) windows (size 1x1 
mm, thickness 100 nm).  The membranes were mounted on the STXM sample holder and imaged 
using STXM at the soft x-ray spectromicroscopy beam line of the Canadian Light Source (CLS) 
(University of Saskatchewan, Saskatoon, SK, Canada). Both control and lys-ND treated cells 
were adjusted to the same optical density and scanned at x-ray energies of 280 to 295 eV of C-1 
edge and absorbance spectra from different identifiable regions on the sample were collected. 
Changes in the absorbance spectra obtained from the cells as a result of ND uptake were 
recorded. 
5.6.8 Flow cytometry for lys-NDs 
HeLa cells were plated on a 6 well plate at a density of 2x10
5
 cells/ well and incubated at 37 ᵒC 
and 5% CO2 to allow attachment. Thereafter, the cells were treated with lys-NDs at a 
concentration of 25 µg/mL, 100 µg/mL and 250 µg/mL. Untreated cells were used as controls. 
The treatments were terminated after 20 hours followed by washing with 1xPBS three times for 5 
minutes each. The cells were then harvested using trypsin and 0.25% EDTA and centrifuged at 
95 g and 4 ᵒC for 5 minutes to obtain cell pellets. The individual cell pellets were resuspensed in 
500 µL of 1xPBS, transferred into 5mL flow cytometer tubes and the amounts of ND particles 
taken up by the cells were analyzed using BD FACS Calibur™ (BD Biosciences, CA, USA). The 
101 
 
laser beam (488 nm) illuminates cells in the sample stream. It is then  scattered by the cells at 
narrow angles to the axis of the laser beam is called forward scattering (FS) and at about a 90° 
angle to the axis of the laser beam called side scattering (SC). The intensities of FS and SS are 
proportional to the size and intracellular complexity, respectively. 
5.6.9 Laser scanning confocal microscopy 
To evaluate whether lys-NDs can be detected in the cells based upon their intrinsic fluorescence, 
laser scanning confocal microscopy was performed. HeLa cells seeded at the density of 40,000 
cells per well were allowed to adhere to coverslip placed in 12 well plate, for 24 hours. The cell 
media were replaced with 1 mL of lys-NDs dispersion prepared at a concentration of 50 μg/mL. 
After 6 hours, FBS was added to the media of the cells at a final concentration of 10% (w/v). The 
cells were incubated for a total of 24 hours and then washed three times with PBS (5 minutes 
each). Slides of the live cells were prepared and imaged with a Leica TCS SP5 laser scanning 
confocal microscope (Leica Microsystems Inc., Benshein, Germany; WCVM, University of 
Saskatchewan, Saskatoon, Canada) using a 63X oil immersion objective. The sample excitation 
was carried out with a 476 nm argon laser source and the emission was collected from 492 to 677 
nm. A total of 44 z-sections of cells were imaged, each with a step size of 0.38 μm. 
5.6.10 Flow cytometry for lys-ND/siRNA diamoplexes 
Flow cytometry was used again to evaluate the cellular association of lys-NDs as diamoplexes by 
complexing them with FITC labelled control siRNA. HeLa cells were seeded and plated similarly 
as above. FITC labelled siRNA was complexed with lys-NDs dispersed in aqueous and DMEM 
at different weight ratios of siRNA to lys-NDs ranging from 1:20 to 1:50 by incubating the 
dispersion with siRNA for 30 minutes at room temperature. The attached cells were then treated 
with lys-ND/siRNA diamoplexes diluted in serum supplemented or serum free DMEM. The final 
concentration of siRNA in each well was 75 pmoles. Untreated cells and lys-NDs treated cells 
were used as controls.  The treatments were terminated after 24 hours followed by washing, 
harvesting and resuspending as described above. FITC fluorescence was measured using BD 
FACS Calibur™ (BD Biosciences, CA, USA). Fluorescence from FITC siRNA was recorded 
using FL1-H band pass filter (530/30 BP) by plotting log of fluorescence intensity versus number 
of events. Healthy cell population was gated and a total of 10,000 events were recorded in the 
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gated region per sample. The data was analyzed using BD CellQuest™ Pro software (version 
6.0). Relative fluorescence shift (from negative to positive) for diamoplex treated cells were 
compared to the auto fluorescence of the untreated cells and fluorescence from lys-NDs treated 
cells through the marker (M1). This marker was applied to quantify the positive shifts resulting 
from the treatments.    
Fraction of FITC siRNA fluorescence was calculated using % fluorescence shifts as follows: 
                                   
                                     
                                         
  ………… (Eq 5.2) 
Flow cytometry was also used to analyze cellular association of COOH-FNDs as diamoplexes 
with FITC siRNA. Fluorescence from COOH-FNDs was recorded using FL3-H long pass filter 
(670 LP), while fluorescence from FITC labelled siRNA was recorded using FL1-H BP filter.  
5.6.11 Statistical Analysis 
Flow cytometry results for cellular association of lys-NDs and COOH-FNDs in aqueous medium 
were expressed as the mean of n=3 ± S.D. One way ANOVA and Tukey’s post hoc multiple 
comparisons were used for analysis when samples were normally distributed and had 
homogenous variance. Kruskal Wallis ANOVA and Mann Whitney U test for post hoc 
comparison were used for analysis when samples were not normally distributed or had non-
homogenous variance. The significant differences were considered at p ≤ 0.05 level of 
significance (α). 
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5.9. Supplementary Information  
Table S 5.1 Particle size distribution and PDI for lys-NDs in aqueous medium on days 1, 3, 15 
and 25 
Aqueous dispersions of lys-NDs 
 
Time Point 
(Days) 
Particle size range  
(nm) 
Mean 
volume* (%)  
PDI 
1 33-91 
106-190 
89 % 
10% 
0.142 
 
3 
33-91 
106-190 
220-295 
43% 
38% 
13 % 
 
0.180 
15 
33-91 
106-190 
220-295 
37% 
51% 
11% 
0.126 
25 
33-91 
106-190 
220-295 
34% 
50% 
14% 
0.130 
*Each size distribution data indicates mean of six measurements with 10 individual runs 
Table S 5.2 Particle size distribution and PDI for lys-NDs in serum DMEM and after serum 
incubation at different time points. 
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Time Point  Particle size 
range (nm) 
Mean volume* 
(%)  
PDI 
Lysine NDs in serum free DMEM 
Day 1 
106-190 
290-342 
396-615 
712-955 
1.3% 
14% 
42% 
23% 
 
0.259 
Lysine NDs after incubation with FBS  
FBS alone (Day 1) 
 
4-11 
14-21 
 
 
98% 
1.2% 
 
0.592 
Lys-NDs alone (Day 
1) 
 
33-91 
106-190 
 
 
89 % 
10% 
 
0.142 
 
Lys-NDs/ FBS (Day 
1) 
 
59-91 
106-190 
220-295 
342-531 
615-955 
3% 
18% 
21% 
33% 
20% 
 
 
0.265 
 
Lys-NDs/ FBS (Day 
3) 
59-91 
106-190 
220-295 
342-531 
615-955 
2 % 
21% 
25% 
32% 
16% 
 
 
0.234 
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Figure S 5.1 Overlay of flow cytometry spectra and graphical comparison for percent 
fluorescence shift  for untreated (black), Naked siRNA (orange), lys-ND alone (green),  lys-
ND/SiRNA (20:1) diamoplex (purple), lys-NDs/siRNA (40:1) diamoplex (pink) and lys-
NDs/siRNA (50:1) diamoplexes (blue) treated cells. 
 
Figure S 5.2 Overlay of flow cytometry spectra for percent fluorescence shift for untreated 
(green), lys-NDs alone (blue) & lys-ND/FITC labelled siRNA treated cells (40:1) (red) in 
absence of serum. 
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Figure S 5.3 Overlay of flow cytometry spectra for percent fluorescence shift for untreated 
(green), lys-NDs alone (blue) & lys-ND/FITC labelled siRNA treated cells (40:1) (red) in the 
presence of serum. 
 
Figure S 5.4 Overlay of flow cytometry spectra for percent fluorescence shift for untreated 
(green), lys-NDs alone (blue) & lys-ND/FITC labelled siRNA treated cells (40:1) (red) in 
wavelength range of FITC. 
 
Figure S 5.5. Overlay of flow cytometry spectra for percent fluorescence shift for untreated 
(green), lys-NDs alone (blue) & lys-ND/FITC labelled siRNA treated cells (40:1) (red) in 
wavelength range of COOH-FNDs 
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Figure S 5.6 Percent fluorescence shift for untreated (green), COOH-FNDs (blue) & COOH-
FNDs/FITC labelled siRNA treated cells (40:1) (red) in wavelength range of COOH-NDs (670 
LP filter) 
 
 
 
0 
5 
10 
15 
20 
25 
       COOH-FNDs  
P
e
rc
e
n
t 
Sh
if
t 
o
f 
Fl
u
o
re
sc
e
n
ce
 
in
 M
ar
ke
d
 R
e
gi
o
n
 (
%
) 
 108 
 
Figure S 5.7 Dose dependent cellular uptake of lys-ND particles evidenced as increasing side 
scattering. Untreated cells (A), cells treated with lys-NDs at concentrations of 25 µg/mL (B), 100 
µg/mL (C) and 250 µg/mL (D). 
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Figure S 5.8 Optical images of untreated cells, cells treated with lysine-NDs on silicon nitride 
windows prepared for STXM analysis 
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6.2 Abstract 
Lysine functionalization of NDs presents as a novel approach to limit aggregation and to 
maintain long term stability of these carbon nanomaterials. The cationic surface of lysine 
functionalized NDs is capable of binding the nucleic acids optimally and hence shows 
tremendous potential as gene delivery vectors. Determination of optimum stability and cellular 
uptake of lys-NDs alone and as diamoplexes served as a foundation to evaluate the functional 
efficiency and biocompatibility of this vehicle in the biological system. Flow cytometry analysis 
aimed at studying the efficacy of lys-NDs to deliver functionally active siRNA revealed 
promising results for gene delivery and expression. GFP knockdown of ~17% was recorded when 
the cells were treated with NDs/siRNA diamoplexes at a ratio of 20:1. However, this decrease is 
not significant compared to the lipofectamine control (~44%) and demand further modification of 
the system to enhance the gene delivery efficiency. Ratios of NDs/siRNA diamoplexes lower and 
higher than 20:1 did not show any reductions in the fluorescence. Subsequent analyses regarding 
the effect of NDs to prevent cellular proliferation and their effect on cellular death, namely 
apoptosis confirmed that they are innately biocompatible and amino acid-functionalizations do 
not compromise their biocompatibility.  
6.3 Introduction 
Non-viral vectors for gene delivery have gained much attention after the discovery of 
immunogenicity and oncogenecity of the viral vectors. 
265, 266, 267, 268
 Among the variety of 
different alternatives 
269, 270
 carbon nanomaterials also confer several advantages due to stability 
and several possibilities for functionalizations. Use of carbon nanomaterials including NDs for 
genetic therapy is discussed in chapter 1. 
Cellular internalization of NDs both alone and as diamoplexes, as described in earlier chapters, 
served as a promising basis to identify the system’s functional capacity. Therefore, the ability of 
lys-NDs to deliver functionally active siRNA capable to exert biological effect was tested using 
GFP knockdown assay. Primary amines as carriers for siRNA have been successfully used 
previously by other hard nanoparticulate systems. Amine groups are induced on the surface either 
through artificial synthetic methods like chemical reduction of anionic gold NPs 
271
 or through 
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non-covalent attachment of biomolecular peptide like poly-L-Lysine via secondary modifications 
on the surface. 
272
 In contrast to these previous attempts, the mode we adopted to introduce 
primary amines on the surface was to conjugate covalently the natural amino acid (AA) residues 
on the surface. This renders the system to be more native and compatible to the biological 
environment, which consist of these AAs in abundance. Covalent conjugation also protects 
against the loss of functionalized surface characteristics secondary to non-specific 
macromolecular and electrolytic disturbances in biological media.  
Another important parameter requiring investigation was the safety of functionalized NDs. 
Despite of the fact that several reports indicate the innate biocompatible nature of NDs, 
208, 148, 71
 
it was crucial to investigate whether AA-functionalization affects this biocompatibility. 
Therefore, cellular toxicity of lys-NDs and lysyl-histidine NDs was analysed using a standard 
MTT analysis. It is also important that the materials used as carriers in therapeutics should be 
completely inert in order to achieve a predictable response of delivered therapeutic moiety. This 
inertness for lys-NDs as gene carriers was confirmed through Annexin V assay to elucidate 
carrier induced apoptosis of cells.  This chapter provide details of assays performed to evaluate 
the functional capacity and biocompatibility of functionalized NDs.  
6.4 Materials and Methods 
6.4.1 Materials 
Materials and chemicals used for these experiments were similar as mentioned in chapter 5 with 
following additions: 
Anti GFP siRNA, Silencer® GFP (eGFP) siRNA (50 µM, 5nmoles) was purchased from 
Ambion, ON, Canada. FITC Annexin V/Dead Cell Apoptosis Kit with FITC annexin V and 
propidium iodide for flow cytometry was obtained from Invitrogen, NY, USA. Melphalan was 
purchased in powder form by Sigma-Aldrich ON, Canada. HyClone™ D-PBS (with calcium and 
magnesium and w/o phenol red) was obtained from ThermoFisher Scientific Waltham, MA. 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) was purchased from 
Invitrogen, NY, USA and was prepared as 5mg/mL solution in PBS. Dimethyl sulfoxide 
(DMSO) was purchased from ThermoFisher Scientific Waltham, MA. LipofectamineTM 
RNAiMAX was also purchased from Invitrogen, NY, USA. 
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6.4.2 Primary NDs dispersion 
Primary dispersions of lys-NDs were prepared in purified deionized water at a concentration of 2 
mg/mL. YTZ grinding media was added in all dispersions at a weight ratio of 1:1. The 
suspension was subjected to ultrasonication for 4 hours at a frequency of 25 kHz without heating. 
The ultrasonicated dispersions were then centrifuged at 5200 g for 5 minute to sediment the YTZ 
grinding media and the aggregated ND particles.  
6.4.3 Flow cytometry analysis for GFP knockdown 
Flow cytometry was used to evaluate the transfection efficiency of lys-NDs/anti-GFP siRNA 
diamoplexes prepared at ratios 10:1 to 40:1. HeLa/GFP cells were treated with the diamoplexes 
similarly as described for cellular association assay. Cells treated with lipofactamine/siRNA 
complexes were used as positive control and untreated cells were used as negative control. The 
final concentration of anti-GFP siRNA in each well was 75 pmoles and the treatments were 
terminated after 48 hours. GFP fluorescence was then measured using FL2-H band pass filter 
(585/42 BP). A total of 13000 events were recorded for each sample. In order to analyse the 
negative shift in GFP fluorescence, the histograms representing GFP intensity were divided into 
four regions (no-GFP, low-GFP, mid-GFP and high-GFP). Relative downshift in GFP 
fluorescence intensity from high to low region (i.e. Percent GFP knockdown) was determined by 
combining moderate and high GFP quadrants and comparing with untreated cells as follows: 
                   
                                                                
                                                            
      … (Eq 6.1) 
6.4.4 MTT assay for Cellular Proliferation 
Cytotoxicity of pNDs, rNDs, lysine NDs and lysyl-histidine NDs was evaluated in HeLa cells by 
MTT (3-(4, 5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide) assay. The stock 
dispersions of NDs were made at a concentration of 1 mg/mL in aqueous medium. The cells were 
plated in 96 well plate at a density of 5,000 cells per well and incubated at 37ᵒ and 5% CO2 to 
allow attachment to the plate surface. The cells in different wells were then treated with NDs at 
concentrations ranging from 10 µg/mL to 250 µg/mL (100 µL volume). After 20 hours, the 
treatments were terminated and the cells were washed with 1XPBS three times each. 10 µL of 
MTT stock solution (5mg/mL of MTT in PBS) diluted in 90 µL of serum supplemented media 
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was added in each well, and the cells were incubated at 37ᵒC/5% CO2 for one hour. Thereafter, 
the supernatant was removed, and formazan crystals resulting from the mitochondrial reduction 
of MTT were extracted using 100 µL of dimethyl sulfoxide (DMSO). The plates were incubated 
for another 10 minutes to remove air bubbles. The absorbance was read at 550 nm using 
microplate reader (BioTek® Microplate Synergy HT, VT, U.S.A.). Untreated cells were used as 
the control. Percent cell viability was calculated using the following formula: 
                 
                 
                 
     ………………………………………………. (Eq 6.2) 
6.4.5 Annexin V Assay for Cellular Toxicity 
The cells were plated in 6 well plates at a density of 1x10
5
 cells per well and incubated at 37ᵒ and 
5% CO
2
 to allow attachment to the plate surface. The cells in different wells were then treated 
with aqueous lys-NDs dispersions diluted to concentrations of 25 μg/mL, 50 μg/mL, 100 μg/mL 
and 250 μg/mL using serum supplemented media (2.5 mL volume). Melphalan was used as a 
positive apoptotic control and the solution was prepared in acidified ethanol at an initial stock 
concentration of 50 mM. The solution was diluted with acidified ethanol to 3.6 mM. Subsequent 
dilutions were made using serum supplemented media at final concentrations of 36 µM, 26 µM 
and 16 µM. The treatments were added in the cells. All the treatments were terminated after 20 
hours, and the cells were washed with 1XPBS three times for 5 minutes each. The cells were 
harvested using trypsin and 0.25% EDTA and centrifuged at 95 g and 4 ᵒC for 5 minutes to 
obtain cell pellets. The individual cell pellets were resuspended in 500 µL of D-PBS (with 
calcium and magnesium and w/o phenol red), transferred into 5mL flow cytometer tubes and the 
cellular apoptosis resulting from the treatments was analyzed using BD FACS Calibur™ (BD 
Biosciences, CA, USA). 5 µL of Annexin V and 5 µL of PI were added in all cell samples just 
before the analysis. The cells were analysed using two filters i.e. FL1-BP (530/30) for Annexin V 
detection and FL2-BP (585/42) for PI detection. Healthy population was gated and 10,000 events 
were obtained in the gated region. Secondary gating was applied on the graph showing cellular 
distribution of Annexin V vs Propidium Iodide to distinguish following populations Annexin V
–
/PI
–
 (non-apoptotic), Annexin V
+
/PI
–
 (early apoptotic), Annexin V
+
/PI
+
 (late apoptotic) labelled 
R1, R2 and R3 respectively. % of events in each quadrant was obtained to compare the treated 
and untreated cells. Untreated cells stained with Annexin V and PI separately was used for 
compensation of the filters.  
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6.5 Results 
6.5.1 Flow cytometry analysis for GFP knockdown 
RNA interference using small interfering RNA (siRNA) is a powerful tool to suppress abnormal 
gene expression to treat malignant diseases like cancer. 
273, 274
 siRNA is a small fragment of RNA 
containing 21-23 nucleotides. Upon cellular entry, it binds to RNA interference induced silencing 
protein complexes and targets specific RNA sequence. Subsequent steps during RNA 
interference involve unwinding of siRNA duplex and degradation of the complimentary mRNA 
sequences by endo and exonucleases. 
275, 276
 In order to investigate the ability of lys-NDs to 
function as delivery vehicles, anti-GFP siRNA was complexed to them at different weight ratios 
to form diamoplexes. The cells treated with lys-ND/anti-GFP siRNA diamoplexes (ratios ranging 
from 10:1 to 40:1) were compared to the cells treated with anti-GFP siRNA complexed with 
lipofectamine, as a standard transfecting agent.  
The untreated HeLa/GFP cells show very high fluorescence with ~67% of the population 
appearing in moderate and high GFP regions (Figure 6.1A). When naked siRNA (i.e. without any 
delivery vehicle) was introduced in the cells, ~63% of cells exhibit moderate or high GFP 
fluorescence which shows that this approach do not produce any GFP knockdown (Figure 6.1C). 
However, when siRNA was delivered by lipofectamine, the cells producing moderate or high 
intensity GFP fluorescence dropped down significantly to ~37% (Figure 6.1B). In contrasts to the 
controls, lys-NDs/anti-GFP siRNA diamoplexes showed a promising decrease in cells exhibiting 
moderate and high fluorescence to ~55% at a ratio of 20:1 (Figure 6.1E). However, there were no 
reductions in the cellular fluorescence at lys-ND/anti-GFP siRNA ratios 10:1, 30:1 and 40:1 with 
~66% (D), 64% (F) and 65% (G) cells in moderate and high GFP regions (Figure 6.1).  
Quantitative GFP knockdowns obtained through various treatments were calculated for better 
representation of the results (Figure 6.2). As expected, lipofectamine showed 44% i.e. the highest 
reduction in GFP fluorescence. When the same amount of siRNA was delivered without any 
vehicle, only 5.3% knockdown was obtained. This is due to the anionic nature of siRNA which 
hinders its cellular internalization through the negatively charged cell membrane. Moreover, it is 
not practical to deliver naked siRNA in vivo as well, since it can be rapidly degraded by 
exonucleases in the blood circulation. Complex chemical modifications to the nucleotide 
backbone are required to deliver naked siRNA in vivo for therapeutic purposes. These 
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modifications can delay the degradation from minutes to hours but cannot prevent it for longer 
time periods unlike carrier mediated delivery. 
277
 Moreover, these modifications should be 
extremely selective to minimize the loss of potency and maintain targeted activity of siRNA. 
278
 
In comparison to naked siRNA and lipofectamine mediated siRNA delivery, lys-NDs only 
showed a promising GFP knockdown of ~17% at a ratio of 20:1. It was shown to be the lowest 
effective ratio at which lys-NDs were able to bind and retard the movement of siRNA in gel 
electrophoresis (Chapter 4). Therefore, at a lower ratio of 10:1 no GFP knockdown (~1%) was 
observed. Additionally, at higher lys-ND/anti-GFP siRNA diamoplexes ratios of 30:1 and 40:1 
the intensities of GFP fluorescence remained high and an insignificant knockdown of only ~4% 
and ~2% was obtained respectively. Progressive decline in siRNA delivery upon increasing the 
mass ratio of lys-NDs to siRNA can be due to an extensive binding and packing of siRNA, which 
renders the diamoplex incapable of releasing the nucleic acids in the cells.  
Although a notable GFP knockdown was obtained at 20:1 weight ratio, it was not significant 
compared to the lipofectamine control. Moreover, we were not able to validate this positive effect 
through successive trials. Non reproducible nature of the transfection demands analysis and 
modifications to the system to enhance its functional efficiency. The major reason to diminished 
siRNA activity can be related to the endosomal trafficking and degradation in the cells. For 
successful gene delivery and expression, it is important for the diamoplexes to escape from the 
harsh acidic environment of late endosomes and lysosomes. 
279
 This can be achieved by 
introducing pH sensitive molecules like histidine that can disrupt the endosomal membrane to 
release the diamoplexes in the cytosol. This was aimed by synthesizing lysyl-histidine NDs, 
which now requires further modifications for enhanced surface loading. The idea of introducing 
histidine moiety on ND surface will be further discussed in the last chapter of the thesis under 
future directions to optimize functionalization.  
 It is also important to keep in mind the highly toxic nature of lipofectamine during the treatment 
period. 
280
 Morphological changes were observed within one hour of the treatment induction and 
a significant cell loss was observed at the end of the treatment period. Although the healthy cell 
population was gated during the analysis and uniform numbers of cells were counted for all 
samples, substantial changes in the cellular morphology and function due to lipofectamine 
induced toxicity may contribute towards reducing the GFP fluorescence intensity of these cells. 
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Figure 6.1 Flow cytometry outputs showing the distribution of untreated cells (A) and 
siRNA treated cells (B to G) in high, mid, low and no GFP regions. The figure also shows 
the negative shift of cellular population from mid and high GFP regions to low and no GFP 
regions secondary to treatments with anti-GFP siRNA in naked form (C), through 
lipofectamine (B) and as lys-NDs/siRNA diamoplex ratio of 10:1 (D), 20:1 (E), 30:1 (F) and 
40:1 (G). GFP knockdown was only observed for cells treated with lys-NDs/anti-GFP 
siRNA at a ratio of 20:1, in comparison to the lipofectamine control.  
 
Figure 6.2 Quantitative percent GFP knockdown calculated through flow cytometry 
outputs for the cells transfected with anti-GFP siRNA as naked (blue), through 
lipofectamine (green) and as lys-NDs/anti-GFP siRNA diamoplexes at a ratio of 10:1 
(orange), 20:1 (red), 30:1 (purple) and 40:1 (pink). The highest percent GFP knockdown of 
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17% was recorded for the cells treated with diamoplexes at a ratio of 20:1 in comparison to 
the lipofectamine control (44%). Except lipofectamine, each bar represents the mean ± S.D. 
of three measurements. 
6.5.2 MTT assay for cellular proliferation 
It is crucial that a delivery vehicle should not impose any cytotoxic events upon interaction with 
the mammalian cells. Therefore, biocompatibility of NDs before and after AA functionalization 
was monitored at a wide range of concentrations. Results reveal no significant reduction in cell 
viability for all NDs treated cells compared to the control (Figure 6.3). Kruskal Wallis ANOVA, 
p value>0.05) which ultimately indicates their innate biocompatible nature. The mean cellular 
viability after treatment with pNDs remained in the range of 83-91% (Figure 6.3), while with 
rNDs was in the range of 78-91% (Figure 6.3) indicating that COOH NDs may harm the cells at 
high concentrations. Comparatively, mean cellular viability after lys-ND treatment remained in 
the range of 83-91% (Figure 6.3) indicating that lysine functionalization does not affect the innate 
biocompatibility of NDs. Lysyl-histidine NDs showed mean cellular viability almost similar to 
rNDs (79-91%) for concentrations ranging from 10-100 µg/mL (Figure 6.3). A slight increase to 
110% was observed in cell viability at 250 µg/mL suggestive of an unexpected proliferation. 
However, further investigations are required to elucidate this effect.   
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Figure 6.3 MTT assay for cytotoxicity of pNDs (blue), rNDs (red), lysine NDs (green) and 
lysyl-histidine NDs (purple) in HeLa cells at a concentration ranging from 10 µg/mL to 250 
µg/mL  (Kruskal Wallis ANOVA, p-value > 0.05)  
Biocompatibility of lysine NDs was also evaluated with respect to the presence and absence of 
serum. The mean cellular viability after treatment with lysine NDs at concentrations ranging from 
10 µg/mL to 75 µg/mL in the presence of serum remained in the range of 87-90% (Figure 6.4), 
while reduced to of 74-83% in the absence of serum (Figure 6.4). Although the decrease observed 
for the cells treated with lys-NDs in the absence of serum was statistically significant, its clinical 
relevance cannot be concluded. Additionally, lack of available nutrients required for cell growth 
and proliferation can also be a contributing factor. Conclusively, it can be said that the presence 
of serum proteins further protect the cells in the presence of NDs. 
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Figure 6.4 MTT assay for cytotoxicity of lysine NDs in the presence and absence of serum at 
concentration of 10 µg/mL (blue), 25 µg/mL (red), 50 µg/mL (green) and 75 µg/mL (purple). 
Statistically significant decrease was observed in cell viability after treating the cells with 
lys-NDs in the absence of serum (One-Way ANOVA, p-value<0.05, *Tukeys’s post hoc 
analysis, p-value<0.05).  
6.5.3 Annexin V Assay for Cellular Toxicity 
Apoptosis is a programmed cell death, a phenomenon in which cells induce self-destruction. 
281
 It 
is a widely researched mode of treatment induced by therapeutic genes 
282
, drugs 
283
 and 
antibodies 
284
 targeting chronic life threatening dysfunctions. However, carrier induced apoptotic 
injury is one of the major drawback for a controlled therapy. The carriers should ideally be inert, 
non-toxic and least reactive, to allow optimal control and prediction of the efficacy for the 
delivered therapeutic moiety. As indicated through MTT analysis, NDs are innately 
biocompatible at a wide concentration range irrespective of functionalizations. In order to further 
confirm this finding, annexin V FITC assay was performed to evaluate lys-ND inertness and 
safety. Loss of the plasma membrane integrity is the first step in this pathway, which ultimately 
translocates the phospholipid phosphatidylserine (PS) to the external membrane surface. Annexin 
V being a calcium dependent phospholipid binding protein binds to the exposed PS and can be 
used for the detection of early apoptosis after conjugation of a fluorophore. Therefore, early 
apoptosis is identified as an Annexin V
+
/PI
-
 population of cells indicated as R2 in Figure 6.5. 
Untreated cells exhibit a very tight population in the healthy cells quadrant (R1) and show no 
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events in the R2 quadrant indicating complete absence of apoptosis (Figure 6.5A). On the other 
hand, melphalan which is an apoptosis inducing agent used for melanomas 
285
 shows a distinct 
apoptotic population, with 10%, 15% and 11% events in R2 quadrant at 16µM, 26µM and 36µM 
concentrations respectively (Figure 6.5B to D and Figure 6.6). There is a positive correlation 
between melphalan concentration and apoptotic changes identified as annexin V uptake. 
However, at a higher concentration of 36µM majority of events are shifted towards R3 quadrant 
i.e. the late apoptosis stage and hence shifts down the population in R2 quadrant. In comparison 
to melphalan, lys-NDs did not induce apoptosis as observed in Figure 6.5E to H. There is no 
separate population observed in the R2 quadrant indicating an absence of annexin V uptake. Lys-
NDs exhibited 0.53% ±0.27, 0.31 ±0.08, 0.49 ±0.21 and 3.88% ±0.61 uptake in annexin V at 25 
μg/mL, 50 μg/mL, 100 μg/mL and 250 μg/mL concentrations respectively (Figure 6.6). Slightly 
higher counts observed for 250µg/mL does not necessarily depict an increase in apoptotic 
population and can be considered an anomaly related to the high scattering from NDs internalized 
by the cells. Rather than achieving a separation between the apoptotic and healthy population as 
in melphalan treated cells, the cellular distribution after lys-NDs treatment shifted upwards as a 
whole in a tightly compacted fashion. Therefore, it cannot be attributed to an increased apoptosis, 
but rather related to interference from concentration dependent increase in the side scattering 
following ND internalization as explained in Figure 5.4.  
The number of events observed in the R3 quadrant reveals Annexin V
+
/PI
+
 cellular population. 
This quadrant captures the cells which are either undergoing end stage apoptosis or dead. PI is a 
membrane impermeable DNA stain and is taken up by the cells once the membrane integrity is 
completely compromised and the cell is in the necrotic stage. 
281
 Melphalan treated cells exhibit 
populations separated from the healthy cells with a concentration dependent increase in dead cells 
or the cells undergoing late apoptosis being 2.38%, 3.51% and 13.48% at 16µM, 26µM and 
36µM concentrations respectively (Figure 6.5B to D). In contrast, the lys-NDs treated cells 
exhibits an upward shift of a whole tightly connected population, which cannot be a true 
representative of dead cells, since they show no distinction from the healthy cellular population 
as described above.  
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These analyses reveal that lys-NDs do not induce any apoptotic injury or reduce cellular viability 
at a wide range of concentrations. Moreover, innate biocompatibility of NDs irrespective of 
functionalizations and serum presence is concluded.  
 
Figure 6.5 Flow cytometry plots indicating early and late apoptotic cellular distribution 
based on annexin V vs Propidium Iodide uptake for untreated (A), melphalan at 16 µM (B), 
26 µM (C), 36 µM (D) and lys-NDs at 25 µg/mL (E), 50 µg/mL (F), 100 µg/mL (G), 250 
µg/mL (H) treated cells. Quadrant R1, R2 and R3 indicate annexin V
–
/PI
–
 (non-apoptotic), 
annexin V
+
/PI
–
 (early apoptotic), annexin V
+
/PI
+
 (late apoptotic) cell populations.   
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Figure 6.6 Flow cytometry analysis for lys-ND induced apoptosis at 25 µg/mL (red), 50 
µg/mL (purple), 100 µg/mL (pink) and 250 µg/mL (blue) concentration in comparison with 
melphalan induced apoptosis at 16µM (grey), 26µM (brown) and 36µM (green) 
concentrations.  
6.6 Conclusion 
This study provides a basis of hope to further modify AA functionalized NDs in order to increase 
their efficiency as gene delivery vehicles. A slight success was observed regarding its function as 
gene carriers, but this was not significant in terms of therapeutics. Possible reasons mainly the 
endosomal degradation can be targeted by introducing pH sensitive molecules on ND surface as a 
mode of improving its function in the future trials. However, the study confirmed that NDs 
remain biocompatible after functionalizations and are inert in the cellular environment. No 
apoptosis was observed even at very high concentrations of lys-NDs, which laid a benefit to 
design a system which can ensure predictable response of the therapeutic moiety. 
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7 Conclusive Discussion 
This study has addressed three phases for developing a novel carbon nanomaterial called 
nanodiamonds (NDs) as gene carriers for RNAi therapeutics. The first phase elucidated the 
development of amino acid (AA) functionalized NDs as competitive systems capable of optimum 
binding and delivery of therapeutic genes in mammalian cells. The second phase of the study 
involved physicochemical characterizations of functionalized NDs and the development of an 
optimized treatment protocol for in vitro applications. The final phase of the study probed 
multiple aspects regarding the behavior of functionalized NDs in the biological environment 
including: interactions of the reactive surface with physiological proteins, cellular uptake of bare 
NDs and the diamoplexes (ND-gene complexes), effect of proteins on the cellular uptake process, 
assessment of gene delivery efficiency and finally their  biocompatibility profiles. This is the first 
report to our knowledge of AA functionalization of NDs for gene delivery purposes. 
The major aspects covered in the individual phases of the study are discussed as follows: 
7.1 Phase 1 
The first phase was aimed at functionalizing the surface of NDs with basic AAs. This 
functionalization was performed to achieve two major objectives: 1) to minimize aggregation for 
formulating a stable colloidal dispersion and 2) to create a cationic surface to electrostatically 
bind the nucleic acids for cellular delivery. Additionally, histidine was introduced in the system 
as a pH-sensitive AA for avoiding lysosomal entrapment of diamoplexes in the cells.  
Functionalization of NDs through covalent conjugation of lysine and lysyl-histidine on the 
innately reactive surface comprised of three major steps: homogenizing the surface by pre-
treating the NDs through oxidation, increasing the reactivity of the surface functional groups and 
covalently attaching the AAs to the surface through a three carbon chain spacer (Scheme 1 and 2) 
. The presence of peaks corresponding to carbonyl and amine groups and absence of peak for 
hydroxyl group in the infrared spectra of functionalized NDs elucidate the formation amide 
linkage between NDs and amine terminated spacer attached to the AAs (Figure 4.9). 
Thermograms of NDs after functionalization further confirms the presence of AAs on the surface 
through a significant weight loss induced upon heat induction (Figure 4.10). This weight loss 
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corresponds to the breakage of covalent linkages at high temperatures and loss of surface 
functional groups.  Thermogravimetric analysis also reveals that the surface loading of 
carboxylate functionalities significantly increased after re-oxidation, which later facilitated the 
formation of lysine terminated ND surface (Table 4.1). Functionalization enhancement after re-
oxidation of the surface resulted due to increased possibilities for the formation of amide 
linkages. It served as a better approach to increase the overall surface loading of the chemical 
conjugates on NDs in comparison to other modes previously reported in the literature. NDs 
previously functionalized with long alkyl chains directly on the partially hydroxylated pristine 
surface produced a surface loading of 0.3-0.4 mmoles/g. 
286
 In contrast to that, the re-oxidized 
NDs having an almost completely carboxylated surface allowed the surface loading to increase 
up to 1.97 mmoles/g (Table 4.1).  Another example of biomolecular conjugation on NDs is 
presented through covalent bonding of lysozyme on the surface with a loading capacity of 0.2-
0.25mg of lysozyme on 1 mg of NDs. 
287
 Here lysozyme was directly conjugated to the native 
ND surface after the activation of functional groups. Apparently, an additional re-oxidation 
process used to synthesize lysine functionalized NDs (lys-NDs) improved the surface loading to 
0.61 mg of lysine on 1 mg of NDs. 
In order to design NPs for gene delivery, the creation of a cationic surface is the most feasible 
and commonly employed approach. It is achieved through varieties of covalent and non-covalent 
surface functionalizations. 
67, 68, 69
 Use of native biological molecules for this purpose is rare and 
is mostly mediated through physical adsorption. 
67
 However, soft NPs like Gemini lipids 
covalently functionalized with amino acid conjugates have shown significant potential as gene 
carriers due to functionalization stability and optimum binding with nucleic acids. 
288, 289 
 
Keeping in view this commendable efficacy of bio-molecular cationic surface for gene delivery, 
NDs were functionalized for the first time with lysine and lysyl-histidine AA conjugates. 
134
 The 
positive zeta potential of lys-NDs (Figure 4.12) indicates the dominance of cationic primary 
amines on the surface capable of binding the anionic genetic materials and also to 
electrostatically interact with the cell membrane.  
Unlike lysine conjugation, lysyl-histidine functionalization on NDs was not successful possibly 
due the larger surface area of the conjugate; creating a stearic hindrance against adjacent COOH 
groups for functionalization.  
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7.2 Phase 2 
This phase characterized the physicochemical properties of functionalized ND (fNDs) based gene 
carriers. NDs have tremendous potential as delivery vehicles in nanomedicine; however the 
strong aggregation tendency complicates their application to a great extent. Stirred media milling 
is used as a principal physical approach to counter aggregation; however it poses a challenge of 
bead contamination and long term maintenance of a stable well-dispersed formulation. 
82,
 
125
 
Chemical functionalization of the surface capable of reducing non-specific interactions between 
individual particles can complement the mechanical method of disaggregation to achieve long 
term stability. 
286
 Functionalization of NDs with long alkyl chains have enhanced their dispersion 
stability in organic solvents by reducing the particle size to nanometer size range (15 µm to 150 
nm). 
286
 Similarly, decorating the surface with fluorine 
15
 and borane 
14
 reduced the size of 
pristine NDs up to 160 and 50 nm respectively. In my work, lysine functionalization created a 
homogenous cationic surface capable of dominating the repulsive forces between particles to 
minimize aggregation. 
Physicochemical stability testing was performed in various biologically relevant media to 
evaluate the stability of NDs through this mechanochemical approach. These characterizations 
were also aimed at developing a treatment protocol for in vitro dosing application. Lys-NDs 
exhibited highest long term stability and uniform particle size distribution in the aqueous 
medium. Previously, it was reported that lysine functionalization limited aggregation of NDs in 
the aqueous environment for a short period of time. 
134 
Here, the analysis further reveals that lys-
NDs are well-dispersed and remain stable in water for an extended time period of 25 days (Figure 
5.1). This is due to the fact that water does not compromise the positivity of surface 
290
 and 
maintain the electrostatic repulsion between adjacent cationic surfaces to hinder core aggregation. 
In order to achieve the similar long term colloidal stability in the aqueous medium, CNTs another 
very common gene delivery vector were also physically functionalized with natural and synthetic 
dispersants. 
291
 However, unlike lysine functionalization which is capable of maintaining ND size 
in the range of 50-90 nm in water (Figure 4.11), these approaches failed to reduce the size of 
CNTs below 400 nm during an almost same time interval. 
291
  
In contrast to lys-NDs, lysyl-histidine NDs exhibited poor stability in water, producing a system 
with a particle size distribution centered in the range of 615-955 nm (Figure 4.11). This resulted 
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due to an uneven functionalization that failed to maintain the electrostatic repulsion between 
adjacent ND surfaces. 
In addition to optimum physicochemical characteristics of colloidal fNDs dispersion, their 
suitability as gene carriers was exhibited by their ability to bind the plasmid DNA and small 
interfering RNA effectively at minimum ratios of 1:1 and 1:20 respectively (Figure 4.13 & 4.14). 
In contrast to polymer functionalized NDs (polyallylamine hydrochloride) which requires a high 
mass ratio of 1:70 for complete binding, 
217
 lys-NDs are required in very low amounts to form 
stable diamoplexes. This provides a promising opportunity to reduce the overall ND exposure 
during in vivo treatments. Moreover, the diamoplexes of lys-NDs with siRNA remain intact in the 
in vitro biological environment rendering the system capable for intracellular delivery of the 
genes.  
7.3 Phase 3 
This phase of the study provided comprehensive understanding regarding the behavior of fNDs in 
the biological system and addressed two major aspects: interactions with the physiological media 
and interactions with the mammalian cells.  
Despite of the inherent stability of lys-NDs, physicochemical changes mediated through the 
biological growth medium can modulate their transfection efficiency. Therefore, it was crucial to 
identify the most suitable dosing medium to formulate NDs and diamoplexes treatments for 
cellular experiments. Unlike aqueous formulations which maintained stability of lys-NDs for an 
extended time, formulations in cell culture medium exhibited poor stability possibly due to high 
ionic strength of the media promoting flocculation of the colloidal system (Figure 5.2). 
111, 231, 232  
In addition to the cell culture medium, physicochemical characterization and dispersion stability 
testing were also performed in other biologically relevant media (including water, phosphate 
buffered saline (PBS) and methylcellulose). The dispersions of lys-NDs in PBS showed extensive 
sedimentation within 3 days due to the high ionic strength of PBS that disturbed the surface 
charges and promoted random van der Waals interactions (Figure 5.1). 
225, 226
 On the contrary, 
lys-NDs in 0.5% methylcellulose gel and water showed minimum aggregation during 3 days 
(Figure 5.1). However, methylcellulose being an amphiphilic molecule can reduce the positive 
charge density of the surface in the long run through random surface adsorptions. 
228
 Due to this 
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fact and the overall dispersion quality of the aqueous ND formulation, water was selected as the 
choice for the dosing medium.  
In addition to the dispersion stability, the ability of fNDs to interact with the macromolecules in 
the physiological systems can serve as another contributing factor for changes in their innate 
characteristics. Like all other charged nanoparticles, NDs can also interact with proteins forming 
a corona that can change the overall surface reactivity. 
261, 184, 220, 188 
Due to positively charged 
surface of lys-NDs, there is an increased possibility for the adsorption of proteins with low iso-
electric points (<5.5) such as albumin. 
235
 Massive increase in the particle diameter and the 
change of potentials to high negative values occurring immediately after protein adsorption 
indicated the formation of an anionic protein corona around fNDs (Figure & Table 5.2). 
Thickness of the protein corona remained constant for 3 days, however the surface characteristics 
changed drastically indicating the dynamic nature of protein adsorption. This illustrates that the 
identities of adsorbed proteins may change over time leading to variations in the surface charges; 
but the total amount of proteins on the surface remains roughly constant. Evaluation of their 
interaction with physiological proteins can provide useful understanding regarding their behavior 
in the blood stream. 
After the development of best dosing formulation, interactions of lys-NDs with mammalian cells 
were evaluated. At first, Internalization of bare lys-NDs and diamoplexes (i.e. ND-gene 
complexes) was observed through a combination of spectroscopic, microscopic and light 
scattering techniques previously reported in the literature 
217, 292, 293
 and through novel techniques 
such as STXM. Results reveal that lys-NDs internalize the cells in a dose dependent fashion and 
localize mostly around the cellular edges and the cytoplasm, with some being in close proximity 
to the nucleus (Figures 5.3-5.6). They are found to significantly overlap with intracellular and 
growth medium derived proteins. Unlike carboxylated anionic NDs, lys-NDs shows optimum 
binding and internalization of siRNA in the cells (Figure 5.7). Additionally, the protein corona 
also contributes towards maintaining the stability and facilitating the cellular uptake of 
diamoplexes (Figure 5.8). It was shown as a significant increase of 1.8 folds in the fraction of 
siRNA fluorescence in the presence of serum (Figure 5.8) as compared to the serum-free 
environment and is speculated to be the result of serum-induced increase in the particle size of 
diamoplexes which can switch the internalizations pathways to favour the uptake of large 
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complexes. Increase in the overall particle size of the protein coated diamoplexes can switch the 
most prominent clathrin mediated endocytosis of NDs to claveoli mediated endocytosis, 
255 
which 
is responsible for the uptake of complexes sized around 500 nm or above. 
256, 257
 Moreover 
albumin, the main component of FBS can also facilitate towards the alteration of internalization 
pathway by acting as a ligand that binds to the albumin-binding protein on the claveolar plasma 
membrane. 
182, 260, 261
 
After demonstrating the cellular uptake of lys-NDs alone and the diamoplexes, functional assays 
were conducted to evaluate its transfection efficiency. Lys-NDs showed a promising GFP 
knockdown of ~17% at a ratio of 20:1 (Figure 6.1 & 6.2), evidencing binding, delivery and 
release of functional siRNA in the cells. Unfortunately, this level of transfection is not enough in 
terms of therapeutics especially when compared to other functionalization approaches like 
polymer adsorption (polyethyleneimine) which showed a 4 fold higher transfection in contrast to 
the naked DNA delivery. 
69
 The major reason for reduced functional efficiency of lys-ND derived 
diamoplexes is their endosomal trafficking and subsequent intra-endosomal degradation of the 
genetic materials. It can be improved through various chemical modifications on the system that 
will be discussed later in the thesis.  
Finally, the biocompatibility of NDs before and after AA functionalization was monitored at a 
wide range of concentrations. Results reveal no significant reduction in the viability for the cells 
treated with pristine NDs, re-oxidized NDs, lys-NDs and lysyl-histidine NDs at all 
concentrations, confirming their innate biocompatibility (Figure 6.3). It was further confirmed by 
conducting an apoptosis assay to assess the inertness of fNDs. In comparison to a standard 
apoptosis inducing chemotherapeutic drug ‘melphalan’, the cells treated with lys-NDs did not 
show any uptake for Annexin V, a phospholipid binding protein that binds to the exposed 
phosphatidylserine (Figure 6.5 & 6.6). This validates the intact nature of the cell membrane and 
absence of apoptotic injury through NDs unlike other carbon nanomaterials particularly CNTs. 
294
 Moreover, NDs also do not fragment DNA 
37
 or alter protein expression profiles of the living 
cells at wide range of concentrations and particle sizes. 
72
 Previously reported studies and current 
biocompatibility analysis confirms that NDs are the most biocompatible members of the carbon 
nanofamily.    
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8 Future Directions 
 
Evidences regarding disaggregation, well-maintained stability, optimum cellular uptake, 
intracellular delivery and expression of siRNA and biocompatibility obtained through this study 
paved the way for future evaluations and modifications aimed at improving this nanocarrier. The 
future directions will focus on the following aspects of NDs as delivery vehicles: 
8.1 Mechanistic studies for identifying endocytotic pathways and subcellular 
localization 
Most nanocarriers internalize the cells through the process called pinocytosis which internalize 
fluids and molecules within small vesicles formed by the cell membrane folding. As mentioned 
earlier, the internalization pathway adopted by nanoparticles (NPs) significantly affects their fate 
in the cells. Therefore, clear understanding of internalization pathways will provide a unique 
opportunity to adjust the properties of nanodiamonds (NDs) in order to overcome the cellular 
barriers for gene expression. However, lack of biocompatible labels for long term tracking of NPs 
in the cells is a principle obstacle for the study of these pathways in detail. Following strategies 
will be directed in the future to study this aspect: 
 Selective mechanistic inhibition will be performed to determine the most prominent 
internalization mechanism for functionalized NDs and the diamoplexes. Standard inhibitors 
of various endocytotic machineries will be used to evaluate the changes in the diamoplex 
uptake and siRNA expression in the cells. This assay will be performed by using two 
techniques: 
 Transmission Electron Microscopy (TEM) to show the specific changes occurring in the 
cell membrane elucidating the uptake pathway (e.g. pseudopods demonstrating 
macropinocytosis or formation of pits indicating clathrin or claveoli mediated endocytosis).  
 Flow cytometry for quantitative detection of diamoplexes uptake secondary to the selective 
inhibition of various endocytotic pathways. This assay would utilize the side scattering 
patterns of the treated cells to correlate the amount of diamoplexes internalized in the cells.  
 Upon successful investigation of pathways involved in the uptake of diamoplexes, functional 
assays for gene expression would be conducted using flow cytometry to evaluate the most 
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optimum pathway allowing efficient gene release and expression. Knowledge regarding the 
effect of internalization pathways on the functional efficiency of diamoplexes will serve as a 
basis for future design modifications in NDs (particularly particle size) to adopt the most 
optimum internalization route for maximum efficacy.  
 Next step would be to investigate the subcellular localization of diamoplexes by using 
artificially doped fluorescent NDs (FNDs). FNDs can be functionalized on the surface with 
AA conjugates, since they can be tracked easily through various techniques due to its bright 
fluorescence. Confocal microscopy with selective organelle labelling will be carried out to 
create color composite maps illustrating the subcellular distribution of functionalized-FNDs.   
8.2 Design modifications to optimize the formation of lysyl-histidine NDs 
Histidine is a positively charged polar AA having an imidazole ring which becomes fusogenic at 
physiological pH. As explained earlier, introduction of histidine as a pH sensitive AA on the ND 
surface will act as an endosomal destabilizer to cause the release of the genetic materials in the 
cytosol (Figure 9.1). 
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Figure 8.1 Schematic illustration of histidine mediated endosomal escape  (A) endocytosis of 
diamoplex by cell membrane (B) formation of endosome, acidification and subsequent 
protonation of histidine to become fusogenic (C) disruption of hydrophilic/hydrophobic 
balance within endosome (D) rupture of endsosomal membrane and release of diamoplex in 
the cytosol (E) Binding and expression of siRNA by RNA-induced silencing complex (RISC) 
in the cytoplasm (F) Transfer of pDNA to the nucleus for expression by nuclear membrane 
transport proteins  
Design modifications to optimize lysyl-histidine NDs will be directed towards overcoming the 
stearic hindrance posed by the large size of the conjugate impeding complete surface 
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functionalization. The new strategy to synthesize lysyl-histidine NDs will be influenced by the 
process of lysine functionalization in lieu of the optimum surface loading achieved for lysine AA 
conjugate. This process will primarily form lysine functionalized NDs followed by secondary 
histidine functionalization onto the lysine functionalized ND surface as illustrated in scheme 5.  
 
Scheme 5 Design modification to synthesize lysyl-histidine functionalization. (1) 
Conjugation of lysine with the spacer to form N’- (Nα,Nε-bis-boc-lysyl)-N”-cbz-
diaminopropane & N’- (Nα-fmoc,Nε-boc-lysyl)-N”-cbz-diaminopropane conjugates (2) 
Deprotection of the spacer moiety to form N’- (Nα,Nε-bis-boc-lysyl)-N”-diaminopropane & 
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N’- (Nα-fmoc,Nε-boc-lysyl)-N”-diaminopropane (3) Attachment of N’- (Nα,Nε-bis-boc-lysyl)-
N”-diaminopropane & N’-(Nα-fmoc,Nε-boc-lysyl)-N”-diaminopropane to acyl chloride 
functionalized NDs (Cl-C=O) (4) Removal of fmoc protecting group to form  N’- (Nα,Nε-bis-
boc-lysyl)-N”-diaminopropane & N’-(Nα,Nε-boc-lysyl)-N”-diaminopropane functionalized NDs 
(5) Attachment of histidine to fmoc deprotected lysine residue to form N’- (Nα,Nε-bis-boc-
lysyl)-N”-diaminopropane & N’- (Nα-bis-boc-histidne, Nε-boc-lysyl)-N”-diaminopropane 
functionalized NDs (6) Removal of boc protecting groups to form lysine-diaminopropane & 
lsyl-histidne-diaminopropane functionalized NDs.  
Cbz= Carboxybenzyl; fmoc= Fluorenylmethyloxycarbonyl; boc= Di-tert-butyl oxycarbonyl 
 
The following is the proposed structure of lysine-lysyl-histidine functionalized NDs (Figure 9.2) 
 
 
Figure 8.2 Structural illustration of lysine-lysyl-hitidine functionalized NDs 
Amine terminated 
three carbon spacer 
(1, 3-diaminopropane) 
Lysyl-histidine 
Lysine 
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9 Conclusion  
This study demonstrated for the first time that covalent immobilization of basic amino acids 
(AAs) mainly lysine directly on the ND surface render their utilization in gene therapeutics by 
forming stable diamoplexes with  nucleic acids. This mode of surface transformation also limits 
aggregation to design a well-dispersed aqueous formulation, which is promising for its stability in 
the biological milieu. Like all other NPs, AA functionalized NDs also attract proteins and form a 
corona around its surface. However, this protein corona stabilizes ND-siRNA complexes and 
facilitates the process of cellular uptake. The increased cellular uptake in the presence of serum 
proteins is another promising finding, rendering them amenable for parenteral administration for 
gene therapy. Although not significant in terms of therapeutics, lys-NDs show an encouraging 
functional efficiency to deliver siRNA in the cells. Major reasons for its weak activity can be 
targeted in future to improve their functional capacity. The study also elucidate that NDs remain 
biocompatible after functionalizations and are inert in the cellular environment. No apoptosis was 
observed even at very high concentrations of lys-NDs, which laid a benefit to design a system 
which can ensure predictable response of the therapeutic moiety.  Future analyses regarding 
mechanisms of cellular uptake and subcellular localization can reveal further insight regarding 
possible modifications to optimize the delivery system.  
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10 Appendices 
10.1 Excerpts of Chapter 2: Nanodiamonds as Novel Materials for Therapeutics 
10.1.1  Production of Nanodiamonds (Section 2.4) 
NDs naturally exist in different levels of universe. Carbonaceous chondrites which are a special 
type of stony meteorite 
295
are the major naturally occurring source of NDs sized 2.5 nm. These 
NDs also contain hydrogen, nitrogen and oxygen impurities. 
90
 
 NDs are synthetically produced by many different approaches. Each method yields particular 
sized diamond nanoparticles (NPs), which are suitable for specific applications. Based on the 
primary particle size, NDs are categorized into nanocrystalline particles (1 to ≥150 nm), 
ultrananocrystalline particles (2 to 10 nm), and diamondoid structures (1 to 2 nm). 
296,
 
84
 
Ultradispersed diamond NPs (Figure 2.1a) ranging from 2-8 nm are produced by detonation and 
are widely researched for biomedical applications. 
93
 In this process NDs are synthesized by 
detonating a mixture of trinitrotoluene (TNT) and hexogen in a negative oxygen balance to 
facilitate carbon-carbon interaction (Figure 2.1b). Detonation involves transformation of the 
explosive material; it requires constant maintenance of optimal thermodynamic conditions. 
During detonation pressure and temperature is maintained at levels capable of allowing the 
appearance of free carbon in the product and at the same time also inhibiting diamond to graphite 
transition due to explosion. 
297
 The process creates soot containing nano-sized diamond particles 
which are then isolated and purified. To maximize the yield up to 90 % the soot is subjected to 
high energy electronic irradiation and heat treatment at 800 ᵒC followed by rapid cooling. 
Isolation of NDs from the soot is carried out by boiling in acid at high temperature of 3000°C–
4000 °C and high pressure of 20–30 GPa for 1 to 2 days. 84, 16, 298, 113 Despite of various novel 
approaches for ND synthesis, detonation NDs holds primary focus to generate NDs for 
nanomedicine research, majorly as therapeutic delivery vectors. 
100,
 
101,
 
134
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Figure 10.1 (A) Schematic representation of ND synthesis in a detonation chamber. (B) 
High-resolution transmission electron microscopic image of detonation nanodiamonds 
(NDs). (A) Explosion of TNT and hexogen in negative oxygen balance created by nitrogen 
carbon dioxide and water produces soot containing core aggregates of ND particles which 
are then isolated and purified. (B) Reprinted with permission from 
84
 “Copyright (2013) 
Dove Medical Press” 
Novel techniques for generating NDs synthesis focus primarily on reducing the formation of core 
aggregates in the synthetic process and producing disaggregated primary diamond NPs. 
299
 The 
core aggregates are formed mainly due to sp
2
 graphitic carbon contamination present in the soot 
resulting from detonation. 
85
 Most of these novel techniques involve conversion of graphite into 
diamond structures by creating optimal conditions of temperature and pressure through different 
modes. 
299,
 
300,
 
301
 One of such high temperature and pressure technique kept forward involves 
decomposition of graphitic carbon nitride to produce uniform sized, single phased NDs with no 
graphite contamination. 
299
 Graphitic carbon nitride treated at 800-900 ᵒC and between 22 to 25 
GPa pressure decomposes directly to diamond and nitrogen. 
302
 Unlike detonation, this approach 
is centered upon creating high temperature and high pressure conditions during the synthesis 
phase of NDs. It offers many advantages over detonation. Mainly it produces pure ND crystals 
with virtually no graphitic contamination; and hence allows their utilization in as-synthesized 
form with minimal requirement of post synthetic purification. 
299
  
Ultrasonic cavitation is another approach to synthesize NDs based on high pressure high 
temperature technique. 
300
 This process involves transition of graphite into diamond in organic 
A B 
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liquid at temperature of 120 ᵒC and atmospheric pressure but in presence of ultrasonic waves. 
Ultrasonic cavitation acts as super-high pressure shock waves producing necessary combination 
of temperature and pressure to facilitate this transformation. However, this process produces very 
low yield of up to 10 %. 
300
 
High energy laser irradiation of graphite is an alternate method of producing NDs. 
301,
 
303
 This 
technique involves irradiating the graphite powder with high energy pulsed laser beam at room 
temperature and atmospheric pressure. Pulsed laser energy produces high temperature which 
heats the raw graphite powder, followed by rapid cooling that generates high pressure. Thus high 
temperature and high pressure combination is created to form nanosized diamond particles of 5 
nm with fewer impurities as compared to detonation process. 
301
 
While these alternative techniques offer high quality NDs, the major source of biomedical 
applications today remains the detonation NDs particularly due to high yield and convenience for 
its application at industrial scale. 
10.1.2 Fluorescence imaging (Section 2.8.3.1) 
Internal structural defects and impurities cause NDs to emit visible fluorescence, which show 
some advantages compared to the conventional dyes used for fluorescence imaging. Under the 
same excitation conditions, a single 35nm sized diamond NP is significantly brighter than 
commonly used dye molecules such as Alexa Fluor 546. 
105
 In addition to higher fluorescence, 
NDs also resist photobleaching and fluorescence blinking for longer duration of 5 minutes unlike 
Alexa Fluor which photobleaches within 10 seconds. 
105
 Photobleaching is one of the major 
deficiencies of imaging probes, where the fluorophore undergoes chemical degradation due to the 
generation of reactive oxygen species (ROS) in biological system as a by-product of florescence 
excitation. 
304
 Fluorescence blinking is the phenomenon showing intermittent light and dark 
bands upon continuous illumination, common in hard nanomaterials like quantum dots. 
305
 
Fluorescence blinking presents as a problem for single-molecule spectroscopy 
305
 due to lack of 
image consistency. In addition to the above mentioned problems, auto-fluorescence of cellular 
structures like mitochondria and lysosomes is also a concern in the design of imaging probes. 
306
 
It usually arises in the emission wavelength range common to many fluorescent dyes (i.e. 510-
560 nm), and therefore creates intense background signals making the detection of the probe 
increasingly challenging. However, NDs when excited with 532 nm wavelength light, produces 
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an emission between 650-720 nm thereby reducing the interference of cellular auto-fluorescence. 
105
  
Various approaches have been utilized to induce or enhance the fluorescence centres in NDs. One 
of such techniques involves irradiation of NDs with helium ions (He
+
) at 40 keV followed by 
thermal annealing at 800ᵒC to create vacancies. 199 Hydrogen ions (H+) at 3 MeV are also used in 
place of helium to induce nitrogen vacancy centers in ND core. 
307
 Another way to create 
nitrogen vacancies is to directly incorporate nitrogen atoms as native nitrogen 14N 
308
, its isotope 
15N 
309
 or as cyanide (CN
-
) ions 
310
 directly in the core. To preserve fluorescence from the 
nitrogen vacancies NDs are encapsulated by bulky groups like phenols, which reduces the non-
radioactive decay pathways of colored centres. 
311
 Fluorescence can also be produced through 
surface conjugation. For example, NDs can be functionalized with a hydrophobic molecule 
octadecylamine producing bright blue fluorescence and can be useful for imaging hydrophobic 
components of the body.  
312
 
Opportunities to induce and enhance the  florescence centres in NDs  along with its innate 
biocompatibility at all levels has attracted their use as cellular biomarkers for tracking natural and 
therapeutic processes 
176
 
313
 
314
 Fluorescence of NDs can be clearly detected in the treated cells 
and allows detailed localization of NDs and the conjugated the therapeutic moiety (Figure 2.13). 
 
Figure 10.2 Left panel: Bright-field image of a HeLa cell after uptake of 35-nm fluorescent 
NDs. Most of the internalized NDs are seen to distribute in the cytoplasm. Right panel: 
Epifluorescence image of a single HeLa cell after the ND uptake. An enlarged view of the 
fluorescent spots (denoted by “1” and “2”) with diffraction-limited sizes (FWHM ≈ 500 nm) 
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is shown in Inset. The separation between these two particles is ≈1 μm. Reprinted with 
permission 
105
 from “Copyright (2007) National Academy of Sciences” 
 
Fluorescent NDs are also employed for targeted bio-imaging to study ligand-receptor binding 
kinetics. NDs bio-conjugated with transferrin were observed through laser scanning fluorescence 
microscopy to evidence the over expression of these receptors on cancerous cells. 
315
 Here, the 
NDs act both as a carrier for tranferrin and as an imaging tool, hence no additional imaging probe 
is required to study these interactions. Fluorescent NDs are also considered as candidates of 
interest for long term cell tracking and sorting using flow cytometry. 
316
  
More recently, theranostic applications of NDs are examined, which enables their utilization for 
multiple purposes like delivering therapeutic molecules, imaging biological processes and 
tracking treatment approaches at the same time. This is particularly done by artificial induction of 
enhanced fluorescing centers and simultaneously inducing specific surface functionalizations to 
confer affinity for therapeutic drugs and biomolecules. 
317
 A recent example of such an approach 
is the conjugation of ND with an anti-cancer drug cisplatin both through physical and chemical 
conjugation. Here, NDs acted as a delivery vehicle for cisplatin and also as a probe for cellular 
imaging. 
318
 
In biomedical analyses, the nitrogen vacancy centers in NDs can also be used as a light source for 
imaging optical microscopic imaging. 
248
 It provides a fluorescence alternative to scattering 
imaging of cells and can ensure less photo damage.  
248
 
10.1.3 Combined Fluorescence and Magnetic Imaging (Section 2.8.3.2) 
Magnetism is an additional property of NDs that can impart further advantages for bio imaging. 
Magnetic NDs can serve as contrast agents in magnetic resonance imaging (MRI), 
319
 a 
commonly diagnostic tool. NDs can provide a safer alternative to traditional gadolinium which is 
a free solubilised ion and is considered highly toxic especially in renally impaired patients. 
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NDs due to their biocompatibility can alleviate this health concern and serve as MRI reporting 
marker to elucidate metabolic fate and distribution of nanoparticulate delivery systems. 
319
  
Alternative to complete replacement of traditional contrast agents, NDs can also be conjugated 
with these contrast agents for better resolution and localization. 
78
 Gadolinium/ND complexes are 
useful for long term cellular examination and evaluation of disease progression. NDs tend to 
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attract water molecules to the surface of gadolinium and increase the relaxivity of the contrast 
agent, resulting in higher resolution imaging compared to traditional gadolinium tracers. 
78
 
Recent investigations focus of modulation of NDs by magnetic resonance and serve to develop a 
highly proficient technique called deterministic emitter switch microscopy, which can enable 
super-resolution imaging particularly useful for nanomedicinal research. 
321
 
10.1.4 Scattering imaging (Section 2.8.3.3) 
Elastically scattered light from a single 55 nm diamond is 300 folds brighter than that of a single 
cell organelle of the same size. As compared to the metal based scattering labels like gold and 
silver, ND also produces a stable image with minimum photo damage. 
247
 Therefore, NDs are 
investigated to improve optical bioimaging. 
247,
 
322
 NDs also produce a sharp Raman signal and 
an isolated signature peak at 1332 cm
-1
, therefore can be detected in the cells through Raman 
mapping. 
323,
 
324
 A nano-complex prepared by conjugating lyzosyme to NDs is shown to provide 
useful information regarding the interaction of the enzyme with bacterial cells through Raman 
spectroscopic mapping. 
150
 In this complex, NDs not only act as carrier for the enzyme, but also 
serve as a nano-probe to track the biomolecular changes resulting from enzyme delivery. 
150
 
While these techniques are mainly employed on laboratory scale for in vitro processes, there is a 
growing understanding that they might be expended into clinical applications for medical 
imaging and diagnosis. 
10.1.5 Nanodiamonds for Small Molecule Delivery (Section 2.8.4.1) 
Many studies have elucidated the use of NDs as effective drug delivery vehicles due to diverse 
surface characteristics. Opportunities to modify the surface of NDs according to functional 
groups of the drug attract their utilization for drug delivery to specific targets. High surface 
loading, physicochemical stability of the complexes in physiological system and opportunities to 
target ND complexes towards specific cells encourage the administration of minimal drug 
quantities to hit the optimum efficacy standards. These properties prevent the toxicity and 
adverse effects associated with the drug and also limit the drug wastage. NDs are investigated for 
both, localized and systemic delivery of drugs. 
NDs can serve as a potential carrier for systemic drug delivery due to its nano size range, diverse 
surface area and several possibilities of surface functionalizations as described earlier. 
95
 NDs, 
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like other nanosized carriers can overcome the physiological barriers, reduce systemic exposure 
times and allow delivery of potent drugs like chemotherapeutic agent to targeted tissues. An 
apoptosis inducing anti-cancer drug doxorubicin hydrochloride (DOX) was conjugated 
successfully to NDs. 
325
 
326
 This complex provided slow and sustained dissociation of the drug 
from the complex with maximum release after 16 hours of administration in vitro. This builds a 
potential to utilize NDs for reducing the dosing frequency and synthesizing controlled drug 
delivery system. ND-DOX complexes accumulated in the tumour after systemic administration 
and subsequently the efficacy of DOX increased to four times. Accumulation in kidneys and 
associated nephrotoxicity was reduced compared to free DOX. 
325
 However, it was postulated 
that NDs alone also possess some anti-cancer properties which could add to the effect of the drug 
and contribute to prolonged life span in tumour induced mice. 
325
 Elaborative investigations are 
required to study this effect more clearly. Release of potent drugs from ND complexes can be 
tightly controlled by producing pH dependent adsorption and desorption. 
327
 It can be achieved 
by attaching acid phosphatase, an enzyme responsible for switching the drug on ND surface with 
other substrates in acidic medium. 
327
 This study provides a proof of concept for designing 
nanocarriers for target-specific actions. 
 NDs complexes also overcome drug efflux processes in chemoresistant tumours. 
213
 The 
cancerous cells which were treated with ND-DOX complexes retained higher amount of the drug 
(0.26 µg/mL) compared to free DOX (0.02 µg/mL) after 4 hours of efflux. The overall intensity 
of DOX action is slightly reduced after complexation, however, these complexes are still able to 
elicit significant cell death for tumour suppression. 
213
 
Polymers like polyethylene glycol (PEG) adsorbed on ND surface can increase the drug loading 
capacity of NDs. 
165
 The PEGylated ND complex allowed for a  slower drug release producing a 
peak of drug concentration after  20 hours which remained constant up to 80 hours. This 
sustained release of drug highlights the potential to design controlled delivery systems 
particularly for potent drugs. The cell death mechanisms of chemotherapeutic drugs like DOX are 
preserved after ND conjugation. 
165
 
Another example of utilizing NDs for cancer chemotherapy involves their conjugation with 
active plant alkaloids like paclitaxel, which have anti-cancer properties. 
34
 This complex is 
generated by covalent immobilization of the alkaloid on ND after a series of surface treatments. 
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This complexation mediated a dose dependent cellular uptake of paclitaxel and promoted cell 
death through mitotic arrest and apoptosis. 
34
 The activity of paclitaxel conjugated to NDs 
produced similar activity in vitro at 50 μg/ml concentration when compared to 50 nM of 
paclitaxel alone after 24 hours. The ND-paclitaxel complex also significantly reduced the tumour 
size at an average of 25 mm
3
. 
34
 
NDs are also employed to reduce challenges associated with hydrophobic drug delivery. 
Administration of drugs with low aqueous solubility always presents a problem to leading to a 
reduced bioavailability. 
328
 Low aqueous solubility also creates formulation challenges to prepare 
these drugs for systemic delivery. Water insoluble drugs can be conjugated with NDs for passage 
within the hydrophilic body environment to reach its targets. A variety of hydrophobic drugs like 
purvalanolA, 4- hydroxytamoxifen (4- OHT) and dexamethasone are investigated for delivery as 
ND complexes. 
100
  The particle size of these drugs greatly reduced from micrometer to 
nanometers after complexation with NDs (for example purvalanol changes from 340 µm to 556 
nm), indicating greater dispersibility in aqueous medium. The effective surface charge also 
changed to positive values, presumably because the water molecules have higher affinity to 
hydrate the charged form of the drugs resulting from complexation compared to the neutral 
forms. 
100
 
Multi-component ND based system were also designed for systemic delivery by conjugating on 
the surface diagnostic, therapeutic and targeting chemical species. 
317
 One of the examples of a 
versatile ND construct was synthesized by conjugating NDs with monoclonal antibodies to 
induce receptor mediated endocytosis in tumour cells and chemotherapeutic drugs like paclitaxel 
to induce tumour cell death. The drug is attached to the NDs through fluorescently labelled 
oligonucleotides for intracellular tracking of conjugated therapeutics. 
317
 
In addition to systemic delivery, NDs are also frequently used to design topical drug delivery 
systems.  An effective topical drug delivery system must possess a structure which is innately 
biocompatible, inert, allows adjustable release rates and is highly resistant to deformation. Design 
of multi-layered ND films presents as a successful approach to localize combinations of 
molecules in a single delivery system. 
329
 ND films are synthesized using layer-by-layer 
deposition, in which initially poly-L-lysine is deposited on a plain negatively charged quartz 
surface. This layer creates a positive surface charge which was then interacted electrostatically 
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with NDs to form a secondary layer.  This assembly creates inter-layer cavities for drug loading, 
and impart high stability to the system through electrostatic interactions between NDs and the 
peptide. A multi-layered ND film provide an advantage of high drug loading capacity and 
controlled release of the drug, and therefore is investigated for  topical administration of an anti-
inflammatory glucocorticoid called dexamethasone. 
329
 The multi-layered film continuously 
eluted the drug in a sustained fashion over 24 hours. The film and inter-layer cavities can be 
constructed with full control, thus further reduction in drug elution rate can be achieved through 
incorporating the drug into the inner layers. 
329
 These films can also be used to simultaneously 
administer both cationic and anionic drugs without using multiple delivery systems. However, 
limited studies are available regarding the synthesis of multi-drug delivery NDs systems.  
ND microfilms are also synthesized as implants using polymers like parylene C for 
unidirectional, slow and continuous release of chemotherapeutic drugs for prolong time periods. 
330
 This system was used to investigate the release of an anti-cancer drug DOX. The rate of drug 
elution was at least three times higher over the first day for uncovered ND-DOX complexes as 
compared to the complexes sandwiched between the polymer films. The film created an 
additional elution control layer, which resulted in constant drug release and prevention of an 
initial burst release. 
330
 The incorporation of such potent drugs into this form can reduce the 
adverse effects associated with sudden rise in drug levels immediately after administration.  
10.1.6 Nanodiamonds for Protein Delivery (Section 2.8.4.2) 
NDs are also investigated for the delivery of proteins particularly hormones or enzymes. An 
example of such an application is the development of ND-insulin complexes designed for local 
delivery of insulin as a growth hormone to heal wounds. 
101
 This system specifically elute insulin 
in alkaline medium of wounds associated with bacterial infections, thus increase the local 
concentration of the therapeutic protein. During the investigation, NaOH was used as an alkalinic 
medium while water was used for comparison as a non-alkalinic medium. The amount of insulin 
released by the first day was more than 20 times higher in the alkaline medium compared to 
water.  This pattern also continued similarly on the fifth day with 46% insulin released in alkaline 
medium in comparison to only 2% drug released in the water. This change in the release of 
insulin from ND complexes can be correlated with the change occurring in the charge distribution 
due to pH variations. Insulin in the aqueous medium possesses a net negative charge, which 
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becomes much stronger upon increasing the alkalinity of the medium. Electrostatic interactions 
between NDs and insulin are disturbed at this instance causing desorption of the protein.  The 
amounts of the insulin desorbed are directly proportional to the increase in the alkalinity of the 
medium from pH 9 to pH 11.5. Most importantly, the functional capacity of the protein was not 
compromised due to this pH switching and desorption.  
As an analytical tool cytochrome C was investigated as a potential biomarker to evaluate 
conformational changes occurring to proteins in solution and on the surface. 
331
 
332
 Conjugated to 
NDs, cytochrome C could generate an optimized probe for fluorescence and optical microscopy. 
12
 In addition to proteins, fluorescent peptides such as thiolated peptide are also conjugated to ND 
surface through connecting groups like maleimide (H₂C₂ (CO) ₂NH) functionality for 
fluorescence bio-imaging. 
13
  
NDs are also employed as matrix for matrix-assisted laser desorption ionization (MALDI) mass 
spectrometry to specifically capture and analyse glycoproteins. 
333
 This opens new avenues to 
utilize NDs for proteomic research. 
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10.2 Use of Scanning Transmission X-ray Microscopy for Characterizing Nano-
Delivery Devices 
X-ray absorption spectroscopy has always been a valuable tool for assessing novel nanomedicinal 
approaches. 
334, 335, 336 
The technique has further developed over decades, with particular 
advancements made in synchrotron dependent X-ray based analysis. 
337, 338
 Synchrotron sources 
offer generation of X-rays with enhanced brightness that allows tremendous improvement in 
spatial resolution and spectral fingerprints. 
339, 340
 Synchrotron based X-ray absorption techniques 
mediates a diversified combination of spectroscopy and microscopy as spectromicrocopy and 
microspectroscopy. 
341
 The term spectromicroscopy relates to the microscopic imaging combined 
with detailed spectral sensitivity, which further encompasses microspectroscopy that allows 
recording spectra from small spots on the image. 
341
 
Scanning Transmission X-ray Microscopy (STXM) is one of such modern characterization 
techniques. STXM follows near-edge X-ray absorption spectroscopy (NEXAFS) as its 
characteristic contrast mechanism, which describes the interaction of soft x-rays with matter at 
absorption edges. 
239
 STXM utilizes synchrotron generated soft x-rays of λ ranging from ~50 to 
100 Å to cause the ionization of inner shell electrons, and collect fine scale details of the 
spectrum at each absorption edge. 
244
 These spectral details can be used to deduce the chemical 
structure of unknown compounds or to locate and quantitate the elements of known features in 
substrate like cell or tissues. Upon first incidence of x-rays over an absorption edge, the structure 
associated with electronic excitation to the lowest unoccupied molecular level (π electrons of 
unsaturated double or triple bonds) is revealed, followed by the structure associated with the 
transition of electrons to highest unoccupied molecular levels (σ electrons of saturated single 
bonds). 
244
 Since these transitions greatly depend upon conformation 
342
 and bonding 
environment, 
343, 344
  the NEXAFS spectrums of individual samples can serve as a fingerprint. 
Work flow of scanning X-ray microscope is straight forward. It picks up high energy x-rays from 
the source and produce an intensified focal spot of diameter 50 nm and 3-10 µm wide 
244
 on the 
image. This focal spot is generally created through a Fresnel zone plate which works to maximize 
the exposure of photons to smallest spot size on the sample. 
345
 The sample is raster-scanned by 
the transmitted x-ray signals from the focal spot to create an image. 
239, 244
 Microspectroscopy can 
be done by exposing x-ray beam at the spot of interest followed by scanning of photon energy 
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from the specified spot. 
244
 For biological applications, all X-ray microscopic studies including 
STXM are usually done using photon energies in the range of K shell absorption edges of oxygen 
i.e. 543 eV and carbon i.e. 284 eV . 
346
 
STXM provides many advantages over conventional techniques used for characterizing 
nanoparticles (NPs) and investigating their cellular interaction. 
239, 240, 241
 Most importantly, it can 
be applied to fully hydrated biological materials, which allows functional analysis of molecular 
mechanisms in a living cell under native biological environment. 
242
 Soft X-rays also provide 
spatial resolution better than 50 nm 
244, 243
 and spectral resolution on the order of 100 meV, 
244, 245
 
that can sufficiently differentiate between classes of biomolecules and can identify NPs as 
therapeutic carriers in cell and tissues. 
240
 Unlike electron microscopy, soft X-ray based 
techniques like STXM allows imaging of unsectioned cell with full thickness to produce high 
contrast images without any stains, exclusively based on intrinsic cellular components. 
347
 
Moreover, it also offers an understanding of solvent mediated NP interactions since it greatly 
depends upon the surrounding environment. 
348
  Unlike confocal laser microscopy, STXM offers 
the possibility to distinguish between wide variety of individual NPs sized to few tens of 
nanometers and having different chemical compositions. 
348
 
10.2.1 STXM for characterizing hard nano-delivery systems 
Challenges associated with the delivery of therapeutic drugs and genes to targeted cells and 
tissues are greatly addressed by advances made in nanotechnology. 
349, 350, 351, 352, 353
 Several NP 
based delivery systems are designed to target gene therapy, particularly by RNA interference 
(RNAi) therapeutics as personalized treatments of chronic illnesses. 
354, 355, 356
 NPs provide a 
cohesive system to protect naked genetic materials from endogenous enzymatic degradation and 
deliver it to the target cells. 
357
  Elaborative physicochemical and biological characterization of 
NPs is required to ensure the development of safe, reproducible and controllable delivery vectors. 
Recently, STXM is employed as a potential tool for characterizing hard core NPs like carbon 
nanomaterials and evaluating their interactions with biological systems.  
STXM due to its dependence upon NEFAXS spectroscopy offers good sensitivity to define the 
structural properties and composition of carbon based materials. 
358
 Single-walled and multi-
walled carbon nanotubes (CNTs) are the members of carbon nano family which are utilized as 
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gene carriers. Several surface functionalization attempts are done on CNTs to induce 
complexation with genetic materials. 
359, 360, 361, 10
 Evidence suggests that STXM is advantageous 
to overcome complications for characterizing CNTs due to its small size and complex chemistry. 
362
 Unlike STXM, other X-ray absorption techniques can only analyze large sample size, which 
often presents interferences due to the signals of impurities (graphitic soot, reaction catalyst etc). 
362
 STXM can avoid these complications effectively by allowing microspectroscopy of selected 
clear zones having identified isolated CNT. Moreover, it is also efficient to provide better spatial 
resolution and less radiation damage as compared to other techniques like scanning 
photoemission microscopy or transmission electron spectromicroscopy. 
363, 364
 Transmission 
electron microscopy (TEM) combined with STXM has been applied to provide detailed 
understanding of structural features of CNTs. 
362
 TEM was used to pick meaningful regions for 
analyzing individual CNT devoid of impurities and aggregated carbon nanomaterials. Stack 
microspectroscopy was done through STXM to obtain sequence imaging over a range of photon 
energies. The results were capable of providing complete quantitative chemical mapping of CNTs 
in the region of interest. Furthermore, the analysis was also successful in differentiating between 
an isolated CNT (rectangle), mixture of carbon impurities and CNTs (trapezoid) and the substrate 
(pentagon) by unique NEFAXS spectrums (Figure A1.1A). Comparison between the spectra 
from different regions in the image highlights similarities and differences which elaborate further 
details of the structures and morphologies (Figure A1.1B). 
362
  
    
Figure A2. 1 (A) STXM images at 285.2eV (MWCNT signal enhanced) and 289.0eV 
(Formvar substrate signal enhanced), and corresponding TEM picture (B) (a) Spectra of 
arc-discharge MWCNT, MWCNT+CNP powder, and Formvar substrate (b) One pixel 
spectra taken on the MWCNT and on MWCNT and on the CNP. Reprinted with 
permission from 
362
 Copyright © 2006 American Institute of Physics 
B A 
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STXM is also applied to study the surface functionalization of CNTs in combination with other 
techniques (Infrared, Thermogravimetry and Raman Spectroscopy). 
365
 Key advantage of using 
STXM over other characterization techniques is the possibility to visualize specific regions of 
functionalization, which can interpret dependence of the process upon factors like orientation and 
exposed environments. Figure A1.2 highlights specific regions of functionalization and spectral 
fingerprints before and after dodecyl derivatization of CNTs. 
365
 Similar concept can also be 
applied to determine cellular uptake of carbon nanomaterials. 
366
 Since STXM can differentiate 
differently bonded carbon atoms, members of carbon nano family can be mapped and 
distinguished with other carbon containing biomolecules in the cell (e.g. proteins, lipids etc).  
 
Figure A2. 2 STXM of the dodecyl-functionalized WCPP (wet chemical purification 
procedure- SWCNT (single-walled CNT): (left panels) C 1s reference spectra used to fit the 
C 1s image sequence in order to derive the associated component maps (right panels). 
Component maps of (a) horizontal SWCNT (π*-weak); (b) vertical SWCNT (π*-strong); (c) 
oxidized SWCNT; (d) carbon onions and other carbon contaminations (CNP); (e) dodecyl. 
Reprinted with permission from 
365
 Copyright © 2010 American Chemical Society.  
Quality of CNTs can also be analysed through STXM by investigating spectral differences due to 
vertical and horizontal orientations (dichroic effect). The samples having strong dichroic effect 
indicate optimum quality and low impurities. 
365
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Fullerenes, also known as buckyballs are another class of carbon nanomaterials widely 
researched for its potential application as delivery vectors. 
367, 368, 369
 Metallofullerene is a novel 
modification which comprise of a metallic molecule trapped inside a fullerene cage. They are 
recently investigated to overcome resistance of cancer cells towards platinum based anti-cancer 
drugs. 
370
 Metallofullerenes have unique electron transfer properties from the encaged metal ions 
to surrounding carbons, 
371
 which protect the metallic therapeutic moiety against leakage and 
dissociation. 
372
 Additional to drug delivery applications, metallofullerenes are also investigated 
for immunomodulatory responses. Though immune active responses can propagate fullerene 
induced inflammation, 
373, 374
 but this activity is also researched as targeted immune therapy for 
tumour-bearing patients. 
375
 Poly-hydroxylated metallofullerenol (Gd@C82(OH)22) have been 
shown to polarize the release of cytokines, stimulate T-helper cells and macrophages and induce 
tumor cell apoptosis. 
375
 Recently, STXM was applied to study the cellular uptake of poly-
hydroxy metallofullerenes and its ability to activate macrophages to release pro-inflammatory 
cytokines. 
372
 NEFAXS spectrum of Gadolinium (Gd) was first generated at M-edge to obtain an 
estimation of its absorption energy. Mouse macrophages were then scanned at specified photon 
energies after in vitro and in vivo peritoneal delivery to obtain Gd distribution map, which 
correlates with the cellular distribution of metallofullerenols (Figure A1.3). 
372
  
For gene delivery applications, quantum dots (QDs) are also widely researched. 
376, 377, 378
 STXM 
was employed in analyzing sub cellular localization of cadmium based QDs having telluride 
element as one of its component. Chemical mapping of telluride element at its specified 
absorption energies are indicative of the cellular distribution of QDs. 
379
 These studies suggest 
that STXM is suitable to be applied for element-specific analysis. 
152 
 
 
Figure A2. 3 Internalization of metallofullerenol by macrophages (in vivo and in vitro). (A) 
A Gd M-edge NEXAFS spectrum obtained from Gd@C82(OH)22 nanoparticles. (B) Soft X-
ray STXM dual energy contrast images of Gd@C82(OH)22 internalized by a primary mouse 
peritoneal macrophage in vivo. (C) Soft X-ray STXM dual energy contrast images of time-
dependent uptake of Gd@C82(OH)22 by primary mouse peritoneal macrophages and RAW 
264.7 cell line in vitro. (D) ICP-MS quantification of time-dependent uptake in macrophages 
of primary mouse peritoneal macrophages. Reprinted with permission from 
372
 Copyright 
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA Weinheim.  
STXM is also applied to characterize NP mediated ionic therapy for malignant cancers. 
380
 
Adsorption of sodium ions on nanodiamond (ND) surface was investigated at photon energies 
above and below K-edge of sodium. Intracellular delivery of sodium ions was also analysed 
using STXM images of the cells taken at sodium specific photon energies. The amount of 
intracellular sodium was compared as a function of presence and absence of serum proteins in the 
cell culture medium. 
380
  
STXM served as an impressive tool to evaluate tissue penetration and distribution of hard NPs 
applied for topical treatment approaches. 
240
 Analysis of membrane interaction at individual 
particle level is possible. Variable sized gold and silica core NPs having silica and gold shell 
respectively were analyzed for penetration in human skin using STXM in combination with other 
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conventional microscopic imaging. Scanning of images at photon energies specific to gold and 
silicon revealed degree of penetration and distribution of NPs in different layer of the skin. 
Conclusively, synchrotron dependent x-ray microscopy serves as a convenient tool to evaluate 
hard nanomaterials employed in different therapies as carriers. The technique provides ease of 
performing microscopic imaging in combination with detailed spectral analysis to build 
meaningful interpretations regarding novel treatment approaches. 
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